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This dissertation assembles data obtained during my Ph.D research project, 
developed at Instituto Gulbenkian de Ciência (IGC) under the supervision 
of Miguel Che P. Soares from May 2010 to September 2014. 
 
This thesis is structured in 6 chapters, preceded by a summary written in 
English and Portuguese, outlining the aims of the projects, results and 
outcomes of the project. 
 
The first chapter provides information about general knowledge on malaria, 
the importance of naturally occurring anti-α-gal antibodies and 
immunological aspects of these antibodies. This chapter also includes the 
specific aims of this work. The second chapter describes the detection of 
α-gal on the surface of Plasmodium sporozoites. Moreover, it shows that 
Plasmodium spp. express α-gal during the exo-erythrocytic stage and 
erythrocytic stage of the infection in mammals. The third chapter provides 
insight about the fate of Plasmodium sporozoites when facing anti-α-gal 
antibodies in the dermis of their mammalian host. The fourth chapter 
provides information about the role of complement system in this 
protective mechanism driven by anti-α-gal antibodies. The fifth chapter 
hopefully opens new doors in the field by presenting the role of gut flora in 
triggering this natural protective mechanism against malaria transmission. 
The last chapter provides an overall discussions and conclusions of this 
study. It also contains the future perspectives of the work developed 
during my Ph.D studies. 
 
Data described in this Ph.D thesis dissertation is the result of my own work. 
This study has never been submitted for any degree at this or any other 



























Malaria is an infectious disease of humans and other animals including 
birds, reptiles and most mammals. It is transmitted via the inoculation of 
Plasmodium sporozoites into the skin through the bite of an infected female 
Anopheles mosquito. Although every year, around 700.000 lives are 
perished, mainly children under the age of 3-5 years old, to Plasmodium 
infection this deadly parasite has a relatively low efficiency of transmission 
from mosquitoes into humans. This argues for a natural protective 
mechanism, which presumably acts during the early stages of Plasmodium 
infection in the human host. Using a rodent model of Plasmodium infection 
to mimic the transmission of disease in humans, this PhD thesis 
demonstrates that such a mechanism does exists and is mediated through 
the action of natural antibodies recognizing specifically the Galα1-3Galb1-
4GlcNAc-R (α‑gal) carbohydrate. It was shown that these T-cell dependent 
circulating anti-α-gal antibodies can be produced upon antigenic exposure 
by α-gal expressing specific components of the intestinal microbiota and 
target Plasmodium sporozoites in the skin, immediately after their 
inoculation by Anopheles mosquitoes in mice. Additionally, anti-α-gal 
antibodies are associated with protection against P. falciparum infection in 
humans, as shown for individuals from a malaria endemic area. 
Complement and polymorphonuclear (PMN) cell-dependent mechanisms 
contribute to the mechanism via which these antibodies prevent the 
migration of sporozoite from the skin into the liver and inhibit hepatocyte 
invasion, suppressing the establishment of liver stage of infection. Our 
findings also reveal that this natural host defense mechanism reduces the 
rate of disease transmission and provides sterile protection against malaria. 
Importantly, vaccination against α-gal protects mice against malaria 
transmission, suggesting that a similar vaccination approach may reduce 



























A Malária é uma doença infecciosa que afecta humanos e animais, como 
aves, répteis e mamíferos. Causada por parasitas do género Plasmodium, 
esta doença é transmitida por inoculação de esporozoítos na pele, através 
de uma picada de um mosquito fêmea, do género Anopheles. Apesar de 
anualmente serem perdidas cerca de 700,000 vidas, em particular crianças 
de idade inferior a 3-5 anos, devido a infecções por Plasmodium, esta 
infecção muitas vezes mortal, apresenta uma eficiência de transmissão 
relativamente baixa, o que argumenta em favor de um mecanismo natural 
de protecção do hospedeiro, que presumivelmente actua durante os 
primeiros estadios da infecção. Nesta tese de Doutoramento, recorrendo a 
um modelo de infecção por Plasmodium em roedores, foi demonstrado que 
tal mecanismo é mediado por anticorpos naturais que reconhecem 
especificamente um epitopo existente em carbohidratos, denominado 
Galα1-3Galβ1-4GlcNAc-R (α‑gal). Este epitopo está presente na estrutura 
celular do parasita, nas diversas fases do ciclo de vida, mas ausente em 
células humanas, permitindo assim a produção de elevados níveis de 
anticorpos anti-α-gal, o que ocorre naturalmente e de forma dependente de 
células T. Anticorpos anti-α-gal do tipo IgM e IgG, tais como os presentes 
em indivíduos adultos residentes em áreas endémicas de malária, inibem 
os esporozoítos de Plasmodium na pele, imediatamente após a inoculação 
por mosquitos Anopheles. Estes anticorpos naturais estão também 
associados à protecção contra a infecção por Plasmodium falciparum em 
humanos, como foi demonstrado em áreas endémicas de malaria. Esta 
protecção envolve mecanismos que dependem do sistema de complemento 
e de células polimorfonucleares (PMN), prevenindo a migração de 
esporozoítos da pele para o fígado, bem como inibindo a invasão de 
hepatócitos, e consequentemente, suprimindo o estabelecimento do estadio 
de infecção no fígado. De acordo com esta ideia, as nossas descobertas 
revelam um mecanismo natural de defesa do hospedeiro em que 
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anticorpos naturais conferem protecção estéril contra a malária, reduzindo 
a taxa de transmissão da doença. De salientar que a vacinação contra α-gal 
protege ratinhos deficientes em α1,3Gt contra a malária, sugerindo que 
estratégias semelhantes de vacinação poderão igualmente reduzir a 
transmissão de malária em humanos. 
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Abbreviations and Acronyms  
α‑gal   Galα1-3Galβ1-4GlcNAc-R  
α1,3Gt  UDP-Galactose:β-galactoside-α1-3-galactosyltransferase 
ACP  alternative complement pathway 
ALUM  aluminum hydroxide Cɣ 
BSI-IB4  lectin from Bandeiraea simplicifolia 
CFA  complete Freund’s adjuvant 
CSP  circumsporozoite protein 
CT  cell traversal 
EEF   exo-erythrocytic form 
GF  germ-free 
GFP   green fluorescent protein 
GI  gastrointestinal 
IFA  incomplete Freund’s adjuvant 
mAb  monoclonal antibodies 
NAbs   naturally occurring antibodies 
NK  natural killer 
ODN  oligodeoxynucleotide 
PV  parasitophorous vacuole 
PBS  phosphate buffered saline 
PbA  Plasmodium berghei ANKA 
Pf  Plasmodium falciparum 
Py  Plasmodium yoelii 17XNL 
PMN  polymorphonuclear cells 
RBC   red blood cell 
rRBCM rabbit RBC membrane 




































































































1.1 Malaria: An Ancient Disease 
1.1.1 History of the disease 
Malaria is one of the most anciently described diseases, reported originally 
in a Chinese document as early as 2700 BC, in which fever and enlarged 
spleen were recorded as the major clinical symptoms1. Later on, 
Mesopotamian clay tablets from 2000 BC, Egyptian papyri from 1570 BC 
and Hindu texts from the 500 BC, provided more medical information 
about this disease1,2. Knowledge related to malaria continued to increase in 
the early Ancient Greece with Homer (~850 BC), Empedocles of 
Agrigentum (~550 BC) and Hippocrates (~400 BC) describing its clinical 
signs (i.e. poor health, intermittent fever and enlarged spleen in people 
living in marshy places), holding the first clear recordings of malaria 
infection in ancient times3. However, many other studies were required in 
order to identify the causative agent(s) of the disease, i.e. Plasmodium.  
 
The various reports4 on malaria throughout the history of medicine, 
spanning more than 4,000 years5 made it clear that the manifestations and 
the causes of disease, including fevers and other symptoms were to be 
considered as miasmas rising from swamps 1 . Modern scientific 
understanding of malaria however, began only to emerge by the end of the 
19th century with the germ theory and the beginning of microbiological 
studies. The very first understanding of malaria transmission dates back to 
1880 with the detection of parasites in the blood of an infected patient, 
reported by Charles Louis Alphonse Laveran4. Meticulous examination of 
blood samples collected from more than 200 patients revealed that in 150 of 
those there was a clear detection of “crescentic bodies” that were never 
detected in healthy individuals. This led Charles Louis Alphonse to 
conclude that a parasitic protozoan, which he named as Oscillaria malariae 
was the causative agent of the disease called malaria4. These observations 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1!The word malaria comes from the Italian mal'aria meaning spoiled air.!
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made possible the advance of scientific discoveries by Ronald Ross, a 
British officer of the Indian Medical Service, in 1897, who demonstrated 
that avian malaria is a disease transmitted via mosquito biting, 
incriminating for the first time mosquitoes in this vector-borne disease4. 
Ronald Ross described how parasites develop within the midgut of 
mosquitoes, from where they eventually migrate to the salivary glands6. He 
was able to successfully transmit the disease to healthy birds from an 
inoculum isolated from infected mosquitoes, thus inferring for the first 
time that transmission of avian malaria occurred via the bite of an infected 
mosquito. This was subsequently confirmed in a study carried out with a 
human parasite by Battista Grassi and colleagues7. These scientists also 
identified female Anopheles mosquitoes as the main vector of human 
malaria. In 1890, Grassi and colleagues reported for the first time, that two 
malaria parasites, named Plasmodium vivax and Plasmodium malariae, are 
able to infect humans4. This finding was based on a simple experiment in 
which mosquitoes fed on an infected patient in Rome were sent to London 
where they were able to transmit the disease to two healthy volunteers8. In 
1897, William H. Welch identified a third malaria parasite, named 
Plasmodium falciparum and in 1922, John William Watson Stephens, working 
in West Africa, described yet another human malaria parasite, which 
resembled P. vivax and was named Plasmodium ovale9. Thirty more years 
passed until Plasmodium knowlesi was identified as another Plasmodium 
parasite able to infect humans10. 
 
Despite the discovery of several life threatening Plasmodium strains, 
information on the mechanisms by which Plasmodium infects and 
proliferates in humans was still lagging until the beginning of 20th century. 
In 1902, Friedrich Schaudinn described that Plasmodium vivax infective 
sporozoites contained in the salivary glands of mosquitoes could infect 
human red blood cells (RBCs)4. This was confirmed in 1948 by Cyril 
Garnham and Henry Shortt, who infected rhesus monkeys using 
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mosquitoes, which carried Plasmodium cynomolgi parasite. The authors 
demonstrated that when transmitted by mosquitoes, Plasmodium 
sporozoites undergo a first round of multiplication, differentiation and 
maturation in the liver before being released into the bloodstream11. These 
steps represent the first evidence for the occurrence of a ‘tissue phase’ of 
Plasmodium infection as formally demonstrated in 194811. An American 
clinician, Wojciech Krotoski showed that in some strains of Plasmodium 
vivax, the liver stage of infection could remain dormant for several months, 
called as hypnozoites1. Seventy years passed until the major human tissues 
targeted by Plasmodium were finally identified (discussed later on in this 
chapter). 
 
1.1.2 Malaria outcome – current situation 
Malaria is a global health problem, affecting more than 100 countries with 
an estimated 3.4 billion people at risk of developing the disease, i.e. half of 
the world population. Malaria acts as the 10th leading cause of mortality 
worldwide12 13, driven by severe anemia, respiratory distress, multi-organs 
failure and cerebral malaria. World Health Organization (WHO)14 reported 
in 2012 that 219 million individuals were infected with Plasmodium parasite 
(uncertainty range between 135 to 287 million) of which 660 000 succumbed 
to malaria (uncertainty range between 473 000 to 789 000). In 2013, the 
WHO Malaria Report showed that ongoing malaria transmission occurs in 
97 countries and territories14. Moreover, 7 countries in which Plasmodium 
transmission started to be observed again are subjected to preventive 
measures and this makes to a total of 104 countries to be considered 
endemic to malaria (Figure 1.1). Another striking fact related to this disease 
is that 90% of the deaths occur in children and pregnant women. In other 




Figure 1.1 Worldwide malaria distribution and burden. Although mortality 
among infected individuals is “low” (0.3-04%), malaria remains a major health 
problem and one of the largest scourges in many tropical and subtropical regions. 
Adapted from15. 
 
According to the WHO Malaria Report of 2012, the death toll imposed by 
malaria was reduced by 20-25% from 2000-2010, (a decrease of 33% in 
Africa), presumably due to the introduction of malaria control programs by 
the WHO14. However, this decrease is not due to lower parasite viability, 
given the emergence of drug resistance strains of Plasmodium. So far, there 
is no efficient licensed vaccine, which will eventually act as a “game-






1.2 Biology and Life Cycle of Plasmodium  
1.2.1 Plasmodium spp.  
Plasmodium is a heteroxenous protozoan parasite, i.e. the completion of its 
life cycle involves a vertebrate host and an arthropod vector. It belongs to 
the Apicomplexa phylum, the less phylogenetically well-known taxonomic 
group (only 0.1% of the all species named to date)16. The genus Plasmodium 
was first described in 1885 by Ettore Marchiafava and Angelo Celli4,17 and 
today, it is known to be infective to a variety of possible hosts, including 
reptiles, birds and mammals18. There are four described human infectious 
Plasmodium species: P. falciparum, vivax, malariae, and ovale. In addition, P. 
knowlesi19, which infects macaques that inhabit the forested areas of 
Southeast Asia, has recently developed the ability to infect humans and is 
considered as the fifth causative agent of human malaria. These Plasmodium 
species differ regarding morphology, life cycle and pathologic outcomes 
imposed to their hosts. Differences include a) blood stage morphology 
(erythrocytic schizogongy consists of 3-5 rounds), b) characteristics 
associated with liver stage (a dormant phase called hypnozoite observed in 
P. vivax and P. ovale), c) sequestration of trophozoite- and schizont-infected 
RBC in microvasculature (exclusive to P. falciparum) and clinical 
manifestations with prolonged pre-patent period for P. vivax, ovale, and 
malariae up to several months, d) intensity of febrile attacks or e) duration 
of clinical symptoms. 
 
P. falciparum is by far the most virulent species to mankind, which accounts 
for ≈ 85% of all malaria infections, and virtually all malaria-associated 
morbidity and mortality. The high pathogenicity of this parasite hints that 
P. falciparum may be a recent human parasite transferred from a nonhuman 
host20,21. 
 
In 1948, Ignace Vincke and Marcel Lips identified and isolated the first 
rodent malaria parasite, P. berghei, from Grammomys surdaster (an African 
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tree rat) in Central Africa4. Since then, three other strains, i.e. P. yoelii, P. 
vinckei and P. chabaudi were identified, isolated and successfully 
transferred/adapted to laboratory rodents, thus allowing the establishment 
of rodent models of the human disease4,22,23. The life cycle, physiology and 
morphologic structure of these parasites resembles in many aspects the 
human infecting Plasmodium spp. and therefore, rodent parasites are 
considered valuable surrogate models of human malaria4,22,23. However, 
there are reasonable concerns as to what extent the rodent models of 
malaria mimic disease pathogenesis and immunity in humans. In any case, 
the spectrum of murine malaria models obtained when using different 
hosts and parasite strains reflects to a large extent the diversity of human 
disease with specific parasite-host combinations capturing most if not all 
the specific aspects of the human disease. 
 
1.2.2 Life-cycle of Plasmodium in mammals and mosquitoes 
The life-cycle of Plasmodium can be extremely complex as it involves 
different stages occurring in disparate host species such as an arthropod 
vector and a vertebrate host. Since the original description of the different 
stages of Plasmodium infection, scientists have been trying to understand 
the life-cycle of Plasmodium in further detail. Briefly, the life-cycle in 
mammals consists of a pre-erythrocytic, erythrocytic and sporogonic phase 
(Figure 1.2). Each of these is explained in detail above. The pre-erythrocytic 
stage (Skin and Liver Stage) begins when a female Anopheles mosquito 
injects sporozoites, i.e. the infectious form of Plasmodium parasites, into the 
skin of a vertebrate host. Parasites spend a certain amount of time in the 
dermis (from 15 minutes to a couple of hours) before reaching a dermal 
microvascular blood vessel, through which they are transported via the 
blood stream, into the liver. At this point, Plasmodium sporozoites invade 
hepatocytes in two minutes, where they mature within 40-48 hours. The 
erythrocytic stage (Blood Stage) of infection begins after the rupture of 
liver schizonts (mature parasites in the liver), also referred as 
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exoerythrocytic forms (EEFs), and subsequent release of infectious 
merozoites into the bloodstream. RBC invasion occurs within 1-2 minutes 
and then parasites undergo rounds of asexual multiplication leading to 
RBC disruption and to the clinical outcomes of the disease. In the 
sporogonic stage (Mosquito Stage), during a blood meal a mosquito 
ingests, differentiated male and female Plasmodium gametocytes from an 
infected host. Fertilization occurs in the mosquito midgut and the resulting 
zygotes develop into ookinetes that mature into oocysts, where thousands 
of sporozoites develop. This final form of the parasites in the mosquito 
vector migrates to the salivary glands, where it stays until it is injected into 
another vertebrate host. Each phase of infection is explained in further 
detail in the next paragraphs.  
 
The skin stage of infection is a rapid, clinically silent and apparently 
immunologically innocuous phase of Plasmodium infection. This initial step 
is critical for the establishment of the infection in the mammalian host24. 
Most of the injected sporozoites, in average 15-123 sporozoites per blood 
meal, are inoculated into the extravascular matrix of the dermis25,26 and not 
directly into the bloodstream as initially thought. This was first 
demonstrated by Boyd and Kitchen, in 1938, who found the presence of 
Plasmodium sporozoites in human dermal tissue27, finding as well that 
removal or heat treatment28 of the skin area targeted by the mosquito 
dramatically decreased Plasmodium infection29. It argues strongly that 
sporozoites are first deposited into the dermis, while the mosquito probes 
for a blood vessel and salivates. In further support of this notion, when the 
mosquito ingests blood it actually re-ingest a proportion of its sporozoites 
driven by the inward blood pressure, which overrides outwards salivation 
pressure30,31. The development of intravital imaging techniques fully 
confirmed that most sporozoites are injected into the dermis at low, but still 
highly variable inoculums. 
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Mosquito bites are also associated with the ejection of saliva that contains 
vasodilators like tachykinins and anti-coagulants like thrombin- and Fxa-
directed molecules, which increase blood flow and inhibit platelet 
aggregation32, presumably facilitating blood ingestion33. During a mosquito 
bite, approximately ~1–2.5 sporozoites are released per second through the 
proboscis. In malaria endemic regions, individuals can be bitten by 1-100 
mosquitoes during one single night corresponding to 0-4 infective bites34. 
Considering around 4-5 minutes of mosquito salivation, an Anopheles 
mosquito injects on average about 300 sporozoites per bite in a human 
host35,36.  
 
When delivered into the dermis Plasmodium sporozoites show significant 
level of motility before reaching the extracellular matrix of the blood 
vasculature and contacting with vascular endothelial cells28,33. Sporozoites 
glide in three-dimension with an average velocity of ~1–2 µm per second 
during the first 30 minutes after injection. While they continue to move for 
more than one hour, their speed decreases significantly over time. Once 
Plasmodium sporozoites start migrating randomly in the cutaneous tissue, 
one of four different scenarios will decide their fate. These are dictated by 
many factors, including blood vessel density at the biting site, saliva 
components released by the mosquito and the parasite species itself. In any 
case, it should be noted that out of the ejection of 70-100 Plasmodium 
sporozoites in mice during salivation only 15-25% of those deposited in the 
skin will manage to successfully establish infection35. Under the first 
scenario, once deposited into the skin sporozoites move at high speed by 
gliding motility37 and traverse38 host cells, piercing host membranes until 
they find a blood vessel as a way to reach the liver, a process that lasts a 
couple of minutes29,39,40. However, a small proportion of Plasmodium 
sporozoites can accumulate in the skin-draining lymph nodes in the 3 
hours that follow the injection41. These can reach lymphatic rather than 
blood vessels, and develop into small exoerythrocytic forms (EEFs), within 
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the first hours after mosquito bite40,42. The development is arrested after a 
short period of time and small EEFs are cleared from the host. Moreover, 
this processes can initiate the immune response against Plasmodium 
infection as suggested by the appearance of sporozoite specific cytotoxic T 
lymphocytes (CTLs) that can accumulate in the skin-draining lymph nodes, 
as early as two days after the intradermal injection of irradiated 
sporozoites42. The other possible scenario is when the deposited Plasmodium 
sporozoites fail to reach a draining blood or lymphatic micro-vessel in the 
dermis, as it occurs for approximately 50% of the cases. It is estimated that 
10% of these initiate the development of EEFs in the skin hair follicles, 
which can persist for days without leading to infection43,44. The last scenario, 
as observed by Kebaier and Vanderberg, is when Plasmodium sporozoites 
are re-ingested by mosquitoes30, with 90% of the mosquitoes re-ingest a 
highly variable number of sporozoites (1-400 sporozoites) while actively 
imbibing blood. Among these four scenarios only the first one allows for 
successful establishment of an infection. 
 
The mechanism via which Plasmodium sporozoites manage to proceed with 
microvascular blood vessel invasion is still not fully understood. Surface 
phospholipase is important to breach host cell membranes during 
sporozoite migration and in the absence of this protein, sporozoites’ ability 
to cross through vascular endothelial cells is impaired, with significant 
reduction of infection45. This reveals that transit from the dermis 
extracellular matrix, where sporozoites are initially deposited, to the blood 
microcirculation is a tightly regulated process presumably involving 
several gene products encoded by sporozoites as well as by the host. 
Transit from the dermis extracellular matrix into blood vessels is associated 
with decreased Plasmodium sporozoite gliding speed, triggered upon 
contact with endothelial cells, which are then crossed within few minutes46. 
When sporozoites enter blood vessels, they are rapidly transported through 
the blood circulation and are arrested thereafter in the liver. 
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Figure 1.2 The life cycle of Plasmodium. A female mosquito transmits a motile 
Plasmodium sporozoite into the skin of a vertebrate, acting as the transmission 
vector of malaria40,43. When sporozoites reach blood vessels, they are arrested in the 
liver, invading hepatocytes, where thousands of merozoites are produced38,47. 
Upon maturation, merozomes are release into blood circulation, reach the lungs48 
and infect RBC, initiating a series of asexual multiplication cycles. Then, an 
uninfected mosquito bites an infected host, taking up Plasmodium gametocytes 
along with the blood meal35. Fertilization and maturation take place in the 
mosquito midgut and when fully developed, Plasmodium sporozoites migrate to 
the salivary glands. 
 
Liver stage is the second short-lived and innocuous (asymptomatic) stage 
of Plasmodium infection in vertebrates, characterized by sporozoites 
migration through the liver sinusoids as to gain access to hepatocytes. 
During this process that occurs via an unknown mechanism, sporozoites 
switch from migrating into invasive mode and settle down in a final 
hepatocyte within two minutes after reaching blood vessels. The tropism of 
Plasmodium sporozoites towards the liver, rather than other organs, 
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suggests the existence of a selective process between parasite- and host-
encoded molecules. One example of a Plasmodium encoded-protein 
involved in this process is the circumsporozoite protein (CSP), a molecule 
distinctive of the Plasmodium genus that accounts for the predominant 
surface protein covering the entire surface of Plasmodium sporozoites, not 
found in any other Apicomplexa parasite49,50. Switching to invasive mode 
correlates with CSP interaction with host heparan sulphate proteoglycans 
(HSPGs) expressed at the surface of hepatocytes and hepatic stellate cells. 
These present a significantly higher degree of sulphation when compared 
to other tissues51, which may explain the initial tropism of Plasmodium 
sporozoites towards the liver. An early study by Victor Nussenzweig’s 
group showed that CSP binds to the hepatocyte microvilli within the space2 
of Disse52,53, migrating along fenestrated endothelial cells that allow for 
direct contact with hepatocytes. Presumably, this allows for sinusoidal 
barrier crossing and migration into the hepatic parenchyma, where 
sporozoites traverse several hepatocytes before invading the final one, 
where they differentiate47. During hepatocyte invasion38, each Plasmodium 
sporozoite forms a parasitophorous vacuole (PV)47 and resides in it during 
the liver stage of infection54. 
 
Survival of sporozoites in the liver requires cell traversal (CT) motility, a 
wounding and crossing process via which Plasmodium parasite passes 
through host cell plasma membranes and migrates freely in the cytoplasm 
of host cells, including hepatocytes. During this process, hepatocytes are 
wounded, releasing so called infection-susceptibility-inducing factors55,56, 
e.g. hepatocyte growth factor (HGF)57, required to promote final hepatocyte 
infection38. In support of this notion CT-deficient sporozoites display highly 
impaired liver infection in vivo, even though normal hepatocyte invasion 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 !Also known as perisinusoidal cells or Ito cells. They are pericytes found in the 
perisinusoidal space (a small area between the sinusoids and hepatocytes) of the liver -
known as the space of Disse.!
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and development are observed in vitro58,59. While pre-erythrocytic stage 
proteins such as the ones essential for cell traversal (SPECT), cell traversal 
protein for ookinete and sporozoite (CelTOS) or phospholipase (PL) were 
thought to be essential for cell migration, sporozoites deficient in the genes 
encoding these proteins can still invade hepatocytes and complete a liver 
stage development similarly to wild type sporozoites58,59. Little is known 
about the mechanism by which Plasmodium sporozoite switches from 
migration through hepatocytes to invasion of a hepatocyte. 
 
Once inside hepatocytes, sporozoites can develop and replicate within the 
PV, generating EEFs60 via asexual multiplication. This culminates in the 
presence of tens of thousands of infectious merozoites in ~2 days, which 
ultimately will proceed to the blood stage of infection61. However, little is 
known about the cellular and molecular interactions between parasite and 
host during this stage of the Plasmodium life cycle. 
 
The final important step of Plasmodium development in the liver is the exit 
from the hepatocyte involving the PV lysis and the release of newly formed 
merozoites contained in vesicles, called merozomes62. These bud off from 
hepatocytes into the sinusoidal lumen, remaining covered by hepatocyte–
derived membrane, which is thought to be important initially to afford 
protection against host innate immune system. Once released into the host 
circulation, merozomes are ruptured and the hepatic merozoites are free to 
invade the red blood cells. 
 
The blood stage of infection is associated with all the clinical symptoms of 
malaria. After the release of merozomes into the blood circulation, shear 
forces inside the hepatic and other larger veins break down merozomes 
into smaller units called merozoites. Later, merozomes reach the lung 
microvasculature, in areas of low macrophage density and reduced shear 
force presumably enhancing their infection ability48. Once merozomes are 
! 33!
ruptured in the lung microvasculature, merozoites are released and upon 
first contact with RBC membranes invade RBC in a short period of time 
(27-28s). RBC invasion occurs through several phases (Figure 1.3) that 
involve receptor–ligand interactions involving more than 50 surface and 
secreted proteins63. First, merozoites attach to the RBC surfaces (Phase 1, 
Pre-Invasion). Then apical reorientation of the parasites occurs, which 
allows for a tight-junction formation between merozoites and RBC surfaces. 
This provides an entrance mechanism into the RBC through a movement 
that propels the merozoites into the host cells (Phase 2, Invasion). A final 
process allowing for the release of the RBC membrane is associated with 
potassium and chloride efflux resulting in RBC water loss (Phase 3, 
Echinocytosis) and the initiation of parasite maturation in RBC begins64.  
 
Figure 1.3 Kinetics of RBC invasion. Merozoite achieves infection of RBC in three 
phases. In Phase 1, merozoite attaches to RBC and causes dramatic RBC 
deformation and recovery process, afterwards. In Phase 2, merozoite is 
internalized within the RBC and later on, in Phase 3, dehydration-type 
morphology occurs in infected RBC (iRBC) and parasite maturation in RBC begins. 
Adapted from64. 
 
After RBC invasion, parasites progress through a ring and a mature 
trophozoite stage, dividing during the subsequent schizont stage and 
giving rise to 8-32 daughter merozoites contained within a single RBC. 
Eventually, RBC ruptures and releases the newly formed merozoites65. 
During the successful cycles of invasion and multiplication inside RBCs, 
the clinical symptoms of the disease begin to appear. However, parasites 
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are partially hidden from immune recognition inside RBC, which lacks the 
expression of major histocompatibility complex (MHC) molecule 
recognized by antigen receptors of the host adaptive immune system. RBC 
also exposes some proteins at the surface, enabling cyto-adherence to 
different endothelial receptors and favoring sequestrations in organs while 
reducing splenic clearance by hemophagocytic monocyte/macrophages 
(Mø)66. 
 
Figure 1.4 Mosquito Stage of Plasmodium. In mosquito gut, gametocytes released 
from burst of iRBC develop further into mature gametes. After the nuclei fusion 
and fertilization in the mosquito gut, actively moving ookinetes form oocysts. 
Inside the oocyst, the ookinete produces thousands of sporozoites by cell division, 
releasing sporozoites that reach the salivary glands. Adapted from68. 
 
After several asexual cycles inside RBC, a fraction of intraerythrocytic 
parasites divert from the asexual multiplication pathway towards sexual 
differentiation, developing highly specialized gametocyte forms (either 
males or females). These circulate in the bloodstream and are taken up 
upon the bite of mosquito. This development process in the Plasmodium 
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infected host is called gametocytogenesis and is triggered by genetic and 
environmental factors67.  
 
Mosquito stage is the last step of the life cycle of Plasmodium infection that 
begins with the uptake of iRBC from an infected vertebrate. This occurs via 
the bite of a female mosquito, which ingests both male and female 
gametocytes that arise during each erythrocytic cycle. Once inside the 
mosquito midgut, gametocytes undergo fertilization, zygote formation and 
development into the motile ookinete69 generating new infectious 
sporozoites. 
 
Male gametocytes undergo the most drastic transformation while 
replicating their own genome. They are segregated into eight flagellated 
male microgametes, whereas female gametocytes transform into 
macrogametes69,70. Exflagellation is a vibratory movement activity that 
allows the release of male gametes from the gametocytes, enabling them to 
find female gametes. Subsequently, this process leads to the formation of a 
zygote, which undergoes meiosis and develops within 24 hours into an 
ookinete. During the differentiation process and development into a 
vegetative oocyst, the ookinete rests between the midgut epithelium and 
the luminal side of the basement membrane of the infected mosquito. 
Following multiple rounds of nuclear division that occur over 10–14 days, 
hundreds of sporozoites develop and are released into the mosquito 
haemolymph70,71. From there, sporozoites are carried away to the salivary 
glands in which they reside until transmission into their next host (Figure 
1.4). Even though most sporozoites reside in salivary glands, large numbers 
are also found in the cavities of secretory cells at the distal end of the 
glands. These are not ejected during the mosquito blood feeding process. In 
fact, only a small proportion of sporozoites reach the narrow salivary ducts, 
and likely also the wide portions of primary ducts. This constitutes a 
releasable pool of parasites to be transmitted to the mammalian host during 
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the next blood meal35. Plasmodium parasites can travel between the distal 
part of the salivary duct system and the tip of the proboscis in just a few 
seconds and the speed of ejection can reach approximately 500µm/sec. 
Surprisingly, the initial period of salivation is extremely important, as 
many mosquitoes were found to eject sporozoites during this period26,35.  
 
1.3 The Biology of Plasmodium Sporozoite 
While Plasmodium sporozoites are lower eukaryotes, they have a genetic 
complexity that is higher than the one found in any bacteria family. This 
genetic complexity is combined with a considerable number of 
polymorphic genes in the haploid genome, which generate antigenic 
diversity72. Therefore, Plasmodium sporozoites have various and highly 
optimized adaptation mechanisms, which allow to exploit their hosts in 
extremely changing situations. This may well explain why the parasite has 
been so successful in surviving throughout the evolutionary selection 
process73. Plasmodium sporozoites also present an active mechanism for 
cellular motility, which is essential to reach and invade host cells (See 
Section 1.3.2) and also utilize their own locomotion for extracellular 
migration through different host tissues31. 
 
1.3.1 Morphology of Plasmodium sporozoites 
Sporozoites are highly polarized and usually elongated cells (defined by 
the presence of an apical complex at their anterior pole) of about 10-15 µm 
in length and 1µm in wide74. They have a thin outer membrane and a 
double inner membrane under which lie the subpelicular microtubules 
anchored to the apical polar ring elongating underneath the inner 
membrane complexes (IMC), forming networks of closely apposed 
flattened vesicles. Plasmodium sporozoites have 3 polar rings extending half 
the length of the body. A morphological hallmark of Plasmodium 
sporozoites is the secretory organelles at the apical tip, called micronemes 
and rhoptries (Figure 1.5). The contents of both organelles are critical for 
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recognition and attachment to the host hepatocytes, generation of the non-
phagosomal parasitophorous vacuole and remodeling of the host cell 
following invasion75. Sporozoite morphology is established during the 
development within oocysts, which is dependent on CSP expression76. The 
sporozoite nucleus is divided into several sub-compartments including the 
nucleolus and the nuclear periphery, presumably involved in transcription 
control. Mitochondrion, apicoplast and microtubules are linked to the 
parasite pellicle via long tethering proteins. This defined structure is most 
likely important to maintain the sporozoite shape77.  
 
Figure 1.5 Structural illustration of a Plasmodium sporozoite. The major 
compartments such as apicoplast, rhoptries, micronemes and visible structures in a 
Plasmodium sporozoite with its anterior ending towards the right. Adapted from78. 
 
Plasmodium sporozoites express so called “invasion proteins” such as CSP 
that localizes mainly on the outer surface and in the micronemes and 
thrombospondin-related anonymous protein (TRAP), which localizes 
exclusively in the micronemes and plasma membrane of sporozoites with 
an irregular distribution. These proteins are often targeted as immunogens 
for pre-erythrocytic malarial vaccines74,78,79. 
 
1.3.2 Different modes of sporozoite motility 
Single-cellular or multicellular organisms possess distinct features that 
support cellular locomotion, which are important for reorientation, homing 
and migration. These provide advantages for development and survival in 
a variety of complex and stressful environments and are essential to 
support Plasmodium sporozoites transit from the skin into the liver and 
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from the liver into the blood. They can occur via three modes: gliding, cell 
traversal and invasion motility, as supported by in vitro and in vivo studies 
(Figure 1.6). 
Plasmodium sporozoites share with the rest of the Apicomplexa phylum a 
rather unique and mysterious process of locomotion, named gliding 
motility was first described in Toxoplasma and later, in other apicomplexans 
i.e. Eimeria, Plasmodium and Cryptosporidium80-82. Given the apparent 
absence of specialized locomotive structures like cilia, flagella or 
pseudopods in Plasmodium sporozoites, crawling via gliding activity 
provides a mode of locomotion37 at rapid and variable speeds ranging from 
1–10 µm/s (Figure 1.7). This mode of locomotion underlies essential 
processes in the life cycle of Plasmodium sporozoites, such as extracellular 
motility, associated with crawling type movement via a substrate-
dependent locomotion on surfaces, as well as intracellular invasion.  
 
Figure 1.6 Three modes of Plasmodium locomotion. Sporozoites deposited into 
the skin by a female Anopheles mosquito exhibit flexing, turning, twisting motions 
and circular gliding, i.e. gliding motility. Plasmodium sporozoites can pass through 
cells in the skin and enter the bloodstream, reaching the liver and migrating 
through several hepatocytes before they invade the final one. This wounding 
movement through hepatocytes is defined as cell traversal and invasion of the last 
hepatocytes with formation of a parasitophorous vacuole occurs via invasion 
motility of Plasmodium sporozoites. Adapted from83. 
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Although, the main components in the core of the machinery regulating 
gliding motility are known, the exact mechanism by which gliding motility 
occurs is not fully understood. Gliding motility relies on the activity of an 
unconventional class of molecules referred to as “neckless” non-muscle 
myosin (type XIV). These are anchored to the inner membrane complex 
(IMC) of the pellicle via actin filaments. Pharmacological disruption of 
microfilaments via inhibition of actin polymerization, using cytochalasins 
or latrunculins, inhibits gliding motility and host cell invasion, arguing that 
Plasmodium motility requires actin filaments polymerization and 
depolymerization for infection84. Although gliding motility mechanisms are 
not fully identified, it is likely that the sheer force of 
polymerizing/depolymerizing actin filaments together with the surface 
molecules spanning the plasma membrane cluster activate a motor 
powered by actin-myosin interactions85. 
 
Figure 1.7 Gliding of sporozoites on a 
glass slide in the presence of albumin. 
CSP containing trails are deposited by 
sporozoites via on-going secretion from 
their trailing ends. Adapted from86.    
 
The very first step towards 
understanding the mechanisms 
underlying gliding motility steam 
from the observation by Dubremetz 
and Ferreira in 1978, who 
discovered that cationized ferritin 
binds the entire surface of Eimeria sporozoites and accumulates rapidly at 
the posterior pole87. Based on this basic observation, a model has been 
proposed for Plasmodium gliding motility, which relies on the ‘capping 
process’ of membrane components. During this process, capped 
transmembrane proteins are directed from the anterior to the posterior end 
of the parasite, by a subcortical actinomyosin complex. It is the backward 
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movement of this complex that allows the sporozoite to move forward80,88. 
Similar observation was done by C. A. King, who demonstrated that small 
latex beads are actively transported across the surface of Eimeria and 
Plasmodium sporozoites, accumulating at the posterior end from which they 
are shed80. Notably, despite scarce experimental evidence of King’s model 
regarding motor activity required for gliding motility and cell invasion, 
this model turned out to be essentially correct. In fact, Vanderberg’s group 
was not only able to confirm King’s model, but also start elucidating which 
Plasmodium surface membrane components are crucial for gliding motility. 
He reported that gliding motility relies on a backward redistribution of 
CSP89, in which CSP is secreted at the apical end of the parasite and then 
translocated towards the posterior end, along the sporozoites’ surface, by 
an actin-dependent and cytochalasin-sensitive process86. Thus, rearward 
movement of this complex drives the parasite forward, releasing surface 
proteins on the substrate, giving rise to the characteristic spiral trails 
visualized by CSP staining. The gliding activity can also be inhibited by 
incubation of sporozoites with anti-CSP monoclonal antibodies90. 
 
Hepatocytes invasion by Plasmodium sporozoites is achieved via a process 
involving cell traversal motility. This type of locomotion is defined as the 
migration of Plasmodium sporozoites and ookinetes through the plasma 
membrane of host cells without forming a PV. This is indispensable for 
Plasmodium to pass through host cellular barriers and reach a hepatocyte as 
to develop into the next invasive stage. CT activity was first described in 
vitro in 1990 by Vanderberg’s group91, which showed that Plasmodium 
sporozoites can repeatedly enter and exit host monocyte/Mø without being 
phagocytosed. Migration through host cells is not restricted to Mø and is 
associated with host cell membrane disruption, with the parasite moving 
into the cytoplasm and subsequently exiting from the host cells. 
Afterwards, Maria M. Mota and colleagues (2001) performed the first 
detailed cell-wounding assay to demonstrate that Plasmodium sporozoites 
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can traverse hepatocytes38, before it matures in the vicinity of the traversed 
hepatocytes, but never inside these injured cells. This observation suggests 
that sporozoites traverse several hepatocytes sequentially before settling in 
a final one38. CT motility is also essential for sporozoites to reach the blood 
circulation after being deposited in the dermis, thus facilitating access to 
the blood vessel wall, as demonstrated by Robert Menard and colleagues58. 
Finally, CT motility is also though to play an important role in avoiding 
sporozoite destruction by Mø as well as by non-professional phagocytes, 
such as dermal fibroblasts92 or hair follicles43.  
 
Invasion motility allows hepatocyte infection. Cell invasion begins with a 
process that involves tight contact between the apical tip of Plasmodium and 
the hepatocyte cell membrane. Parasite secretes microneme and rhoptry 
contents, which form junction-like structure, shaped as “bridges” between 
the host cell cytoskeleton. This allows the parasite motor system to anchor 
to the host cell93 forming a ring shape structure, which is associated with 
the movement of the parasite required to enter the host cell. Intracellular 
sporozoites form a PV in the hepatocytes cytoplasm connecting the vacuole 
membrane to the host plasma membrane. The cell membrane of the 
invaded hepatocyte is not wounded, allowing the parasite to develop into 
the EEF94,95. 
 
The mechanism switching CT to invasion motility remains unclear. During 
the cell invasion process, CSP, which has two conserved 5 amino acid 
sequence at N-terminus and a cell-adhesive motif repeats, called the type I 
thrombospondin repeat (TSR) at the C-terminus, is cleaved. Afterwards, 
the TSR domain is masked by the N-terminus at the skin stage and is 
unmasked thereafter in the liver stage96. This is associated with cell contact-
dependent sporozoite activation, turning off CT motility, which is 
important to avoid lysis of the PV membrane. Sporozoite microneme 
protein essential for cell traversal genes (SpectF and Spect2F) deficient 
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sporozoites that do not have CT activity, readily invade the host cells92. 
While high levels of sulphation of liver HSPGs are likely to contribute to 
mechanism switching CT to invasion motility55, cleavage of 
glycosaminoglycan chains from mouse hepatocytes does not affect 
sporozoite invasion in vitro97. Thus, the mechanism switching from CT to 
invasion requires further investigation to define all the players involved in 
this process.  
 
1.4 Glycans & Natural Antibodies 
1.4.1 The immune system at a glance 
All living organisms encounter thought their life cycle disease-causing 
agents and have developed protective mechanisms against those. This 
occurs even in single cell organisms such as bacteria, which have dedicated 
systems of protection against viral infections. These protective mechanisms 
became more complex and sophisticated as the complexity of organisms 
increases over evolution. Animals have evolved protective systems in 
which soluble molecules, cells and tissues have evolved to deal with 
infections, i.e. the immune system. 
  
Pathogenic microbes can gain systemic access into a potential host at 
different sites including at epithelial surfaces, e.g. skin, respiratory, 
gastrointestinal and the genitourinary tract, or via parenteral routes such as 
those associated with wounds occurring upon injection of pathogens by a 
vector98. The process of microbial invasion, i.e. infection, is countered by 
resistance mechanisms, mediated by the host immune which exert a 
negative impact on pathogens. These rely on specialized cellular and 
soluble molecules that avoid that microorganisms gain systemic access, 
expelling microorganisms at epithelial surfaces or eventually targeting 
microorganisms for destruction.  
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Initially, host can avoid contact with potential pathogens through a crude 
first line of defense called avoidance99. Upon detection of the potential 
pathogenic organisms in the environment, the putative host can trigger 
emotional and cognitive responses that prevent the contact with pathogens 
or with infected individuals99,100. This ancestral behavioral defense 
mechanism relies often on olfactory and gustatory systems, as well as 
visual signals for some species99. 
 
Pathogens that escape from host avoidance mechanisms encounter 
epithelial surfaces that are physical boundaries and protect the host from 
systemic access. These physical barriers have a significant role in slowing 
down or blocking pathogenic invasions and are composed of epithelial 
cells juxtaposed via tight junctions and forming mono or multilayer 
structures. These barriers have a significant role in slowing down or 
blocking pathogenic invasions. The physical barriers of the host are 
composed of epithelial cells, which form mono- or multilayer structures, 
via tight junctions. Epithelial barriers include the skin and mucosal 
membranes such as in the digestive, reproductive, respiratory and 
genitourinary tracts. In the skin, epithelial cells that are held together by 
tight junctions provide a seal against the invaders. There is also a complex 
population of normal skin flora, which can also exclude invaders101. 
Additionally, epithelial surfaces can produce microbicidal chemical 
substances such as lysozymes in tears and saliva that damage bacterial cell 
walls. The acidity of the stomach is another example, in which host 
chemical substances inhibit the growth of pathogens outside barrier tissues. 
Digestive enzymes in the gastrointestinal (GI) tract also create a substantial 
chemical barrier to infection102. Furthermore, resident bacterial flora in most 
epithelial surfaces including not only the skin but also the intestinal tract 
can also provide a protective layer of defense against potential invaders via 
mechanism that control many aspects of host immunity101. Moreover, the 
digestive, reproductive and respiratory tract, as well as sensory organs are 
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covered by mucous membranes that contain enzymes (lysozymes), 




Figure 1.8 Components of immune system. The innate and adaptive immunity are 
two inter-related defense systems103. Innate immunity provides a fast response, 
which relies on soluble molecules and cell types such as basophils, eosinophils, 
neutrophils, mast cells, Mø, dendritic cells and natural killer cells. The adaptive 
immune response provides a slower response but is highly specific and 
encompasses memory. It is mediated by soluble molecules, e.g. antibodies (Abs), as 
well B and T lymphocytes. Natural killer T cells and γδT cells are cytotoxic 
lymphocytes that straddle the interface of innate and adaptive immunity. Adapted 
from104. 
 
When pathogens cross epithelial barriers, they are confronted by the host 
immune system, composed of two inter-related sub-systems (Figure 1.8)103. 
The first, referred as the innate immune system, relies on resistance 
mechanisms activated via a restricted number of germ-line-encoded 
receptors, called pattern recognition receptors (PRR). These recognize 
structural components of pathogens called pathogen associated molecular 
patterns (PAMPs). Innate responses do not have memory, that is, they do 
not change the amplitude or relative strength of response upon re-exposure 
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to the same challenge, i.e. microorganisms, although this notion has been 
put into question more recently105. The second layer of the immune system, 
referred as the adaptive immune system, provides a more specific and 
robust defense mechanism activated via antigen receptors, which trigger 
clonal expansion of antigen-specific effector cells. Contrary to PRRs, 
antigen receptors can refine and increase their specificities and affinities 
towards antigens via a complex process involving gene recombination and 
allowing for affinity maturation102. These two lines of defense serve the 
same purpose - to recognize and eliminate or expel pathogens.  
 
As microorganisms breach epithelial barriers, they are sensed by a 
restricted number of PRRs106,107 that include Toll-like receptors (TLRs), 
soluble receptors (i.e. lipopolysaccharide binding protein and soluble CD14 
receptor, mannan binding lectin, C-reactive protein), scavenger receptors 
(i.e. macrophage scavenger receptor, dectin-1, mannose receptor), 
complement/Fc receptors and intracellular receptor (i.e. NOD-like receptor 
2, protein kinase R and oligoadenylate synthetases). It is estimated that the 
innate immune system can recognize about 103 PAMPs108. 
 
PRRs do not undergo affinity maturation via gene recombination, in clear 
distinction with antigen receptors of adaptive immunity. Engagement of 
PRRs on DCs, monocyte/Mø, polymorphonuclear (PMN) cells, e.g. 
neutrophils, eosinophils, as well as natural killer (NK) cells and 
lymphokine-activated killer cells, triggers innate resistance mechanisms 
that expel or destroy pathogens109. Innate resistance mechanisms include 
microbial opsonization and production of intracellular anti-microbial 
molecules110 as well as granuloma formation103. Other key component of 
innate immunity are soluble anti-microbial peptides111, including defensins 
as well as the complement system that trigger the lysis of microbial cell 
membranes via a proteolytic cascade that forms membrane pores while 
promoting the effector function of innate and adaptive immune cells112,113. 
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In addition, innate immune cells express intracellular enzymes such as 
lysozyme that initiate the digestion of bacterial cell walls. Production of 
free radicals via the NADPH oxidase (NOX) family of reactive oxygen 
species (ROS) generating enzymes is another common resistance 
mechanism used by innate immune cells. This cytotoxic mechanisms can be 
further enhanced by PRR-driven nitric oxidase production, which occurs 
via the induction of the inducible form of nitric oxide synthase 
(iNOS/NOS2) as well as by mechanisms regulation intracellular iron 
metabolism, which impact on the production of free radicals114,115. PRR are 
also expressed on cells of epithelial barriers where they trigger the 
production of anti-microbial defense mechanisms while maintaining the 
functional integrity of tight junctions underlying barrier function integrity. 
 
The inflammatory response triggered by soluble and cellular components 
of the innate immune system must be tightly regulated so that it targets 
microorganisms as soon as these gain systemic access. One of the 
constraints is that soluble and cellular components of innate immunity 
must migrate towards the exact site of infection109. This occurs via the 
expression of a variety of so-called pro-inflammatory genes encoding 
cytokines as well as other small proteins involved in cell-cell 
communication such as chemokines116. This immediate response 
encompasses local increase of microvascular permeability, increased 
expression of adhesion molecules by microvascular endothelial cells, which 
promote leukocytes recruitment at the site of infection. The adhesive and 
chemotactic gradient generated towards the site of infection recruits 
phagocytic cells, i.e. Mø and PMN cells that uptake and destroy 
extracellular pathogens. Cytokines and chemokines also alert other 
components of the adaptive immune system for the occurrence of infection.  
 
Pathogens can evolve strategies to evade resistance mechanisms, such as 
the infection of central cellular components of innate immunity including 
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Mø or PMN cells. These intracellular pathogens can be sensed by cytosolic 
PRRs, expressed in Mø and other innate immune cells such as PMN cells. 
PRR signaling is critical to trigger cell-autonomous immunity underlying 
host resistance to such intracellular pathogens. These intracellular PRRs 
include Nod-like receptors family members governing transcriptional 
responses (NOD1 and NOD2) and the activation of inflammasomes 
(NLRP3, NLRC4, NAIP, NLRP6 and NLRP12) among others. The 
activation of cytosolic PRRs triggers that cell-autonomous immune 
response that cell-autonomous immune response restricts intracellular 
pathogen replication and promotes pathogen clearance. This is assisted by 
non-cell autonomous responses involving NK cells activated in response to 
proinflammatory cytokine i.e. IFN-γ and macrophage-derived cytokines to 
promote cytolytic and proinflammatory mechanisms102,108. Activated NK 
cells release cytotoxic granules such as perforin that forms a pore on 
cytosolic membranes and proteases known as granzymes resulting in 
programmed cell death of infected cells. 
 
When pathogens are not eliminated via innate immune defense 
mechanisms, they can still be detected and eliminated by resistance 
mechanisms mediated by adaptive immunity, encompassing so called 
immunological memory that allows rapid and swift responses upon re-
infection102,117. This second layer of the immune system evolved 
approximately 500 million years ago in early vertebrates118 and affords a 
more robust and specific defense mechanism that neutralizes and thereafter 
removes pathogens. Adaptive immunity is based on antigen recognition, 
that is, the recognition of proteins or macromolecules that elicit an immune 
response. This occurs via antigen receptors expressed on B cells and/or T 
cells, known as B cell receptors (BCRs) and T cell receptor (TCRs), 
respectively. Upon recognition, antigens can elicit an immune response in 
which B and/or T cells are activated. In contrast to PRRs that can recognize 
a fixed structural motif and do not undergo rearrangement, B cell and T cell 
! 48!
receptors are generated through random somatic chromosomal 
rearrangements and can bind a huge variety of antigens. However, PRRs 
play an important role in shaping adaptive immunity since the capacity of 
a given antigen to elicit an immune response relies strictly on antigen 
presentation by called innate antigen presenting cells that are activated via 
the engagement of PRR, upon the recognition of PAMPs103,119 (Figure 1.9). 
This is achieved essentially, but not exclusively, by DCs as well as Mø. 
They sample the environment for the presence of pathogens and recognize, 
engulf and digest antigenic peptides expressed by those pathogens. These 
are subsequently loaded into newly synthesized major histocompatibility 
complex (MHC) molecules to be presented to T cells. The engagement of 
PRRs on DCs and other antigen presenting cells is essential to induce the 
activation of a genetic program underlying the activation of antigen 
presenting cell (APC). This process is required so that APC become 
immunogenic, that is, are capable of triggering an immune response 
against specific antigens expressed by pathogens and loaded into the MHC 
class I and II molecules. This process that links innate and adaptive 
immunity allows for an integrated response of the host immune system, 
which provides protection against infection119. 
 
Figure 1.9 Interaction between innate immunity and adaptive immunity. Innate 
immune components and genetic factors focus the specific adaptive immune 
response against antigenic targets.  
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There are two main components of the adaptive immune system. One 
drives cellular immune response mediated by T cells and the other 
humoral immune response mediated by soluble antibodies (Abs) produced 
by B cells (Figure 1.9). Major determinants of adaptive immune activation 
are dependent on whether the pathogen resides on cytosol, intracellular 
endosomes or extracellular environment102. Main components of cell-
mediated immune system include cytotoxic T cells (CD8+) that recognize 
antigens expressed by intracellular pathogens loaded into MHC class I. T 
helper cells (CD4+) recognize antigens expressed by extracellular pathogens, 
loaded into MHC class II molecules. When sensed by specialized tissue 
resident APCs, pathogens are taken up and digested by the phagolysosome 
system102. This process achieves the destruction of microbial organisms 
while processing and loading antigens onto MHC class I or II molecules.  
Activated, tissue resident APC migrate to secondary lymphoid organism, 
such as lymph nodes and the spleen, in which they interact with antigen-
specific naive T cells102. Antigen recognition in the context of MHC class I 
and II by TCR is essential for T cell activation and differentiation into 
specific effector functions.  
 
Peptide structures derived from extracellular bacteria and toxins are 
presented to CD4+ T cells via MHC class II molecules and can trigger the 
differentiation of naïve TH cells into different effector functions that include 
TH1 and TH2 cells. TH1 cells produce the cytokine IFN-γ whereas IL-4, IL-5 
and IL-10 are the signature cytokines of TH2. There is also a tight 
relationship between the TH cell activation and T cell dependent Ab 
responses by B cells. Activation of TH cells by DCs as well as by B cells, 
towards specific effector functions, such as TH1 or TH2, can drive the 
production of different classes of Abs via cytokine dependent mechanisms 
regulating Ab class-switch recombination. The key transcription factors in 
TH1 differentiation are signal transducer and activator of transcription 4 
(STAT4) and transcription factor T-bet. TH1 cells are effective against 
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intracellular bacteria infections as well as protozoan infections via a 
mechanism involving the secretion of IL-2, IL-12 and IFN-γ. TH1 cells 
induce microbicidal activities of phagocytes and via help of IFN-γ 
stimulation, opsonizing and complement-fixing IgG Abs, which promote 
the phagocytosis of infectious agents102,120. Moreover, IFN-γ induces the 
production of NO, H2O2 and superoxide, thus contributing to pathogen 
clearance. The key transcription factors in TH2 differentiation are trans-
acting T-cell-specific transcription factor GATA-3 and signal transducer 
and activator of transcription 6 (STAT6). TH2 cells are effective against 
extracellular parasites and allergens upon triggering IL-4 and IL-5. TH2 cells 
promote IgE- and eosinophil/mast cell mediated immune activity and also 
activate naïve B cells to secrete IgM and other neutralizing isotype Abs 
afterwards102,120. Although TH2 cells are related with helminth infections, the 
roles of IL-4 and IL-5 in protective immunity remain unclear. The third 
subset of CD4+ T cells is TH17 cells that are protective against extracellular 
bacterial and fungal infection. These secrete IL-17 and IL-22 and are distinct 
from other TH cells in their gene expression/regulation profile and also as it 
relates to their biological functions. Orphan nuclear receptor RORγt and 
STAT3 are the key transcription factors in TH17 cells differentiation. The 
main role of this T cell subset is to provide anti-microbial immunity at 
epithelial/mucosal barriers. However, TH17 can promote inflammation and 
tissue injury in autoimmune disease (i.e. multiple sclerosis)102,120. 
 
Microbial peptide digested from intracellular pathogens are presented to 
naïve CD8+ T cells upon loading into MHC class I molecules. When naïve 
CD8+ T cells are activated they differentiated into functional cytotoxic T 
cells (CTLs) that deliver cytotoxic proteins (i.e. granzymes, perforin and 
serglycin) that kill infected target cells. These cells can decide whether host 
cell is infected or not, signal for self-destruction in which pathogen, namely 
virus, can be eliminated during the process before pathogen has a chance to 
replicate again. In some cases, they signal for the activation of Mø to 
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destroy phagocytosed microbes or secrete cytokines to attract immune cells 
to the site of the infection102. 
 
Memory T cells are derived from CD4+ or CD8+ and persist for years, even a 
lifetime. Upon re-exposure to the pathogen, memory T cells can mount a 
faster and stronger immune response, as compared to the first infection. 
Memory T cells are further divided into two subsets, namely, central 
memory T cells (home to lymph node and function against antigen by 
proliferation and generation of effector cells) and effector memory T cells 
(home to mucosal sites and function against antigen by secreting the 
cytokines). As pathogens are eliminated, effector cells undergo apoptosis, 
while memory cells persist in the circulation by the action of cytokines such 
as IL-7 and IL-15 without the requirement of peptide antigen or MHC 
engagement for homeostatic proliferation. 
 
In contrast to cell-mediated immune system, humoral responses of the 
adaptive immune system are driven by B cells, which develop from 
progenitors in the bone marrow. The BCR is made of immunoglobulins 
(Ig)s. These are referred to as Abs because they can recognize antigens 
through their variable region, recognizing up to 1012 specific epitopes, that 
is, the molecular pattern recognized by an Ab on an antigen102,121. Primary B 
cell responses are generated upon engagement of the BCR and clonal 
expansion and differentiation of naïve B cells that give rise to short-lived 
plasma cells, which produce Abs. A fraction of B cells migrate to the B-cell 
follicle, seed a germinal center, and can persist as dormant memory cells 
that survive in the body for a long term and are called memory B cells122. 
Memory B cells can respond faster and more effectively against re-
infection123. They can produce Abs with higher affinities than primary 
immune response Abs102 124. Re-infection with the same pathogen will 
trigger the response of memory B cell clones to increase generation a 
polyclonal response. Therefore, higher titers of more diverse Ab molecules 
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towards an antigen are produced in the secondary immune response. 
Memory B cells produce soluble high affinity Abs125. 
 
B cell activation occurs through engagement of the BCR in peripheral 
mature B cells, mostly in lymphoid organs as well as in the spleen. This can 
occur with or without subsequent interaction of B cells with TH cells 
recognizing antigenic peptides loaded in the MHC class II of activated B 
cells. Once activated, B cells proliferate extensively and differentiate into 
memory B cells or Ab-secreting cells. 
 
Several genetic mechanisms evolved in vertebrates to generate the 
enormous diversity of the BCR and the soluble Ab-secreting cells. These are 
also relevant to the generation of TCR diversity. These mechanisms include 
somatic recombination, also known as V(D)J recombination. Briefly, in the 
case of the BCR the heavy chain of the Ig variable region contains variable 
(V), joining (J) segment and an additional diversity (D) segment region in 
the light chain. Immature B cells in the bone marrow express surface Ig 
encoded by a combination of one V, D and J gene segment (plus one V and 
J segment for the light chain) as generated through random DNA 
recombination. Approximately, 109 distinct Ab molecules can be generated 
via V(D)J recombination, thus contributing significantly to Ab diversity. 
This is further enhanced by somatic hypermutation, an antigen dependent-
mechanism involving the enzyme activation-induced deaminase (AID) and 
driven by deamination of cytosine to uracil in the variable region of the 
BCR126. Upon activation B cells can undergo a process of BCR affinity 
maturation in which AID driven mutation/repair modifies one nucleotide 
in the Ig V segment per cell division, resulting in increase affinity of BCR 
for cognate antigen recognition in germinal centers of secondary lymphoid 
organs126, i.e. spleen, lymph nodes and Payer’s patches. This process is 
assisted by cognate interactions with TH cells as well as follicular DCs. 
Somatic hypermutation and clonal selection are the processes underlying 
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affinity maturation of the BCR in which somatic hypermutation generates a 
spectrum of BCR affinities and clonal selection eliminates B cells carrying 
BCR with lower affinities while rescuing those carrying BCR with the 
highest affinities. This process also insures through the generation of 
memory B cells, which provide a rapid and high affinity Ab response, 
contributing to host resistance to re-infection with the same pathogen 
expressing similar Ags102,121.  
 
Table 1.1 Ig classes and their functions Adapted from127. 
 
 
B cells also undergo Ig class switch, a process assisted by TH cells in 
primary foci as well as in the germinal centers, which consists in switching 
the production of Abs from IgM (µ) to other Ig classes. This occurs DNA 
rearrangements in the gene segments encoding different Ig heavy chains 
and defining different isotypes, namely IgM (µ), IgD (δ), IgA (α), IgE (ε) and 
IgG (γ). These differ in size, charge, and determine to a large extent the 
effector functions of different classes of Abs (Table 1.1). During the early 
stages of B cell development, immature B cell expresses intracellular µ 
heavy chains that are expressed at the cell surface combined with one κ or λ 
light chain. Primary B cell responses are often characterized by the 
production of secreted IgM without class switching. Activated TH cells can 
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engage several con-stimulatory molecules in activated B cells, e.g. CD40 via 
the CD40 ligand (CD40L) expressed on activated T cells, which favor class 
switch128. There are also subclasses of IgA, e.g. IgAl, IgA2 and IgG, e.g. IgGl, 
IgG2, IgG3, and IgG4 in humans and IgGl, IgG2a, IgG2b, IgG2c and IgG3 in 
mice. Different Ig isotypes (classes) and subclasses have different effector 
functions in host defense108 driven by the binding of heavy chain C regions 
to complement and/or Fc receptors expressed on different immune cells102 
(Table 1.1). 
 
The effector function of Ab relies often on their cognate interaction with 
different Fc receptors (FcRs) on the surface of immune cells including B 
cells, follicular DCs, NK cells, Mø, neutrophils, eosinophils, basophils and 
mast cells, providing an essential link between humoral and cellular 
immunity. In general, Fc receptors can activate different responses such 
endocytosis, phagocytosis, transcytosis, exocytosis, superoxide generation, 
Ab-dependent cell-mediated cytotoxicity (ADCC) and cytokine release. 
FcRs can interact with all Ig classes and the name of each Fc receptor is 
derived from its binding to a specific class of Ig. IgA/IgM receptor 
(FcµR)129,130 is a high affinity receptor expressed mainly on lymphoid cells, 
including B and T cells, enhancing B-cell survival following BCR cross-
linking. When expressed on T cells FcµR can interact with the IgM BCR or 
with soluble IgM/antigen complexes as to facilitate T and B cell 
interactions and enhance B cell activation and IgM production. Moreover, 
FcµR might also activate cytotoxic T cells in IgM ADCC. There are at least 
four types of IgG receptor (Fcγ )131. The FcγRI/CD64 is a high-affinity IgG 
receptor expressed on Mø and neutrophils that promotes phagocytosis. The 
FcγRII/CD32 is a low-affinity IgG receptor also expressed on Mø and 
neutrophils that enhances phagocytosis and inhibits B cell activation. The 
FcγRIII/CD16 is a low affinity IgG receptor expressed on NK cells, 
neutrophils and monocytes and involved in ADCC. The FcRn is a variable 
! 55!
affinity receptor for IgG expressed in placenta and promoting IgG mother 
to fetus transcytosis. Different FcγR are also important for endocytosis of 
soluble proteins. There are two types of Fcε  receptors127 (IgE receptor). The 
FcεRI is a high affinity IgE receptor expressed on Langerhans cells, 
eosinophils, mast cells and basophils and involved in the control of allergic 
responses, triggering cellular degranulation involved in immunity to 
parasites such as worms, e.g. S. mansoni, T. spiralis, F. hepatica102. The 
FcεRII/CD23 is a low affinity IgE receptor expressed on B cells, 
eosinophils, Langerhans cells and involved in IgE transport across the 
intestinal epithelium while also enhancing allergic sensitization and 
expulsion of large sized pathogens. There are at least two Fcα  receptor132 
(IgA receptor). The FcRα/CD89 is a low affinity IgA receptor expressed on 
eosinophils, monocytes/Mø , neutrophils, interstitial DCs and Kupffer cells 
and promoting phagocytosis, superoxide generation, release of 
inflammatory mediators and eventually ADCC. FcRα expression is critical 
to prevent pathogen attachment and invasion of epithelial cells. The 
Fcα/µR is the other IgA receptor expressed on B cells, mesangial cells, Mø 
and promoting endocytosis.  
 
Mice have FcγRI, FcγRIIB, FcγRIII and FcγRIV which are conserved between 
different mammals, however in humans, have FcγRI gene family (which 
includes Fcgria, Fcgrib and Fcgric) and a FcγRII gene family (which includes 
Fcgriia and Fcgriic) and several allelic FcγR variants131. There are similarities 
and differences between mouse and human FcR. Based on genomic 
localization and sequence similarities, mouse FcγRIV is the orthologue of 
human FcγRIIIA, and mouse FcγRIII is most closely related to human 
FcγRIIA131. Moreover, both species have two classes of FcRs, which can be 
distinguished functionally as activating and inhibitory receptors. However, 
the intracellular domains such as human FcγRIIA contain immunoreceptor 
tyrosine-based activation motif (ITAM) is not found in mouse FcγRIII131 or 
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the affinity of the mouse FcγRs for the different IgG subclasses is higher 
than human FcγRs. Moreover, mice do not have FcαRI/CD89 and 
presumably have alternative receptors, such as Fcα/µR133. 
 
Interactions of different Ig classes and subclasses with specific Fc receptors 
in different cells types can trigger different effector mechanisms such as 
phagocytosis, degranulation and cytokine releases that promote the 
destruction of pathogens102. However, some viruses such as flaviviruses can 
use Fc receptors of cells to infect them via a mechanism called Ab-
dependent enhancement of infection. 
 
Figure 1.10 Ab effector functions. Abs exist as membrane-bound BCR expressed 
on B cell surface or are secreted in large quantities. Abs can neutralize toxins and 
viruses, activate the complement system and act as direct antimicrobial agent 
independently of other components of the host immune system. However, Ab-
dependent cellular cytotoxicity and opsonization depend on the expression of Fc 
receptors on other host cells such as T cells and Mø. Individual roles of each Ab are 
summarized in Table 1.1 for humans and depicted in here. Adapted from134. 
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Abs act in different ways to confer host protection against pathogens 
(Figure 1.10). Briefly, membrane-bound Abs act as BCR whereas secreted 
forms neutralize or mark pathogens for the elimination by other effector 
mechanisms by effector cells since Abs alone are not able to kill the 
pathogens. Abs can block the binding of microbes and toxins to cellular 
receptors in host, a mechanism defined as neutralization effect of Abs. IgM 
and IgA Abs are particularly good at this. For instance, envelope 
hemagglutinin of influenza virus or pili of bacteria that help to attach and 
infect host cells can be neutralized by Abs108. IgG Abs can help to opsonize 
microbes by innate immune cells such as Mø, PMN, mast cells or NK cells 
and promote phagocytosis108, via a mechanism involving the expression of 
different Fc receptors in the effector cells108. The phagocytosis is facilitated 
upon binding of Fab portion of the Ab to an antigen and Fc portion of the 
Ab to an Fc receptor on the phagocyte. In this process, an antigen becomes 
coated with primarily IgG Abs to be engulfed later108. Moreover, Abs can 
activate the classical pathway of complement and generate C3b attaches to 
microbial cell surfaces making pathogens susceptible to Mø and 
neutrophils phagocytosis via a mechanism involving the expression of iC3b 
receptor, which are very efficient in promoting phagocytosis. Byproducts of 
complement activation such as C3b and C4b are deposited on the surface of 
the pathogens and contribute to the destruction of pathogen via 
complement system. Pathogen opsonization by soluble Abs can also trigger 
ADCC via IgG and sometimes IgE, whereby an effector cell actively lyses a 
target cell. This process can lead an inflammation to surrounding tissues 
and cause damage to healthy cells. Furthermore, IgM also mediates 
agglutination reactions in which Abs cause cells to clump together. The 
Abs bind multiple particles and join them to create a large complex that is 
attacked and engulfed later by other cells such as Mø for destruction. Lastly, 
Abs can activate complement system to promote bacterial lysis/accelerated 
phagocytic uptake upon Ab binding onto an antigen (discussed in Chapter 
5). 
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1.4.2 Natural Abs 
In 1900, Landsteiner and colleagues demonstrated that humans that were 
not immunized specifically against a given antigen had circulating Abs 
reacting against that specific antigen, as illustrated for blood group 
antigens135. Later on, in 1955, Niels Jerne postulated that the immune 
system generates natural Abs (NAbs) that can recognize antigen without 
prior immunization and revived the NAbs concept by introducing “natural 
selection” theory of Ab formation136. In this context, NAbs were defined as 
those Abs present in the circulation of physiologically healthy individuals 
without traceable immunization against the antigen recognized137,138. These 
are in most cases multi-reactive and low affinity IgM Abs, as detected in 
the circulation of healthy vertebrates, including chickens, rabbits, mice, rats, 
and humans. Growing body of experimental evidence also suggests that 
NAb are produced to a large extent via exposure, i.e. immunization, to 
components of the microbiota. This notion is supported by the observation 
that gut microbiota colonization triggers the development of CD5+ B-1 
lymphocytes, responsible for NAb secretion139. However, germ-free (GF) 
mice that lack microbiota can produce IgM NAbs even when fed with a 
diet free of foreign antigens. This suggests that other factors are involved in 
the clonal selection and development of B-1 cells producing polyreactive 
IgM Abs140. This process can be influenced by microbiota, as illustrated by 
the observation that GF mice mono-colonized with either Morganella 
morganii or segmented filamentous bacteria, produce B1-derived IgM NAbs 
and subsequently stimulates B2 cells to produce IgM NAbs141. This suggests 
that host response to gut flora components can contribute to the production 
of NAbs139,142. These NAbs also display broad reactivity towards a variety 
of self-antigens recognized with low affinity but high avidity3. 
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Figure 1.11 Role of NAbs in infection. Upon an infection, NAbs contribute to the 
to initial recognition and elimination of pathogens. With time, affinity-matured, 
somatically selected Abs are generated and potent adaptive defense mechanism 
against pathogen is enhanced. Adapted from137. 
 
NAbs are thought to provide an efficient first-line of defense against 
pathogens, thus preventing the initial spread of pathogens into vital 
organs143. The physiological roles of NAbs can ascribed to three 
categories137. The first is protection against infectious agents, serving as a 
supplementary or alternative host recognition and defense mechanism, 
preventing the initial spread of pathogens into vital organs143 (Figure 1.11). 
Second, NAbs provide homeostatic balance as supported by indirect 
evidence suggesting that NAbs can present self-antigens and tolerize T 
cells hence minimizing auto-reactive T cell driven pathology. Since NAbs 
are present at high titers in the circulation, they can bind and present self- 
antigens to naïve T cells, possibly without activating co-stimulatory 
molecules required to support T cell activation and proliferation144. In 
addition, NAbs can interact with the inhibitor receptor FcγRIIb to regulate 
B-cell activation/functions. Moreover, NAbs can also contribute to the 
clearance of apoptotic and altered cells through complement-dependent 
mechanisms, inhibiting inflammation and immunogenicity against self 
antigens145. Another possible effect of NAbs is that these might also play a 
pathologic role in that polyreactivity can act directly or indirectly in a 
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pathogenic manner when recognizing self-antigens. For instance, during 
hepatitis C virus infection, IgM NAbs react with the virus specific Abs and 
form pathogenic Ab complexes resulting in systemic vasculitis146,147. 
 
NAbs are produced mainly by a population of long living B1 cells (CD5+ in 
mice and CD20+CD27+CD43+ CD70− in humans) comprising 20-35% of total 
B-cells population148. In general, NAbs can be categorized as “conservative” 
(same in all healthy donors), “allo-Abs” (specific to blood group antigens) 
and “plastic Abs” (concentration of these Abs changes during diseases and 
some temporary conditions)148. A wide variety of NAbs, which are not only 
conservative within a species, but also between species, are directed to 
glycans148. In humans, relatively high levels of circulating poly-specific 
NAbs recognize glycans expressed by microorganisms, including 
pathogens149.  
 
1.4.3 The α-gal glycan as a target of NAbs 
1.4.3.1 Glycans 
Glycans consist of 2–20 monosaccharide residues linked via glycosidic 
bonds150 and  in generic terms, glycans refer to any sugar, an array of 
covalently attached sugars (monosaccharides) or sugar chains 
(oligosaccharides), in a free form or an attached to another molecules. 
Glycans coat all cellular organisms151 and are found on the outer surfaces of 
cellular and secreted macromolecules in multicellular organisms. They 
contribute to several fundamental biologic activities including cell/cell 
recognition and many physiologic mechanisms, i.e., sperm/egg 
interactions as well as host-pathogen interactions and their associated 
pathophysiologic outcomes150. Glycans have surprisingly diverse 
structures, biochemical and regulatory properties and hence, 
characterization of their biologic functions created a new scientific field, i.e. 
glycobiology, in which traditional disciplines of carbohydrate chemistry 
and biochemistry came together to provide understanding of biology of 
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glycans152. During last 10–15 years, important advances have been made in 
terms of our understanding of glycan structures with separation and 
isolation of individual structures probing their functional properties within 
glycoconjugates.  
 
Glycans4 can be conjugated to biological molecules through an enzymatic 
process termed glycosylation. When conjugated to lipids or proteins, they 
give rise to glycolipids and glycoproteins, respectively. When heavily 
glycosylated, glycoproteins are referred to as proteoglycans. These are the 
most abundant glycoconjugates in mammals, being expressed 
predominantly on outer cell walls and secreted fluids153,154. 
Glycosyltransferases utilize specific sugar nucleotide as donor substrates154 
and catalyze a site-specific modification to generate N-linked glycans in the 
ER, or O-linked glycans in the Golgi as well as O-GlcNAc modifications in 
the cytoplasm or nucleus150. 
 
Cell–specific glycan expression patterns are generated via regulated 
expression of specific enzymes that generate glycans, i.e. include 
glycosyltransferases, glycosylhydrolases as well as enzymes that degrade 
glycans, such as glycosidases, exoglycosidases or endoglycosidases. These 
are encoded by up to 2% of the mammalian genome, arguing further for 
the biologic importance of these processes150,156. In keeping with this notion 
specific deletion of genes encoding glycosyltransferases is often lethal in 
mice, arguing that the expression of the corresponding glycans is critical 
for the survival, often at a early stage of development in mice157. 
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4!Any form of mono-, oligo-, or polysaccharides that are either free or covalently attached to 
another molecules. We used glycan and saccharides interchangeably.!
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Figure 1.12 Glycan families. The common glycans expressed by eukaryotic cells 
are categorized according to their linkage to protein or lipid. Glycans serve 
important functions in the cells such as proper protein folding, protein stability 
and cell-cell adhesion. Adapted from150,155. 
 
Glycans abundantly expressed by eukaryotic cells fall into 5 classes (Figure 
1.12)150. (1) Glycans that are either N-linked (nitrogen atom) or O-linked 
(oxygen atom) to proteins. N-linked glycans are covalently bound to an 
asparagine residue in a polypeptide chain. This occurs via a N-glycosidic 
bond, involving N-acetyl-D-glucosamine (GlcNAc) and the Asn-X-Ser/Thr 
peptide sequence. Until now, N-linked glycan attached to secreted proteins 
are the best described. N-linked glycans are generated by 
glycosyltransferases and glycosidases in the Golgi apparatus and provide 
structural components of extracellular matrix and cell wall, increasing 
protein stability and solubility, maintaining growth factor and cytokine 
receptors at the cell surfaces, as well as regulating protein trafficking and 
cell-cell interactions158. In contrast to N-glycans, O-linked glycans are 
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attached via a N-acetylgalactosamine (GalNAc) to the hydroxyl group of 
Ser or Thr in the polypeptide chain of glycoproteins, as found in mucin-
type glycans. O-linked glycans are important in processes supporting gut 
colonization by microbiota, via bacteria binding specific mucins. Other 
biological functions involving O-linked glycans include cellular signaling 
(i.e. insulin signaling and RNA transcription regulation), sperm reception 
by eggs, hematopoiesis and inflammatory response mechanisms150. 
Generation of O-linked glycans is controlled by glycosyltransferases 
analogous to the ones generating N-linked glycans, but their organization 
is slightly different. (2) O-linked GlcNAc glycans are abundant within 
glycoproteins expressed in the nucleus and cytoplasm but they can be 
found in almost all cellular compartments. O-GlcNAcylated proteins are 
linked to O-linked GlcNAc glycans via Ser or Thr through a reaction 
catalyzed by O-N-acetyl-D-glucosaminetransferase. O-linked GlcNAc 
glycans have several important functions that include regulation of 
transcription and translation, protein trafficking, capping phosphorylation 
sites as well as in stress responses associated with increased glycosylation150. 
(3) Proteoglycans (heparan sulphate and chondroitin sulphate) have core 
proteins covalently attached to one or more glycosaminoglycan (GAG) 
chains that are linear polysaccharides composed of amino sugar, uronic 
acid and galactose155. Attachment of the glycans occurs via a xylose residue 
linked to the hydroxyl group of a serine residue150. Proteoglycans are 
produced and secreted into the extracellular matrix in all mammals, but 
can also be integrated in the plasma membrane or made available in 
secretory granules159. They are critical in maintaining tissue structure, 
porosity, and integrity as well as in defining cell specification during 
development and epithelial cell migration, proliferation, and 
differentiation150. (4) Glycophosphatidylinositol (GPI)-anchored glycoprotein 
bridges the phosphatidylinositol and a phosphoethanolamine at the 
carboxyl terminus of a protein160. GPI anchors show some level of diversity 
depending on the organism and proteins involved. Occasionally, GPI 
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anchors can also be found in protein free form in mammalian cell surfaces, 
but their functions are unknown. GPI anchors support essential physiologic 
processes such as membrane protein transportation, cell adhesion, cell wall 
synthesis or cell surface protection160. (5) Glycosphingolipid glycoconjugates 
can be neutral or anionic. They can have glucose or galactose glycan 
attached to terminal primary hydroxyl group of a lipid and can be neutral 
or anionic. These glycans are found in all cell membranes and are the main 
glycans (80% of glycoconjugates) in vertebrates150. Their physiological 
functions include the regulation of cell–cell interactions, signal 
transduction, protein activity, etc. 
 
Broadly, glycans have direct effects on the regulation of cytosolic/nuclear 
functions, immune surveillance, auto-immunity, inflammation, hormone 
action and tumor progression150,155. 
 
1.4.3.2 Evolution of glycans 
There are some shared and unique features in glycan structures across 
different kingdoms and taxa. N- and O-linked glycans are more complex in 
recently evolved taxa and present high level of variation intra and 
interspecies150,154. Presumably, glycans with unique structures generated by 
corresponding glycosyltransferases or other glycan-modifying enzymes 
have more specific biological roles. Genes encoding glycosyltransferases or 
other glycan-modifying enzymes are under natural selective pressure and 
as such the corresponding glycans generated by these enzymes can evolve 
rapidly. One of the reasons for this appears to be the involvement of glycan 
in the establishment of host-microbe interaction at different levels. As such 
modification of glycan structures impacts a major driving force in 
evolution154.  
Like many biological molecules, glycans are prone to undergo rapid 
evolutionary changes due to several selective pressure processes. 
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Divergence of evolutionary lineages is one of the reasons existing glycan 
evolution. Independent mutations on genes responsible glycan synthesis 
and modification shaped the glycan repertoires of different lineages161. For 
instance, the existence of cellulose in plants but not in metazoan is a result 
of divergence. Moreover, due to the divergence, different glycans can be 
recruited over loss one. In contrast, convergence is the opposite process to 
generate diversity161. This can occurs in distantly related lineages gain 
similar subclasses of glycan repertoires. For example, Lewis A antigen in 
catarrhines and plants can be the existence of convergence mechanism. Co-
evolutionary process is the other selective mechanism in glycan evolution 
where organisms from different lineages are constantly in interactions that 
affect their mutual glycome evolution161. Glycans such as sialic acids and 
glycosaminoglycans found in multicellular hosts and their pathogens are 
one of the examples to this class of glycan evolution. Lastly, natural 
selection is one of the most important processes affecting the glycan 
evolution161. This mechanism can maintain the particular glycan or reduce 
the survival of organisms expressing a certain glycan. Disruption of N-
glycans that have lethal consequences to all eukaryotes or negative 
selection of specific glycans could occur when a glycan is exploited by 
highly virulent pathogens. Therefore, there are several major contributors 
for the functionally inactivation of enzymes responsible in the production 
of specific glycan. However, negative selection occurring through natural 
selective pressure is importantly effective in dealing with host-microbe 
interaction. These types of interactions are probably major driving forces in 
the rapid evolution of glycans since many pathogens use glycan-glycan 
interactions as primary or secondary targets to recognize and invade host 
cells. Depending on the pathogen virulence, mutations in the host genome 
that reduce the expression of these glycans should reduce pathogenicity 
and as such may be naturally selected so that the host can evade infection154.  
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Figure 1.13 Red Queen Effect on glycan alteration. An infected host must 
constantly escape the negative impact imposed by pathogens, which is achieved in 
some case by altering its glycan composition. This can occur via natural selection of 
mutations that have a direct impact on the function of genes encoding enzymes 
that catalyze the generation of specific glycans. Examples include genes encoding 
enzymes responsible for the production of soluble glycans such as mucin that act 
as decoy to keep pathogen away from epithelial cell surfaces or can recognize 
pathogen glycan as non-self. However, pathogen can also adjust their glycan 
profiles, via natural selection of genes encoding glycans, interfering with these host 
defense mechanisms. This type of interaction between host and pathogen exert the 
red queen effect in which host constantly tries to escape from the pathogen that 
evolve rapidly. Adapted from162.  
 
On the other hand, microbes can evolve a thousand fold faster that their 
mammalian hosts leading to a “harms race” in which the pathogen is likely 
to win154. Therefore, “Red Queen Effects” drive the changes of glycans on 
complex multicellular organisms, in which multicellular organisms evolve 
rapidly to survive against pathogens that can replicate and evolve faster 
(Figure 1.13). Evolutionary forces potentially and simultaneously generate 
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the diversification of glycan expression in organisms. Therefore, negative 
natural selection on glycan has an active role to limit the pathogen 
interaction with host and consequently, possible infection. For instance, 
sudden elimination of a glycan in an entire evolutionary lineage such as α-
gal led the production anti-α-gal Abs163 that are effective against the 
enveloped viruses that can infect New World monkeys but not Old World 
monkey (α-gal glycan and anti-α-gal Abs will be discussed later in this 
chapter). It is also known that many infectious organisms such as parasites 
and microbes have gained numerous specialized glycans to be effective on 
host cells under the evolutionary selective pressure. 
 
Glycosylation processes generate much of the glycan density, complexity, 
and diversity on cell surfaces. Considering changes occurring in glycans 
structures found cellular surfaces, expression patterns of glycans may show 
a compromise between an evading pathogen and its host. Host can show 
an effort to preserve the specific glycans as much as possible due to their 
important intrinsic functions for the host i.e., serving as an attractive 
molecule for the essential symbionts in GI tract150. However, pathogens also 
try to adapt to the changes in the host organism via generation their own 
glycan structures. Likewise, there are still some common terminal glycan 
structures on different core glycans that are preserved among some species 
by regulated glycosylation. Nevertheless, there are many important 
questions about glycan evolution and functions that remain to be answered.  
 
1.4.3.3 Glycan patterns in protozoan parasites  
Protozoan parasites express O-linked and N-linked glycans with unique 
moieties on several glycoproteins as well as uncommon glycolipid 
structures and polysaccharides (Table 1.1). The core structures of glycans 
expressed by many protozoan parasites are similar. The surface structures 
are often decorated by a glycocalyx, which promotes interactions with 
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mammalian host cells. Additionally, surface structures can also be coated 
by host glycans, often used by parasites to escape immune recognition164.  
Glycans can dominate the antigenic profile of parasites and are readily 
recognized by host Abs. The diversity of glycans and the range of their 
functions is outstanding. The diversity and similarities of glycan among 
protozoan parasites gives insights about their evolutionary relationship. 
Leishmania spp. and Trypanosoma (T.) cruzi or T. brucei (the diseases caused 
by these parasites are explained in Section 1.5) have common GPI 
glycolipids that bind to the C-terminus of proteins during post-
translational modification165. Survival of these parasites in their mammalian 
host is strictly dependent on the expression of these surface 
glycoconjugates. T. brucei trypomastigote surface is covered with highly 
glycosylated variable surface glycoprotein166 carrying at least one N-linked 
glycosylation that is switched into alternative structures upon interaction 
with the host immune system. This allows T. parasites to escape 
complement-mediated lysis. Four classes (I-IV) of variable surface 
glycoproteins exist in T. brucei and most of the parasites are class I or II165. 
Class I has one N-glycosylation site and mannose structures close to its C-
terminus (Man5–9GlcNAc2). Class II has high mannose structures or 
polylactosamine rich structures at C-terminal site, and the inner site 
consists of smaller oligosaccharides whereas Class II has three putative N-
glycosylation sites modified with either high mannose or bi-antennary 
structures. GPI anchored variable surface glycoproteins monomers167 can 
be glycosylated with the α-gal glycans (described later), i.e. 3-6 in class I 
and II has, respectively. Additionally, Class II variable surface 
glycoproteins possess α-gal and β-gal glycan structures165. Moreover, the 
surface coat of the procyclic form of T. brucei contains acidic glycoproteins 
called procyclic acidic repetitive proteins165. EP-procyclic acidic repetitive 
proteins that have glutamate-proline repeats and GPEET-procyclic acidic 
repetitive proteins that have glycine-proline-glutamate-glutamate-
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threonine repeat sequences are the main families of these proteins. These 
procyclic acidic repetitive proteins can be expressed in a cell cycle–specific 
manner and thus, it is thought that oligosaccharide chains may serve as 
lectin binding ligands in fly midgut165. 
 
In contrast to T. brucei that has N-linked glycosylated sites, T.cruzi 
expresses a range of conserved, O-linked glycosylated, small family of 
mucins and glycosylinositolphospholipids (GIPLs)168. The O-linkages are 
generally O-GlcNAc, not O-GalNAc and the overall composition consists of 
GlcNAc and Gal residues169. Moreover, Trypanosomes do not synthesize 
sialic acids and thus, they sialylate their Gal-rich mucin (as an acceptor) by 
capturing host sialic acid (as a substrate) and transfer this sialic acid to β-
Gal residues of the mucin170.  
 
Table 1.1 Glycans in parasites. Adapted from165. 
 
 
In Leishmania, the building blocks for glycoconjugates are quite similar to 
African trypanosomes. Leishmania has a dense cell surface glycoconjugates 
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including lipophosphoglycan, GP63 (cell surface glycoprotein), 
glycosylinositolphospholipids and secreted glycoconjugates, 
proteophosphoglycan and secreted acid phosphatase152,165,169. Although 
different Leishmania strains have different glycan structures and 
antigenicity, the surface of all strains is uniquely coated with 
lipophosphoglycan that shares a similar structure to GPI tail, and is 
localized over the entire parasite surface including its flagellum. These 
structures which have conserved lipid anchor, the glycan core, and the 
Gal(β1,4)Man(α1)-PO4 backbone of repeat units have variations only in the 
carbohydrate chains that divide the main backbone and in the cap 
structures152,158,165. Depending on the strains, they can have a repeated unit 
of β-Gal or β-Glc in side chains. Species-specific differences have 
biologically important roles such as β-1,3-Gal substitutions in core repeat 
carries of L. major that helps parasite to attach to midgut of sand-fly or 
addition of an Ara residue in α-1,2-linkage that helps parasite to detach for 
invasion169. Moreover, glycosylinositolphospholipids are the major 
glycolipids in Leishmania. These structures contain Gal-Man-PO4 repeats 
and resemble LPG without the linker or cap saccharides169. Although the 
function of glycosylinositolphospholipids is clearly yet identified in 
Leishmania, it is thought that they play a role in macrophage invasion. The 
other important structure in Leishmania is GP63, which is the major cell 
surface glycoprotein (1% of all cellular proteins) and found in the flagellar 
pocket and attached to surface via a myristic acid containing GPI 
anchor165,171. It contains N-linked glycans with three potential glycosylation 
sites171. Although the importance of this glycoprotein is not well known, it 
is believed that it has a role of degrading host macromolecules, a ligand for 
the macrophage receptor via complement components. 
 
Compared to the trypanosomatids, the level of glycosylation in Plasmodium 
proteins is much lower. There are a few examples of N- or O-glycosylation 
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in Plasmodium172. GPI anchor glycans are the most prominent and are quite 
similar to other protozoan GPIs. It has been argued that GPIs are 
recognized by mammalian host PRR173 but whether this has an impact on 
host resistance to Plasmodium infection is not clear. The asexual stages of P. 
falciparum and some proteins such as merozoite surface proteins (MSP1 and 
MSP2), a heat shock protein 72 (HSP72), an RBC binding antigen (EBA-175), 
merozoite rhoptry antigen and transferrin receptor were identified as 
glycosylated expressing N- and O-glycans. However, the exact roles of 
glycosylation on these proteins are unknown. In contrast, lack of N- and O-
linked glycans on merozoite surface proteins-1 and -2 was documented and 
proposed that GPI anchors are the major players for glycosylation 
processes Plasmodium174,175. Additionally, Plasmodium parasites can use host 
glycans to avoid detection by the host immune system. Other critical 
processes in the life cycle of Plasmodium are also dependent on 
glycosylation processes, as illustrated for RBC invasion, which relies on the 
interactions of Plasmodium with sialylated glycans expressed on RBC 
glycophorin A in mammalian host while the attachment of Plasmodium to 
midgut of its mosquito host is depend on the interaction with complex 
oligosaccharides176,177. 
 
1.4.3.4 The α-gal glycan 
There is an additional layer of complexity in which regulated glycosylation 
processes can add branching residues and terminal sugars to core glycans 
via a process regulated by glycosyltransferases. Terminal glycosylation of 
core glycan structures falls into Type-1 and Type-2 glycan units. Type 1 
units are generated by β1–3 linkage of galactose to GlcNAc in N-glycans, 
O-glycans and glycolipids. Type-2 glycan units are generated by β1–4 
linkage of galactose to Galβ1–4GlcNAc, also called N-acetyllactosamine. 
Many of these glycosylation processes occur during embryogenesis and 
post-natal period but function of generated natural oligosaccharide 
structures is yet to be fully characterized150. 
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Glycans carrying Gal and GalNAc residues are mutual receptors found on 
several microbial infections such as gonorrhea, sleeping sickness, 
meningitis, diarrhea, pneumonia and influenza178. The involvement of 
anomerity and α- or β- linkage of Gal and GalNAc in various organisms 
generate different glycan structures. Generation of the α-gal glycans, 
namely, Gal1-α-3Gal-R or Gal1-α-4Gal-R, falls into Type-2 unit synthesis in 
which β1–4 linkage occurs both on glycolipids and glycoproteins (Figure 
1.14)179 of many mammals including mouse, sheep, pig, rabbit, cow and 
rat180,181, prosimians and New World monkey. The generation of this glycan 
structure is strictly dependent on an enzyme called UDP-Gal:β-galactosyl-
α1–3-galactosyltransferase (α1,3GT) that is not functional in Old World 
monkey, apes and humans due to the inactivation of the α1,3-
galactosyltransferase gene around 20-28 million years ago (explained in 
details in Section 1.4.4). Therefore, the α-gal glycan is not expressed on Old 
World monkey, apes and humans.  
 
Figure 1.14 Synthesis of α-gal carbohydrate. The synthesis of α-gal is catalyzed by 
α1,3-galactosyltransferase enzyme (shown as α1–3GalT), which uses type-2 glycan 
units on glycoproteins or glycolipids and forms α-gal epitope. Adapted from150. 
 
In 1968, Yamakawa and co-workers described for the first time a glycolipid 
(ceramide pentahexoside) expressing the α-gal epitope182. Galα1-3Gal-R 
and Galα1-4Gal-R structures were detected in carbohydrate chains of the 
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two major glycolipids in rabbit RBC membranes (rRBC): ceramide 
trihexoside and ceramide pentahexoside, further characterized by 
Hakomori and coworkers in 1972183. Later on, it was shown that RRBC 
contains a wide range of glycolipids of different lengths that terminate with 
a α-gal glycan184,185. These glycolipids are probably multi-branched, 
containing 35 and 40 carbohydrates per glycolipid185. Moreover, α-gal 
conjugation to neutral glycolipids and gangliosides 5  lipids was also 
reported on bovine RBCs were reported186,187.  
 
In parallel to the discovery of anti-α-gal NAbs, the presence of α-gal glycan 
 on different organs of animals, including sheep, pig, rabbit, cow and rat180 
and as well as in the thymus tissue of sheep, pig and rabbit181 was 
identified. Expression of the α-gal was also found linked to protein 
structures, as demonstrated originally by Spiro and Bhoyroo for 
thyroglobulin188. Vliegenthart and coworkers showed that α-gal is 
expressed on N-linked glycans from mouse, bovine and porcine cells189. 
Detailed analysis of N-linked glycans extracted from pig kidney tissue 
showed that Galα1–3Galβ1–4GlcNAc-R terminal are found on a variety of 
complex bi-, tri- and tetra-antennary N-glycans190. Later, it was also 
demonstrated that renal proximal convoluted tubules, respiratory 
epithelium, pancreatic ducts, epidermis and vascular endothelium of pig 
contains Galα1–3Galβ1–4GlcNAc-R expressing glycans191. 
 
1.4.4 Anti-α-gal Abs 
Anti-α-gal Abs account for ~1-5% of the total circulating IgM and IgG in 
healthy humans and are produced by corresponding 1% of human B cell 
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repertoire192. In 1983, during his years at Hadassah Hospital in Jerusalem, 
Galili worked on the potential destructive effect of Abs on RBCs from b-
thalassemic patients. He and co-workers discovered that thalassemic RBCs 
carry several hundred IgG molecules that could be eluted at 37°C using 
galactose and galactose-like compounds. Later, it was shown that this was 
also the case for RBC from sickle cell anemia patients193,194. They used 
α-galactosyl coupled to Sepharose column to identify the reactivity of these 
RBC-bound Abs. Surprisingly, 1% of human serum IgG, corresponding to 
30-100 µg/mL, was found to bind α-gal avidly 163. Then, Galili and Macher 
performed immunostaining of rRBC glycolipids by thin layer 
chromatography and showed that NAbs bound to rRBC195. They 
demonstrated as well that these are anti-α-gal Abs, which recognize 
predominantly non-reducing terminal Galα1–3Galβ1–4GlcNAc-R 
structures on glycosphingolipids. They first called this Ab “anti-α-
galactosyl Ab” and later on defined it as “anti-α-gal (Anti-Gal) Ab.” They 
further identified bacteria from the normal human gastrointestinal flora 
that is recognized by anti-α-gal Abs (discussed later) and hypothesized that 
these Abs are produced throughout life as a consequence of a continuous 
stimulus provided by α-gal expression in the gut microbiota196,197. 
Table 1.2 Human blood groups and α-gal. Adapted from198. 
Blood 
Group  






with Anti-α-gal Abs 
A GalNAcα1-3(Fucα1-2)Gal Anti-B  Galα1-3Gal 
   Galα1-3(Fucα1-2)Gal 
B Galα1-3(Fucα1-2)Gal Anti-A Galα1-3Gal 
AB Galα1-3(Fucα1-2)Gal None  Galα1-3Gal 
 GalNAcα1-3(Fucα1-2)Gal   
O (H) Fucα1-2Gal Anti-A  Galα1-3Gal 
  Anti-B Galα1-3(Fucα1-2)Gal 
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Galili also demonstrated the unique binding of anti-α-gal NAbs to a series 
of Galα1–3Galβ1–4GlcNAc-R glycosphingolipids isolated from rRBC, but 
not to glycosphingolipids with Galα1–4Galβ1–4GlcNAc-R structures. This 
demonstrated the fine specificity of the anti-α-gal Abs. It was concluded 
that anti-α-gal Abs detect glycan linkages of the terminal galactosyl 
residues that consist of same carbohydrate sequence, but with different 
carbon configuration195. Further studies revealed differences in the fine 
specificity of natural anti-α-gal Abs in individuals of various blood types. 
Non-reducing terminal GalNAcα1–3GalNAc disaccharide (Forssman 
Antigen) or A blood group structure GalNAcαl–3(Fucαl–2)Gal-R are not 
detected by anti-α-gal Abs. However, these Abs can detect blood group B 
antigen and approximately 85% of purified anti-B-antigen Abs are also 
anti-α-gal Abs198. In contrast, purified anti-α-gal Abs from human sera of 
blood groups B or AB can bind to the α-gal, but not to blood group B 
antigen (Table 1.2)198. Moreover, human sera from blood group A and O 
has a variety of anti-α-gal Abs that bind to the canonical α-gal epitope as 
well as to α-gal epitopes in which a Fuc is linked α-1,2 to the penultimate 
galactose (Table 1.2)198. All these fine specificities of anti-α-gal Abs in 
individuals with various blood types imply that a slight different angle in 
its 3-dimensional form of the α-gal glycan can be detected by these Abs.  
 
1.4.5 Evolutionary inactivation of α-gal expression and emergence 
of NAbs recognizing α-gal 
The discovery of the α-gal glycan led scientists to identify the distribution 
pattern of this glycan and anti-α-gal Abs in mammals. Analysis of primates 
and New World Monkeys from the San Francisco Zoo in USA and São 
Paulo in Brazil, respectively, revealed that New World monkeys and 
lemurs express the α-gal glycan whereas primates, including humans, apes 
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and Old World monkeys do not. The conclusion was that the production of 
anti-α-gal Abs emerged in the complete absence of α-gal glycan in 
anthropoid monkeys, including humans198.  
 
Figure 1.15 Distribution of the α-gal glycan vs. α1,3GT activity and anti-α-gal 
Abs production. New World monkeys, including lemurs, encode the active form 
of α1,3GT and express α-gal as a self-glycan. As such, these fail to produce anti-
α-gal Abs. In contrast, Old World monkeys and humans encode an inactive form 
of α1,3GT and can produce anti-α-gal Abs. Adapted from199,200. 
 
The α1,3GT enzyme catalyzes the synthesis of α-gal glycan on lipids 
and/or proteins. It utilizes as UDP-Gal (nucleotide sugar donor) and either 
a glycosphingolipid or glycoprotein carrying Galβ1–4GlcNAc-R or Galβ1–
3GlcNAc-R (acceptor substrate) as substrates201. α1,3GT is a membrane 
bound type 2 protein around 370 amino acids (a.a.) expressed in the Golgi 
apparatus, where it competes with sialyltransferase for N-
acetyllactosamine non-reducing terminal residues on glycoconjugates202. 
Although the N-terminal region (amino acids 1–99) of α1,3GT varies 
among species, the remaining sequence until the C-terminus, which is 
critical for enzyme activity203, presents high degree of homology. α1,3GT 
New World Monkeys Old World Monkeys
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activity is detected in murine, bovine and New World monkey cells, but 
not in human cells, with a parallel expression of α-gal glycans199 (Figure 
1.15). Galili and colleagues hypothesized that the evolutionary elimination 
of the α-gal glycan could be directly related to the inactivation of α1,3GT 
gene (also called GGTA1) since human cells have both UDP-Gal and N-
acetyllactosamine acceptors199.  
 
Identification of α1,3GT gene in human genome was only possible after the 
murine and bovine counterpart were cloned204,205. Later, the human α1,3GT 
gene have been sequenced and it was found out that it contains several 
frame-shift mutations and internal stop codons. Lowe and his group 
identified the first α1,3GT pseudogene on human chromosome 9, 
containing intronic sequences, and one exonic sequence corresponding to 
the largest part of the catalytic domain of the α1,3GT enzyme and the same 
exon/intron organization as found in mice206. Two point mutations that 
cause a frame-shift and premature stop codon were detected in the α1,3GT 
pseudogene in bases 820-824 and 902-906 rendering the α1,3GT 
pseudogene nonfunctional207. Later on, an additional frame-shift mutation 
was identified in exons 7 and 8 of the α1,3GT pseudogene, suggesting that 
structural mutations such as deletions in the coding regions of the gene 
were the main reasons for the evolutionary inactivation of this gene208. 
Similar observations were made in the chimpanzee genome while only the 
first frame-shift mutation was demonstrated in the gorilla and orangutan 
genomes209. There is a second α1,3GT gene in the human genome located 
on chromosome 12, which does not have intronic sequences210. This 
intronless pseudogene contains several deletions in exon 4 and in a 
fragment encodes last 230 amino acids of the carboxyl-terminal. It is likely 
that α1,3GT cDNA was inserted into chromosome 12210. 
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Although humans and chimpanzees present similar α1,3GT mutations, 
these differ from other Old World monkeys, which carry common 
mutations shared by humans and chimpanzees, suggesting that the α1,3GT 
gene was first inactivated in ancestral primates presumably after the 
divergence of apes and monkeys209. Natural selection of mutations leading 
to the inactivation in the α1,3GT gene was probably driven by a highly 
virulent pathogen associated or with a major catastrophic epidemiological 
event or endemic to the Old World, but in either case should be correlated 
with the almost complete extinction of the hominoid lineage. In keeping 
with this notion, some highly virulent pathogens express the α-gal glycan 
(discuss later in this chapter) and the production of anti-α-gal Abs in 
ancestral primates might have provided immune resistance to these 
pathogens. However, New World monkeys from the American continent, 
which were separated from the African continent almost 35 million years 
ago as well as lemurs, which are found in the Madagascar, an island 
isolated from the African continent 60 million years ago did not undergo 
this selective pressure. This is most probably because they were isolated 
from the Old World continents along distinct geographical boundaries such 
as oceanic barriers179,211. 
 
The existing theories on the evolutionary inactivation of α1,3GT gene that 
results in the suppression of α-gal expression in mammals of the Old 
World can be divided into two categories. The first is based on production 
of anti-α-gal Abs upon elimination of immune tolerance to α-gal glycan 
and consequently, protection against pathogen(s) expressing α-gal212-215. 
Production of large amounts of anti-α-gal Abs should provide immune 
protection against pathogens endemic to the Old World continents, which 
were detrimental to primates expressing α-gal epitopes. The second theory 
proposes that loss of α-gal is associated with the loss of host 
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receptors/ligands required to support infection by virulent pathogens that 
exploit host cell surface glycans for infection. In support of this hypothesis 
α-gal expression can render cells resistant to some pathogens but sensitive 
to others as demonstrated for Clostridium difficile infection. In this context 
the enterotoxin (toxin A) produced by C. difficile, a non-invasive Gram 
positive toxigenic bacterium, can bind α-gal on host cells, also the preferred 
binding sites for viruses and cause cytotoxicity216,217 on the intestinal cells of 
mammalian host218. When α-gal expression is removed enzymatically from 
epithelial cells, toxin A binding is significantly reduced and therefore its 
cytotoxic effect is prevented218. Assuming that this might be the case for 
toxins produced by other bacterial strains, it would suggest that loss of α-
gal expression had a strong selective pressure. In accordance, Old World 
primates that lack α-gal are not susceptible to toxin effect.  
 
Regardless of the event that led to the inactivation of the α1,3GT gene in 
ancestral Old World monkeys and apes, it is safe to state that this was one 
of the major evolutionary events of primates towards humans. 
 
1.5 Anti-α-gal Abs and Infection 
Bacteria. In 1951, it was argued by Wiener that NAbs (i.e. blood group 
hemagglutinins) are produced in response to microbial agents. Later, it was 
shown that glycans similar to those detected by anti-blood group Abs are 
also found in bacteria219. Given that humans produce high titers of anti-α-
gal NAbs throughout adult life this raises an important question about the 
immunogenic stimuli driving the continuous synthesis of these NAbs163. 
Anti-α-gal NAbs recognize α-galactosyl or α-galactosyl-like structures on 
bacterial lipopolysaccharides (LPS) from a variety of Escherichia, Klebsiella, 
Serratia and Salmonella, Clostridia isolates from normal stool or from the 
blood of sepsis patient196,197. It is possible therefore that anti-α-gal Abs 
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would provide resistance to such pathogens. Although these Abs can 
recognize pathogens proliferating in the human body, those found 
specifically in the blood circulation are supporting the idea of that 
pathogens are able to develop protective defense mechanisms against the 
detrimental effects of NAbs191,192. Moreover, anti-α-gal Abs may also play a 
role in some autoimmune phenomena, as suggested by the high titer of 
these Abs in sera of patients with autoimmune thyroiditis, IgA 
nephropathy, and Henoch-Shoenlein purpura, rheumatoid arthritis, 
glomerulonephritis, and Chagas' disease, as compared to normal human 
sera196. 
 
In 1988, Galili and colleagues described that there is a group of bacteria, i.e. 
Klebsiella strains % 18022 and 18033, S. minnesota 1127, E. coli 15293 and 
K92 %and S. marcescens 18021, which are recognized by human anti-α-gal 
Abs196. These bacteria express the α-gal glycan on their cell wall, specifically 
on the LPS structure. In contrast, E. coli O86 expresses α-gal glycan on the 
capsule or the glycoprotein portion of the bacterial wall, rather than on the 
LPS portion. Hamadeh and colleagues in 1992 provided the first example of 
binding of human anti-α-gal Abs to pathogens197 demonstrating that 
binding of anti-α-gal Abs to blood bacterial isolates was higher in sepsis 
patients, as compared to healthy individuals, suggesting that anti-α-gal 
NAbs may confer a survival advantage against systemic infections. In 
keeping with this notion, Hamadeh and colleagues also showed that anti-
α-gal NAbs can recognize up to 66% of bacterial isolates obtained from 
blood samples of patients undergoing gram-negative sepsis, as compared 
to 26% of the entire isolates collected from the stools of healthy laboratory 
volunteers. In principle, the recognition of α-gal expressing bacteria by 
anti-α-gal Abs should trigger bacterial lysis, presumably through 
complement activation. This is however, not straightforward as illustrated 
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for a Serratia marcescens strain isolated from sepsis patients. While anti-α-
gal Abs can binds the LPS portion of S. marcescens, the bacteria manages to 
escape complement-mediated killing, despite the activation of the classical 
pathway of complement and the formation of lytic membrane attack 
complexes (MAC). Complement-mediated lysis is avoided presumably 
because MAC is "relocated" on the surface of bacteria to a LPS portion that 
is not lytic to the bacteria. In that context, anti-α-gal NAbs may promote 
bacterial survival by blocking alternative complement pathway-mediated 
lysis when bound to this decoy α-gal epitope on LPS.   
 
Trypanosoma. Anti-α-gal NAbs can also interact with other classes of 
pathogens, including T. cruzi, a protozoan parasite named by the Brazilian 
physician Carlos Chagas in honor of his mentor, Oswaldo Cruz220. T. cruzi 
is the causative agent of zoonotic Chagas’ disease, commonly transmitted 
to humans and other mammals by blood-sucking triatomine bugs (also 
called kissing bugs or conenose bugs)220. This disease is characterized by 
dilated cardiomyopathy, heart failure, ventricular arrhythmias, heart 
blocks, and sudden death221. The acute phase of disease can last up to 1-2 
months and is characterized by high blood parasitemia detected in fresh 
blood sample. After this stage, a life-long chronic phase begins, which 
correlates with a scarce subpatent parasitemia that can only be revealed by 
haemoculture or xenodiagnostic. Individuals infected with T. cruzi produce 
Abs against parasite proteins that cross-react with blood vessels, 
endocardium, striated muscle, and peripheral nerves, which are thought to 
be involved in the development of degenerative changes in various 
organs222. In 1990, the structure of the N-linked oligosaccharide of 85-kDa 
surface glycoprotein, named Tc-85, expressed by the trypomastigote form 
of T. cruzi was shown223. Presumably, this explains why human and 
experimental animal models infected by T. cruzi produced 10-30 fold 
higher levels of anti-α-gal Abs, when compared to uninfected individuals224. 
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Anti-α-gal NAbs kill the parasite via complement-mediated lysis as well as 
cell-mediated lysis in vitro, suggesting that anti-α-gal Abs contributes to 
protection against T. cruzi infections. However, this protective mechanism 
has never been show in vivo225.  
 
Although Trypanosoma parasites express α-gal glycan on their membrane 
surface, they can escape the cytotoxic action of anti-α-gal Abs using several 
strategies including invasion of host cells. Presumably, this can explain 
why intracellular Trypanosoma parasites are protected from anti-α-gal Ab-
mediated lysis226,227. Moreover, they produce and release 
glycoinositolphospholipids and lipophosphoglycans expressing α-gal227, 
immunizing the infected host chronically against this glycan224. This 
chronic Ab response may contribute to trigger the “autoimmune-like” 
inflammatory reaction associated with acute and chronic Chagas’ 
disease228,229. In keeping with this notion, a study carried out in 1988 
showed that blood group A and O patients with Chagas’ disease display 
significantly higher titers of anti-α-gal Abs, probably explaining the higher 
incidence of severe forms of disease in Chagatic patients of blood groups 
AB and B. Taken together, these studies argue that anti-α-gal Abs might 
provide some level of resistance to Trypanosoma while promoting morbidity 
in Chagatic patients 230,231. 
 
Leishmania. Anti-α-gal Abs may also confer resistance to Leishmaniasis, 
the disease caused by the protozoan parasite Leishmania, transmitted by the 
bite of Phlebotomine sand flies. It was named in 1903 after the discovery of 
Scottish pathologist William Boog Leishman1. L chagasi and L. mexicana 
species are responsible for human visceral leishmaniasis and localized 
cutaneous leishmaniasis or diffuse cutaneous leishmaniasis, respectively 
while L. braziliensis is the main cause of localized cutaneous leishmaniasis 
and mucocutaneous leishmaniasis213. The lipid composition of 
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promastigotes cultures from pathogenic and nonpathogenic Leishmania 
strains revealed that 5-10% of the total lipids are composed of glycolipids 
containing mannose and galactose232. Glycoinositolphospholipids of 
Leishmania contain glucosamine (GIcN) and variable amounts of galactose, 
mannose, glucose and phosphate233. The first correlation between anti-α-gal 
Abs and Leishmania parasites was found in 1987, in that sera from patients 
with American cutaneous leishmaniasis bind strongly to the α-gal glycan222. 
Moreover, titers of anti-α-gal Abs are elevated in patients with cutaneous 
leishmaniasis222,234 and the α-gal glycan is expressed by Leishmania224.  
 
Plasmodium. Impact of α-gal glycan and anti-α-gal Abs in malaria are the 
main focuses of this thesis and are addressed in detail, in Chapter 2.  
 
Viruses. Expression of α-gal and concomitant production of anti-α-gal Abs 
may also have an impact on human viral infections. Virions that are 
produced in cells from species that express α-gal, express the α-gal glycan 
on glycoproteins in the enveloping cellular membrane. This was first 
demonstrated in 1984 for the Friend leukemia virus that contains N-
acetyllactosamine repeating units and in some cases replaced by α-gal235. In 
1994, it was shown that eastern equine encephalitis virus can also express 
α-gal glycan and be neutralized in vitro by anti-α-gal Abs215. Expression of 
this glycan on this virus is dependent on the expression of α-gal by the cells 
producing the virions215, which reflects on the ability of anti-α-gal NAbs to 
neutralize these viruses. This is relevant for influenza virus, for which the 
major envelope glycoproteins consist of hemagglutinin molecules that 
provide recognition of host sialic acids. When produced in species that 
express α-gal, i.e. chicken, pig, and influenza virus expresses α-gal and as 
such can be neutralized by anti-α-gal NAbs236. This suggests that human 
infection by influenza virus derived from animals that express α-gal may 
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be suppressed initially by the immediate responses provided by anti-α-gal 
Nabs. However, this defense mechanism becomes inefficient once the virus 
is transmitted from human to human, based on the lack of α-gal expression. 
Because, virus can manage to find another way to infect human host 
without using α-gal glycan. A similar situation should occur for other 
viruses such as demonstrated for the murine retrovirus of New World 
Monkeys, which can be neutralized by anti-α-gal Abs when grown in cells 
that express α-gal but not in cells that do not express α-gal expression 
could237.  
 
1.6 Aim of This Study: Objectives and Outline 
Mutation in human α1,3GT might have been naturally selected throughout 
evolution to allow for the production of anti-α-gal Abs affording protection 
against pathogens that express α-gal glycan. Serum titers of anti-α-gal Abs 
increase steadily during the first years of life, suggesting that exposure to 
this immunogenic glycan occurs immediately after birth238. Presumably, 
this occurs via recognition of α-gal glycan expressed by specific 
components of the gut microbiota196. Under the assumption that P. 
falciparum can express the α-gal glycan239 and anti-α-gal Abs would confer 
resistance to Plasmodium infection. We reasoned that the relative lack of 
anti-gal Abs in children under the age of 3-5 years old may explain their 
higher susceptibility to malaria14,240,241. If proven correct, this raises a second 
hypothesis, namely that gut bacteria might control adaptive immunity 
against Plasmodium infection, through the activation of anti-α-gal B cells. 
The aim of this study was to establish whether anti-α-gal Abs provide 
resistance to Plasmodium infection and whether this protective effect was 
driven by components of the gut microbiota. To test this hypothesis, we 
used α1,3GT deficient (α1,3Gt-/-) mice, which in a similar to humans can 
produce high titers of anti-α-gal Abs when colonized by components of the 
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gut microbiota expressing α-gal214. We then assessed whether anti-α-gal 
Abs confer protection against Plasmodium infection in mice. The specific 
aims of this study were: 
 
Specific Aim #1: To establish whether Plasmodium spp. express α-gal. 
 
Specific Aim #2: To establish whether anti-α-gal Abs afford protection 
against Plasmodium infection. 
 
Specific Aim #3: To define the immunological components involved in the 
protective mechanism via which anti-α-gal Abs confer protection against 
Plasmodium infection. 
 
Specific Aim #4: To establish whether component of the gut microbiota 
that elicit the production of anti-α-gal Abs afford protection against 
Plasmodium infection in mice. 
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There is a significant interest in developing effective vaccines against life-
threatening infectious diseases, specifically against Plasmodium infection. 
Major progress has been made on the characterization of potential antigens 
associated with surface proteins expressed by blood stage merozoites or 
parasitized erythrocytes that can be used as immunogens for an effective 
vaccine. Glycans expressed by different stages of Plasmodium infection have 
not been considered as antigenic determinants for the generation of 
vaccines. Here, we demonstrate that Plasmodium sporozoites express α-gal, 
a glycan also expressed during the exo-erythrocytic and erythrocytic stages 
of infection. The association of α-gal glycan to Plasmodium proteins was 
demonstrated by Western blot technique. Removal of α-gal from the 
surface of Plasmodium suggests that this glycan is bound to surface 
GPI-anchored proteins. Detection of α-gal glycan in the salivary glands of 
uninfected female Anopheles mosquitoes suggests for an unknown 













Although Plasmodium proteins and lipids can be glycosylated, it is believed 
that the overall glycosylation profile of Plasmodium is somehow lower 
when compared to other protozoan parasites such as trypanosomatid1. It is 
well established that Plasmodium relies on recognition/binding of host 
glycans, expressed by Anopheles mosquitoes and humans, for the 
progression through its life-cycle. This notion is supported by the finding 
that Plasmodium ookinete-to-oocyst transition is inhibited when 
glycoconjugate antigens are targeted by monoclonal Abs (mAbs)2-4. 
Moreover, Plasmodium sporozoites can interact with oligosaccharides such 
as GlcNAc and GalNAc present on mosquito proteins, such as laminin, 
which confers ookinetes the ability to traverse the mosquito midgut and 
allows sporozoites to avoid immune recognition by the mosquito immune 
system2-4. Additionally, Plasmodium merozoites rely on the recognition of 
sialylated glycans, associated to the RBC glycophorin A, for invasion of 
RBC in their human host5. Moreover, GPI-anchors account for the most 
prominent glycan expressed in Plasmodium and can act as putative PAMPs 
recognized by PRRs expressed in mammalian hosts6. It is also known that 
this glycan triggers the inflammatory response that underlies some of the 
clinical symptoms of malaria, including cytokine production (i.e., tumor 
necrosis factor α (TNF-α) and interleukin-1α (IL-1α)), as well as fever and 
hypoglycaemia7. These pathogenic effects can be inhibited by anti-GPI Abs8.  
 
Although glycosylation processes in Plasmodium have not been fully 
characterized, experimental evidence shows that Plasmodium parasites can 
synthesize UDP-GlcnAc and GDP-Man9. However, the intermediate glycan 
produced through the classical N-glycosylation pathway appears to be 
absent, arguing for presence of an unusual type of N-linked 
oligosaccharide in Plasmodium9. However, Plasmodium expresses N-linked 
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glycans, indicating that α-gal can be detected in the asexual blood stages of 
infection in its mammalian host10,11. 
 
Figure 2.1 Detection of α-gal 
epitope on parasites. a) 
Biotin-BSI-IB4 lectin blot of 
protein samples from P. 
falciparum late blood stages 
(P), T.brucei trypomastigotes 
(T), and control, non-infected 
(N) RBC proteins binding to 
BSB4-Sepharose. The asterisk 
indicates the migration 
position of eluted BSI-IB4 that 
also reacts with biotin-BSI-IB4. 
b) Blot of lipids prepared 
from P. falciparum late 
asexual stages (P), and 
control, non-infected RBC lipids (N), reacting with BSI-IB4 lectin (left panel) and 
pooled immune malaria sera (right panel), obtained from a malaria endemic area in 
Uganda. The asterisks show the major lipid species of the parasites that also 
reacted with streptavidin-peroxidase alone or with non-immune human serum 
after treatment with peroxidase-conjugated anti-human immunoglobulin. Adapted 
from12. 
 
Several studies by Ravindran and co-workers also argued for the 
expression of α-gal glycan in Plasmodium as well as for a putative role of 
anti-α-gal Abs in host protection against Plasmodium infection in 
individuals from malaria endemic areas13. The data supporting this notion 
was however, largely circumstantial. The levels of anti-α-gal Abs in 
individuals developing a severe form of malaria know as cerebral malaria 
were found to be lower, as compared to infected individuals that did not 
develop this severe form of disease. This suggested that anti-α-gal Abs 
might act in a protective manner against erythrocytic stages of infection, 
preventing the onset of cerebral malaria. In keeping with this notion, the α-
gal glycan was found on the surface P. falciparum infected RBCs13. More 
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than a decade later, a study by the same group suggested the presence of α-
gal in a wide range of T. brucei bloodstream trypomastigote glycoproteins 
and glycolipids. By comparison, there were relatively low or almost no α-
gal in P. falciparum asexual blood stage glycoconjugates (Figure 2.1)12. 
Nonetheless, a hydrophilic lipid moiety specific to P. falciparum was found 
to react with immune human sera12. 
 
Despite these studies, it was still unclear whether Plasmodium expresses α-
gal or not. Here, we showed unequivocally that Plasmodium spp. present α-
gal during their exo-erythrocytic and erythrocytic stages. Moreover, we 
demonstrated that female Anopheles mosquitoes also express α-gal glycan; 
raising the possibility that this glycan from the mosquito might bind and be 
incorporated to glycoconjugates in Plasmodium sporozoites. 
 
2.2 Materials and Methods 
2.2.1 Parasites maintenance and mosquitoes rearing 
Transgenic P. berghei ANKA strains expressing green fluorescent protein 
(GFP) under the EEF1α promoter, i.e. PbAEEF1a-GFP (259cl1; MR4; MRA-865)14 
or under the hsp70 promoter15 i.e. PbAHsp70-GFP (kindly provided by Robert 
Menard, Institut Pasteur, France), transgenic P. yoelii 17XNL strain 
expressing GFP under the PbA EEF1 promoter (MR4; MRA-817; kindly 
provided by Robert Menard, Institut Pasteur, France)16 were used. 
  
Female A. stephensi mosquitoes (28°C; 70–80% humidity under 12h/12h 
light/dark cycle) were reared17 at the Center of the Instituto de Higiene e 
Medicina Tropical (IHMT), Universidade Nova de Lisboa, Portugal, and 
maintained using 10% sucrose (or glucose) and infected 3-5 days after 
emergence. 
 
For sporozoite production, P. berghei ANKA infected RBC (1x106) were 
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administered i.p. to BALB/c mice and the presence of gametocyte-stage 
parasites capable of exflagellation was monitored in fresh blood 
preparations. Infected BALB/c mice were used to feed 3 to 4-day-old 
female A. mosquitoes (~1h), which were used 18-25 days post-infection for 
subsequent infections. When infected with P. berghei ANKA mosquitoes 
were maintained at 26°C (Center of the Instituto de Higiene e Medicina 
Tropical (IHMT)) whereas mosquitoes infected with P. yoelii 17XNL-GFP18 
were maintained at 24-25°C (Centre for Production and Infection of 
Anopheles; CEPIA, Pasteur Institute, France). Alternatively, P. yoelii 17XNL 
(MR4; MRA-593)16 infected mosquitoes were purchased from Radboud 
University Nijmegen Medical Centre (Nijmegen, Netherlands). P. 
falciparum 3D7 sporozoites were kindly provided by Robert Menard, 
(Institut Pasteur, France)19. 
 
2.2.2 Anti-α-gal monoclonal Abs 
Anti-α-gal hybridomas were cultured in RPMI 1640 (Invitrogen Life 
Technologies) supplemented with 0.1 mM Sodium Pyruvate, 0.01 M 
HEPES, 0.05 mM β-mercaptoethanol and 2% FBS (IgG depleted). The anti-
α-gal IgG2a, IgG2b and IgG3 hybridomas were derived by sub-cloning of 
the original IgG1 (GT6-27) hybridoma and as such have similar affinities 
for α-gal, as described before20,21. Antibodies were purified by affinity 
chromatography using HiTrap Protein G columns (GE Healthcare Life 
Sciences). Anti-α-gal IgG3 purification was carried out by a non-
chromatographic method taking advantage of its euglobulin properties as 
described22. Purified mAbs were extensively dialyzed against PBS. Protein 
concentration was determined using NanoDrop ND-1000 (λ=280nm; 
Thermo Scientific) and purity confirmed by SDS-PAGE analysis. When 
indicated, mAbs were labeled with Alexa Fluor® 647 Protein Labeling Kit 
(A20173), as per manufacturer recommendations (Molecular Probes®, 
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Invitrogen). Anti-mouse IgM total-A647 (Clone: R33.24.12) was used to 
reveal anti-α-gal IgM mAb in immunofluorescence assay. 
 
2.2.3 Specificity of anti-α-gal Abs 
96-well plates (PolySorp; Nunc) were coated with α-gal (α-gal-BSA; 50µL; 
10µg/mL in 0.5M carbonate bicarbonate buffer; pH 9.5; 2h at 37°C or 
overnight at 4°C), blocked with BSA (100µL; 1% w/v in PBS; 1h; RT) and 
washed (5X; PBS/0.05% Tween-20). Plates were incubated (1h; RT) with 
serum serial dilutions in PBS, 1% BSA and washed (5X; PBS/0.05% Tween-
20). Anti-α-gal antibodies were detected using HRP-conjugated anti-mouse 
IgM, total IgG, IgG1, IgG2a, IgG2b or IgG3 (50µL, 1:1-2000 dilution, 1h, RT) 
and washed (5X; PBS/0.05% Tween-20). Purified anti-α-gal IgM23, IgG1 
(GT6-27), IgG2a and IgG2b and IgG3 (GT4-31) mAb20,21 were used as 
standards. 3,3,5,5-Tetramethylbenzidine (TMB) Substrate Reagent Set (BD 
Biosciences) was used to reveal peroxidase activity (15-30min; RT) and 
reaction was stopped using 2N sulfuric acid. Optical densities (OD) were 
reported at λ=450nm and normalized by subtracting background OD 
values (λ=600nm; Victor 3; PerkinElmer). Concentration of each anti-α-gal 
IgG subclass determined, as described24. 
 
2.2.4 Isolation of sporozoites from salivary glands 
Mosquitoes were narcotized (-20°C; 3-5min), washed in 70% ethanol (1X; 
10-20sec) and PBS (3X; 10-20sec; Ambion). Salivary glands were obtained 
by dissection under a zoom stereomicroscope (3X magnification; Nikon 
SMZ800, Japan) and preserved in RPMI 1640 medium (Gibco BRL) or PBS. 
Salivary glands were smashed using Pellet pestles cordless motor (10-15sec; 
Sigma) to release sporozoites and centrifuged (100g; 5min) in LoBind 
microfuge tubes (Eppendorf). Supernatant was filtered (100µm cell 
strainers; BD Falcon™) to exclude debris. Sporozoites were counted using 
KOVA Glasstic Slide 10, with a quantitative grid (Fisher Scientific GMBH). 
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2.2.5 Detection of α-gal in Plasmodium sporozoites 
PbAEEF1a-GFP, PbAHsp70-GFP, P. falciparum 3D7 or P. yoelii 17XNL-GFP 
sporozoites, isolated from the salivary glands of A. stephensi or A. gambiae 
mosquitoes, 18-25 days post-infection were allowed to attach to Teflon 
printed (10 wells, 8mm; no-adherent surface; Immuno-Cell Int.) or to 
diagnostic glass slides. Sporozoites were fixed (20-50µL; 4% PFA; 20-30min; 
RT or 37°C) and washed gently (1X; PBS). Sporozoites were stained with 
Alexa Fluor® 647 conjugated BSI-IB4 (100µL; 200µg/mL; 2h, RT), Alexa 
Fluor® 647 conjugated anti-α-gal IgG1, IgG2a, IgG2b, IgG3 mAb (100µL; 
50µg/mL; overnight; 4°C) or with non-conjugated anti-α-gal IgM (M86) 
mAb (100µL; 50µg/mL; overnight; 4°C) and washed (1X; PBS). Non-
conjugated IgM antibodies were detected using Alexa Fluor® 647 
conjugated goat anti-mouse IgM (100µL; 10µg/mL; overnight, 4°C) 
(Molecular Probes®, Invitrogen). After washing (1X; PBS), slides were 
incubated with 4',6-diamidino-2-phenylindole (DAPI) (100µL; 10µg/mL; 
10min; RT) (Molecular Probes®, washed (1X; PBS) and dried in dark room 
without covering with coverslip (RT). Images of PbA sporozoites were 
obtained by DeltaVision Core immunofluorescence microscopy (Applied 
Precision/Olympus) or Spinning Disk Confocal microscopy Revolution xD 
(Andor Technology) at 100X magnification. Actin was detected using Alexa 
Fluor® 568 Phalloidin (Molecular Probes®; 100µL; 3units/mL; 1h; RT) in P. 
falciparum 3D7 and P. yoelii 17XNL-GFP sporozoites to which was added 
ProLong® Gold Antifade Reagent (Invitrogen) and wells were covered 
with coverslips. Slides were visualized with Axiovert II fluorescence 
microscope (Zeiss). Images were analyzed using bicubic interpolation and 
rescaling with ImageJ software (NIH). 
 
For detection of α-gal by flow cytometry, PbAHsp70-GFP sporozoites were 
isolated from the salivary glands of A. stephensi mosquitoes 19-25 days 
post-infection (105; 30-40ul; PBS; ice cold; 30min), fixed (30-40µL; 4% PFA in 
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PBS; 20-30min; 37°C) and washed (1X; PBS; 9300g; 2min). Staining was 
performed with Alexa Fluor® 647 conjugated BSI-IB4 (100µg/mL; 1h; 37°C). 
Sporozoites were washed (1X; PBS; 9300g; 2min) and Alexa Fluor® 647 
BSI-IB4 signal was detected in CyAnTM ADP flow cytometry (Beckman 
Coulter; USA) with the Summit Software (v4.3; Beckman Coulter), gating 
on FITC (for sporozoite detection) and APC (for α-gal detection). 
 
For detection of α-gal by Western blotting, PbAHsp70-GFP, P. falciparum 3D7 
and P. yoelii 17XNL-GFP sporozoites were isolated from the salivary glands 
of 40-70 mosquitoes, 21-25 days after infection. Briefly, salivary glands 
were collected into LoBind microfuge tubes (PBS; on ice), smashed using 
pellet pestles cordless motor (10-15sec; 2X) and a short spin was applied to 
pellet the debris. Supernatant (30-50µL; 1-2.5x105 sporozoites) was 
transferred into LoBind microfuge tube and aliquots were stored at -80°C 
until used. Number of Plasmodium sporozoites (equivalent to 105 per 
sample) was normalized to corresponding number of salivary glands from 
non-infected mosquitoes. Samples were lysed (50mM Tris/HCl pH 7.5, 
150mM NaCl, 1% TritonX-100, Roche complete EDTA-free protease 
inhibitor cocktail; 1h; on ice) and centrifuged (16.000g; 10min; 4°C). 
Samples (supernatant) were denatured with Laemmli buffer (1% β-
mercaptoethanol; 2%SDS; 95ºC; 2min) and separated in a SDS-PAGE 
gradient gel (12% acrylamide/bisacrylamide gel, 29:1; 100V; 2h). Proteins 
were transferred into a PVDF membrane (90min; 12V), blocked (3% BSA) 
and incubated overnight with anti-α-gal IgG2b mAb (1µg/mL; 50mL). 
Membrane was washed with 20mM Tris/HCl pH 7.5, 150mM NaCl and 
0.1% Tween-20 buffer (TBST, 3X; 5min; RT) and incubated with 
HRP-conjugated goat anti-mouse IgG2b-HRP (SouthernBiotech; 50ng/mL; 
1h; 50mL; RT). Membrane was washed (TBST; 1h; RT) and developed 
(SuperSignal Chemiluminescent detection kit; West Pico, Thermo Scientific). 
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In some experiments, enzyme treatments were processed as described in 
Section 2.2.8 of this chapter.  
 
2.2.6 Detection of α-gal during the erythrocytic stage of 
Plasmodium infection 
P. falciparum 3D7 (kindly provided by Fatima Nogueira (IHMT, Lisbon, 
Portugal) was expanded in human RBCs in vitro (10-12% parasitemia). PbA, 
P. yoelii 17XL and P. chabaudi chabaudi AS were expanded in vivo using 
α1,3Gt+/+ or α1,3Gt-/- mice (10-25% parasitemias)25,26. Blood smears of RBC 
infected with Plasmodium spp. were fixed (2% PFA in PBS; 20-30min; RT), 
washed (1X; PBS) and stained for DNA (DAPI; 10-20µg/mL; 100µL; 10min; 
RT). The α-gal epitope was stained using FITC-conjugated BSI-IB4 (100µL; 
100µg/mL; 2h; RT) and actin was stained using Alexa Fluor® 568 
Phalloidin (Molecular Probes®; 100µL; 3units/mL; 1h; RT). Images for P. 
falciparum, P. berghei ANKA and P. yoelii 17XL were obtained by using 
fluorescent microscopy DeltaVision Core immunofluorescence microscopy 
(Applied Precision). Images for P. chabaudi chabaudi AS were obtained by 
using Andor Spinning Disk Confocal microscopy Revolution xD (Andor 
Technology). Images were analyzed using ImageJ software (NIH). All 
images were analyzed and processed with the ImageJ (NIH), software 
containing the LOCI plugin.  
 
2.2.7 Whole-mount Anopheles mosquito salivary gland staining 
PbAHsp70-GFP infected and non-infected female Anopheles mosquitoes were 
dissected and salivary glands were collected into an ibiTreat, tissue culture 
treated, sterile µ-Slide 8 well (PBS; on ice; Ibidi). Salivary glands were fixed 
(300µl; 4% PFA; 30min; 37°C) and washed (1X; PBS), incubated with BSI-
IB4--Alexa Fluor® 647 (100µl; 200µg/ml; 2h; RT) and washed (2X; PBS). 
Slides were dried in a dark chamber without coverslip (20-30 min; RT) and 
salivary glands were visualized using Spinning Disk Confocal microscopy 
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(Andor) with 10-60x objectives. Images were processed using ImageJ (NIH) 
software. 
 
2.2.8 Enzymatic removal of α-gal 
Removal of α-gal was performed using green coffee bean α-galactosidase 
(50-200µL; 5U/mL; 60-90min; 25°C; Sigma), which hydrolyzes specifically 
the terminal α-gal moieties from glycolipids and glycoproteins27. The α-gal 
glycan was stained thereafter, as described in previous sections. 
 
2.2.9 Removal of GPI anchor from Plasmodium sporozoites 
PbAHsp70-GFP sporozoites were isolated from the salivary glands of A. 
stephensi mosquitoes 19-25 days post-infection (5x105; PBS; ice cold), fixed 
(4% PFA in PBS; 20-30min; 37°C) and washed (1X; PBS; 9300g; 2min).  
Sporozoites were treated with phosphatidylinositol-specific phospholipase 
C from Bacillus cereus (5U/ml; 14-16h; 37°C) to cleave GPI-anchors at the 
sporozoite surface. Detection of α-gal was performed as described above 
and CSP was detected using an anti-CSP mAb (3D11) conjugated to Alexa 
Fluor® 647 in CyAnTM ADP Analyzer (Beckman Coulter). 
 
2.3 Results 
2.3.1 Detection of α-gal in Plasmodium spp.  
The α-gal glycan was detected by immunofluorescence at the surface of 
Plasmodium spp. sporozoites, including the human pathogen P. falciparum 
3D7, as well the transgenic green fluorescent protein (GFP) expressing 
strains of the rodent pathogens PbA or P. yoelii 17XNL. The α-gal was 
detected using an anti-α-gal IgM (M86) mAb23 (Figure 2.2a) or BSI-B428,29 
(Figure 2.2b). Relative binding to α-gal was similar for all anti-α-gal IgG 
mAbs, as assessed by ELISA using α-gal-BSA as a solid phase antigen 
! 122!
(Figure 2.3a) or by immunofluorescence using PbA sporozoites (Figure 
2.3b).  
 
Figure 2.2 Recognition of α-gal in Plasmodium sporozoites. α-gal (red) staining 
of Plasmodium strains using a) an anti-α-gal mAb (M86) or b) BSI-B4. DNA was 
stained with DAPI (blue). Green staining corresponds to the actin staining in P. 
falciparum 3D7 and P. yoelii 17XNL sporozoites and GFP expression in PbAEEF1a-GFP 
sporozoites. Images are at 100X magnification and are representative of two-three 















































Figure 2.3 Recognition of α-gal on PbA sporozoites using anti-α-gal IgG mAbs. 
a) Specificity of mAbs detecting the respective Ig subclass was determined by 
ELISA. b) α-gal staining of PbAEEF1a-GFP using anti-α-gal IgG mAbs (red). DNA was 
stained with DAPI (blue). Green staining corresponds to GFP expression in 
PbAEEF1a-GFP sporozoites. Images were obtained at 100X magnification and are 
representative of two-three independent experiments. Scale bar: 5µm. 
 
Specificity of BSI-B4 for pathogen P. falciparum 3D7 and the rodent PbA 
sporozoites (Figure 2.4a) and anti-α-gal mAbs binding to PbA sporozoites 
(Figure 2.4b) were assessed by enzymatic removal of α-gal, confirming that 






































































Plasmodium sporozoites. IgG2a, IgG2b and IgG3 mAbs are class switched 
mutants derived from the original anti-α-gal IgG1 clone and as such have 
similar affinities for α-gal20. 
 
Figure 2.4 Specificity of α-gal detection was confirmed by its enzymatic removal. 
PbAEEF1a-GFP and P. falciparum 3D7 sporozoites treated with α-galactosidase and 
were stained using a) BSI-B4 and b) anti-α-gal mAbs to detect α-gal (red). DNA 
was stained with DAPI (blue). Green staining in P. falciparum corresponds to actin 
staining using phalloidin (green) and to GFP expression in PbA sporozoites. 
Detection with anti-α-gal mAbs in b) only applied for PbA sporozoites. Images in 
(a) and (b) represent composite staining, at 100X magnification and are 





























Figure 2.5 Detection of α-
gal glycan on Plasmodium 
by flow cytometry. BSI-B4 
was used to detect PbAHsp70-
GFP sporozoites α-gal (red), 
which expression was 
confirmed by its enzymatic 
removal with α-
galactosidase (green). Non-
stained sporozoites were 
used as reference point and 
labeled as control (blue 
histogram). Histograms are 




Expression of α-gal glycan on the surface of PbA sporozoites isolated from 
the salivary glands of A. stephensi mosquitoes was confirmed using flow 
cytometry technique (Figure 2.5). Removal of the α-gal glycan from 
PbAHsp70-GFP sporozoites, using α-galactosidase enzyme, significantly 
reduced the expression of α-gal detected by BSI-B4. Similar results were 
initially obtained by immunofluorescence technique (Figure 2.2b and 2.4a). 
Additionally, the erythrocytic stage of different Plasmodium strains was also 
associated with α-gal expression, as assessed for P. falciparum 3D7, PbA, P. 




Figure 2.6 Detection of α-gal during the erythrocytic stage of Plasmodium 
infection. P. falciparum 3D7 was expanded in vitro in human RBCs (10-12% 
parasitemia). PbA, P. yoelii 17XNL and P. chabaudi chabaudi AS were expanded in 
vivo (10-25% parasitemia). DNA was stained with DAPI (blue). Red corresponds to 
the actin staining phalloidin and green to α-gal. Images are at 100X magnification 
and are representative of two independent experiments. Scale bar: 10µm. 
 
2.3.2 Detection of α-gal in Plasmodium spp. proteins 
The α-gal glycan in Plasmodium sporozoites was associated with proteins, 
as assessed by Western blot using whole cell extracts isolated from 
mosquito salivary glands infected with P. falciparum 3D7, PbAHsp70-GFP or P. 
yoelii 17XNL (Figure 2.7) and confirmed by enzymatic removal of α-gal 









non-treated samples or non-infected salivary glands (NI). Enzymatic 
treatment successfully removed most of α-gal conjugated to proteins. 
Moreover, residual levels of α-gal expression were detected in the salivary 
glands of non-infected mosquito salivary glands suggesting that the α-gal 
may be generated at least partially by Anopheles mosquitoes (Figure 2.7).  
Histone 3 (Hist3) and GFP detecting antibodies were used as loading 
control to show similar amount of antibodies were analyzed.  
 
Figure 2.7 Detection of α-gal was also associated with proteins. α-gal was 
detected in proteins extracted from P. falciparum 3D7 (Pf), PbAHsp70-GFP (Pb) and P. 
yoelii 17XNL (Py) infected or non-infected salivary glands (NI) using anti-α-gal 
IgG2b mAbs. Detection of Histone H3 (Hist3) with a specific mAb was used as a 
loading control. GFP protein was detected in Pb and Py using the GFP (3H9) mAb. 
When indicated, α-gal was removed using α-galactosidase (E). 
 
Then, we asked if the α-gal epitope is bound to GPI-anchors or proteins 
that are GPI-anchored. Expression of α-gal by PbAHsp70-GFP sporozoites was 
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(PLC), as assessed by flow cytometry (Figure 2.8a). In contrast, GPI 
cleavage failed to reduce the expression of circumsporozoite protein (CSP) 
(Figure 2.8b). This suggests that α-gal is bound to GPI-anchored surface 
proteins, including or not CSP which, despite being GPI-anchored30 is 
resistant to PLC cleavage31. 
 
Figure 2.8 GPI-bound α‑gal in Plasmodium. a) Expression of α-gal detected by 
BSI-B4 and quantified by flow cytometry in PbAHsp70-GFP sporozoites treated with 
phospholipase C (PLC) or not. Notice reduction of α-gal expression upon GPI 
cleavage by phospholipase C (PLC) digestion. Histograms are representative of 4 
experiments. b) Expression of CSP detected by anti-CSP mAb and analyzed by 
flow cytometry in PbAHsp70-GFP sporozoites treated with phospholipase C (PLC) or 
not. Notice that there is no reduction of CSP expression upon GPI cleavage by 
phospholipase C (PLC) digestion. Representative of two experiments. 
 
2.3.3 Detection of α-gal in salivary glands of Anopheles mosquitoes 
Bioinformatic analyzes failed to identify putative genes that utilize UDP-
Gal to produce α-gal in Plasmodium. This led us to ask if the α-gal glycan is 
expressed in the mosquito salivary glands, which could act as the source of 
α-gal detected as Plasmodium glycoconjugates. Expression of α-gal was 
detected at the surface of PbAHsp70-GFP in the salivary glands of Anopheles 
stephensi mosquitoes and although to a lower extent in the salivary glands 
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Figure 2.9 Detection of α-gal in salivary glands of A. stephensi mosquitoes. Non-
infected and infected salivary glands of mosquitoes were stained for α-gal using 
BSI-IB4 (red). PbAHsp70-GFP sporozoites in infected salivary glands were detected with 
GFP (green). Images in (a) and (c) are representative of non-infected female 
mosquito salivary glands and images in (b) and (d) are representative of infected 
female mosquito salivary glands. Images in (a and b) and in (c and d) are merged, 
i.e. red and green at 10X and at 60X magnification, respectively and are 








The signal intensity of α-gal expression in non-infected salivary glands was 
lower, as compared to Plasmodium infected salivary glands. In addition, 
when analyzed at higher magnification co-localization pattern between α-
gal and sporozoites was clearly noticed. This confirmed that the salivary 
glands of female A. stephensi mosquitoes express residual levels of α-gal, as 
detected by Western blot technique (Figure 2.7). It suggests therefore that 
α-gal may be generated, at least partially, by Anopheles mosquitoes and 
presumably bound to Plasmodium proteins. 
 
2.4 Chapter Discussions and Conclusion 
The presence of α-gal was initially studied in mammals. It was shown that 
it is abundantly expressed on glycoconjugates of non-primate mammals, 
prosimians and New World monkeys and is absent on Old World monkeys, 
including apes and humans. These studies were later extended for 
pathobiont bacteria in which detection of α-gal glycan was shown32. 
However, expression of this glycan on parasite is still not very clear and 
highly debatable. Our interest, in this part of the study, was to demonstrate 
the presence of terminal α-gal residues in Plasmodium spp.  
 
We demonstrated that the α-gal is expressed during the blood stages of 
Plasmodium spp., including the human pathogen P. falciparum as well as the 
rodent pathogens PbA, P. yoelii 17XNL and P. chabaudi chabaudi AS (Figure 
2.6). Lectin BSI-B4 shows high specificity for α-gal and its binding to mature 
asexual blood stages and merozoites suggested the presence of α-gal-
containing glycoconjugates in the parasites (Figure 2.6), consistent with 
previous observations using the asexual blood stages of P. falciparum11,33. 
The expression pattern suggests that α-gal is located mostly away from the 
infected RBC membrane, specifically on Plasmodium parasites or around PV 
membrane. More importantly, α-gal glycan can also be detected on 
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Plasmodium sporozoites isolated from salivary glands of A. stephensi 
mosquitoes, as assessed by immunofluorescence assay (Figure 2.2) and 
flow cytometry (Figure 2.5) using BSI-IB4 lectin or anti-α-gal mAbs (Figure 
2.3). It is noteworthy that the expression of α-gal on sporozoites was never 
been shown before. These results allowed to conclude that not only 
erythrocytic stage of Plasmodium infection but also exo-erythrocytic stage of 
Plasmodium is associated with α-gal expression.  
 
It was previously demonstrated that human anti-α-gal Abs in the sera of 
individuals from malaria endemic-areas react with a relatively hydrophilic 
lipid present in parasitized as well as with non-infected RBCs. However, 
when compared to glycoproteins, parasite-specific glycolipids seem to react 
weakly, if at all, with BSI-IB4, which prompted us to assess the presence of 
α-gal in parasite proteins, rather than in lipids12. This was achieved by 
detecting α-gal glycan by Western blots technique (Figure 2.7). The results 
obtained here demonstrate that Plasmodium sporozoites, as well as non-
infected female mosquito salivary glands, express α-gal attached to 
proteins. The presence of α-gal conjugated to lipids cannot be excluded 
from our study. This needs to be further characterized. We also confirmed 
using immunofluorescence assays that salivary glands from non-infected 
mosquitoes express α-gal glycan (Figure 2.9). Whether the α-gal detected 
on the surface of Plasmodium sporozoites is produced by the sporozoites 
and/or by the mosquito and to what extent the mosquito may control the 
expression of α-gal on Plasmodium sporozoites and vice versa requires 
further investigation. 
 
We observed a significant reduction in the expression of α-gal by 
Plasmodium sporozoites in which GPI was cleaved by enzymatic treatment 
using phospholipase C (Figure 2.8a). This suggests that α-gal glycan is 
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associated GPI anchored proteins. In contrast, GPI cleavage with 
phospholipase C failed to reduce CSP expression (Figure 2.8b). This 
suggests that α-gal is bound to GPI-anchored surface proteins, that might 
include CSP or not which, despite being GPI-anchored30, is resistant to 
phospholipase C cleavage.  
 
Bioinformatical analysis of Plasmodium genome showed no direct evidence 
of candidate gene(s) for generating an enzyme that can transfer α-gal to 
protein or lipid structures. However, Plasmodium may have some 
unclassified glycosyltransferases genes that can serve for production of α-
gal glycan on its surface34.  Even though the presence of N- and O-linked 
glycans in Plasmodium has been controversial, it is known that N-
glycosylation sites are present in the primary amino acid sequences of 
Plasmodium and there is a little information O-glycosylation in Plasmodium, 
if it occurs at all. GPI anchor linked synthesis may be the only glycosylation 
form of Plasmodium1. However, the source of these glycosylations in 
Plasmodium sporozoites was not addressed34. Our results directed us to ask 
whether α-gal glycan can be obtained from Anopheles mosquitoes since no 
candidate gene was found in Plasmodium. Non-infected female Anopheles 
mosquitoes express the α-gal glycan in the salivary glands (Figure 2.9). 
However, bioinformatics analysis also filed to identify α1,3GT in 
mosquitoes. It is known that mosquitoes have enzymes that support 
glycosylation in the midgut such as galactosyltransferase-I and II, N-
acetylgalactosaminyltransferase-I and N-acetylglucosaminyltransferase-I, 
all of which belong to the glycosyltransferase family of enzymes. In a 
similar manner to α1,3GT enzyme, these mosquito glycosyltransferases 
produce linear heteropolysaccharides, in this case of repeating glucoronic 
acid (GlcA) and N-acetylgalactosamine (GalNAc) disaccharide units35. This 
shows that Anopheles mosquitoes express oligosaccharides on their midgut 
proteins, which are heavily glycosylated with N-linked GlcNAc- and 
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GalNAc-terminal oligosaccharides4. Moreover, carbohydrates are the main 
elements supporting the interaction of Plasmodium parasites with their host 
vector. This is illustrated for the interaction of P. gallinaceum ookinetes with 
a specific type of N-linked glycan expressed in midgut epithelium of A. 
aegypti36. It is possible therefore that Plasmodium sporozoites as they 
traverse the midgut and migrate into the salivary glands may become 
coated with mosquito carbohydrates, as suggested for laminin protein and 
the proteoglycan chondroitin sulphate. We speculate that this type of 
interaction retains the α-gal glycan on surface of Plasmodium sporozoites, 
protecting sporozoites from the mosquito immune system.  
 
In conclusion, our data suggests that different Plasmodium spp. may have a 
yet unidentified homologue of the α1,3GT gene encoding an α-gal 
producing enzyme, suggesting that Plasmodium sporozoites use an 
alternative mechanism, that differs from that in mammals, to utilize UDP-
Gal. Moreover, Plasmodium may have a mechanism that retains the α-gal 
glycan from its mosquito vector while traversing the midgut into salivary 
gland. Nonetheless, our data shows that this sugar epitope can be found on 
several stages of Plasmodium spp. life cycle including human parasite and 
that it can be recognized by anti-α-gal Abs in vitro. 
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Naturally Occurring Anti-α-gal Abs Confer  















Malaria is transmitted to humans via the inoculation of Plasmodium 
sporozoites into the skin through the bite of female Anopheles mosquitoes. 
Relatively low efficiency of Plasmodium infection argues for a natural 
protective mechanism of host, presumably acting at an early stage of 
infection. Here, we tested whether inactivation of the α1,3GT gene in 
ancestral anthropoid primates, which allows for the production of anti-
α‑gal Abs, increases resistance to Plasmodium infection, a major driving 
force in human evolution. Under this chapter, we demonstrate that 
circulating anti-α-gal Abs are associated with protection against malaria 
transmission in humans as well as in α1,3Gt deficient mice, which like 
humans do not express α-gal and can produce anti-α-gal Abs. We also 
show that immunization against α-gal enhances this protective effect. The 
data obtained provides new insight for a natural protective mechanism 
against Plasmodium infection and additionally, suggests that vaccination 










Natural anti-glycan Abs generated in the absence of known specific 
immunization play a major role in enhancing anti-microbial immunity1. 
Paradoxically, these NAbs are also thought to be involved in several 
pathologies such as allergy2, diabetes2, multiple sclerosis3, atherosclerosis2 
and other forms of autoimmunity4. These NAbs are predominately of IgM 
isotype, polyreactive with low affinity, encoded by variable genes in 
germline configuration and often produced by B-1 cells (CD5+ in mice and 
CD20+CD27+CD43+CD70− in humans), which are not subjected to somatic 
hypermutation or affinity maturation5. B-1 cells are one of two main 
populations of B-lymphocytes and mature earlier than B-2 cells, in the 
following weeks after birth. These cells produce IgM NAbs constitutively 
as well as low amount of IgG and IgA while B-2 cells are activated, 
proliferate and differentiate into Ig producing plasma cells upon 
immunization with protein antigens6. Production of NAbs can occur in 
either T-cell independent (immediate response) or T-cell dependent (slower 
response but high-affinity Abs) manner7.  
 
A significant proportion of NAbs recognizes glycans such as α-gal8. High 
levels of maternal driven anti-α-gal IgG Abs are present at birth, decreasing 
during the first few months of post-natal life and increasing thereafter to 
reach a steady state within the first 3-5 years while anti-α-gal IgM NAbs are 
absent after birth but increase considerably with age9-11. NAbs are most 
probably produced in children as a result of exposure to components of the 
gut microbiota expressing glycans, such as the α-gal carbohydrate. 
Anti-α-gal NAbs are also present in serum and secretory fluids, such as 
colostrum and saliva. These NAbs can orchestrate a robust and immediate 
cytotoxic response against α-gal expressing cells, tissues or organs12. This 
cytotoxic response relies on the activation of the classical pathway of 
complement13,14 as well as on ADCC14.  
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The generation of α1,3Gt-/- deficient mice has provided an experimental 
model system to investigate the role of anti-α-gal Abs in the context of 
infection since α-gal is a xeno-glycan for α1,3Gt-/- deficient mice, acting as a 
highly immunogenic epitope15. Ig knock-in α1,3Gt-/- mice have been 
generated to overcome the fact that the frequency of B cells producing anti-
α-gal NAbs in naive α1,3Gt-/- mice is extremely low16. These mice produce 
sufficient amount of anti-α-gal IgM NAbs spontaneously from B cells 
resident in the spleen, bone marrow, and lymph nodes, but not in the 
peritoneum. sIgMhigh IgDlow and CD21high marginal zone B cells in the spleen 
bind the α-gal glycan and hence, anti-α-gal Abs are thought to be produced 
mainly by MZ marginal zone B cells16. 
 
Interestingly, somatic mutations in Ig VH genes were observed in 
hybridomas producing anti-α-gal Abs, suggesting that the production of 
these NAbs may occur in a T cell dependent manner. Studies performed 
using αβ T cell receptor deficient α1,3Gt-/- mice (α1,3Gt-/- Tcrβ-/-) showed 
that the majority of the anti-α-gal Abs are T cell dependent17. Moreover, 
interaction of CD40, a B-cell surface molecule essential for the activation of 
resting B cells by CD4+ TH cells, and CD154, a co-stimulatory ligand 
expressed on activated T cells (CD40L), are required for the production of 
anti-α-gal Ab in vivo17. This suggests again that for the TH cell dependent 
antibody responses, the production of anti-α-gal NAbs requires the cognate 
interaction of B cells with T cells that leads to B cell activation, proliferation 









Figure 3.1 The interaction between B and 
T cell for the activation of B cell. An 
antigen is recognized B cells and 
generates the first signal. CD40 ligand 
(CD40L) on CD4+ T cell engages with 
CD40 receptor on B cell and generates the 
second signal. These two signals lead to B 
cell activation, proliferation and 
differentiation. Adapted from18. 
 
The reason why humans have high 
levels of circulating anti-α-gal NAbs was argued to related resistance to 
pathogens expressing α-gal. In keeping with this notion, these Abs can be 
highly cytotoxic in vitro towards α-gal expressing pathogens, as 
demonstrated for bacteria19, protozoan parasites20  and viruses enveloped 
by xenogeneic α-gal expressing cell membranes21. Whether anti-α-gal Abs 
confers resistance to infection by pathogens, including Plasmodium, has not, 
to the best of our knowledge, been established. In this chapter of the thesis, 
we tested whether when present at the time of infection, anti-α-gal Abs 
could orchestrate a protective effect against murine Plasmodium22-24. We 
demonstrated that preformed anti-α-gal Abs can target Plasmodium 
sporozoites immediately after inoculation and contribute critically to 
reduce malaria transmission. 
 
3.2 Materials and Methods 
3.2.1 Subjects and clinical samples  
The Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry 
at the University of Sciences, Technique and Technology of Bamako, and 
the Institutional Review Board of the National Institute of Allergy and 
Infectious Diseases, National Institutes of Health approved the cohort 
study. Written, informed consent was obtained from adult participants and 
from the parents or guardians of participating children. In May 2011, just 
before the 6-month malaria season, 695 individuals aged 3 months to 25 
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years were enrolled in a cohort study in the rural village of Kalifabougou, 
Mali. Individuals were invited to participate after random selection from 
an age-stratified census of the entire village population (n=4394). 
Enrollment exclusion criteria were hemoglobin level <7 g/dL, axillary 
temperature ≥37.5°C, acute systemic illness, use of anti-malarial or 
immunosuppressive medications in the past 30 days, and pregnancy. After 
enrollment, individuals were followed during the malaria season for 7 
months. Clinical malaria was detected prospectively by self-referral and 
weekly active clinical surveillance. All individuals with signs and 
symptoms of malaria and any level of Plasmodium parasitemia detected by 
light microscopy were treated according to the National guidelines in Mali. 
The research definition of malaria was parasitemia ≥2500 parasites/µL, 
temperature ≥37.5°C and no other cause of fever discernible by physical 
exam. During scheduled clinic visits, blood was collected by finger prick 
every two weeks on filter paper. Detection of asymptomatic Plasmodium 
infection by PCR was done retrospectively at the end of the surveillance 
period. For each participant, PCR was performed on blood samples in 
chronological order from enrollment onwards until the first P. falciparum 
infection was detected. Detailed methods for P. falciparum PCR detection 
have been described before25. α-gal-specific IgM and IgG Ab levels were 
determined by ELISA on plasma collected at enrollment from the subset of 
individuals who were confirmed to be negative for Plasmodium infection by 
PCR.  Statistical analyses were described in Section 3.2.15. 
 
3.2.2 Mice 
Mice were bred and maintained under specific pathogen-free (SPF) 
conditions, according to protocols approved by the Instituto Gulbenkian de 
Ciencia (IGC) and by the Portuguese National Entity (DGAV - Direção 
Geral de Alimentação e Veterinária. All murine experiments followed the 
Portuguese (Decreto-Lei nº 113/2013) and European (Directive 
2010/63/EU) legislations, concerning housing, husbandry and animal 
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welfare. C57BL/6 α1,3Gt-/-deficient mice15,26 were provided originally by 
Prof. Peter Cowan (Immunology Research Centre, St. Vincent’s Hospital, 




C57BL/6 JHT-/-27, Aid-/-28, µS-/-29 and Tcrβ-/-30 were crossed with α1,3Gt-/- mice 
to generate α1,3Gt-/- mice lacking circulating Ig (α1,3Gt-/-JHt-/-), IgM α1,3Gt-/-
µS-/-), IgA, IgG and IgE (α1,3Gt-/-Aid-/-) and T cells (α1,3Gt-/-Tcrβ-/-). Mice 
were genotyped by PCR using tail genomic DNA and primers above.  
 
3.2.3 Mice genotyping 
Total genomic DNA was isolated from the tail using a standard protocol. 
Briefly, tails (0,5 to 1 cm) were obtained and submerged into DirectPCR 
Lysis Reagent (200-300µL; Viagen Biotech, Inc.) containing Proteinase K 
(100µg/mL) and incubated (overnight; 55°C) under vigorous agitation. 
Next day, samples were centrifuged (16000g; 5-10 sec; RT) and supernatant 
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(1µL) was amplified by PCR: 95°C (15min), 30 cycles of 94°C (45sec), 60°C 
(90sec) (except Aid-/- genotyping; 63°C), 72°C (90sec) and 72°C (15min).  
Visualizations of PCR results were done on 1.5-2% agarose gel (80-100V; 1-
2h). µS-/- mice were phenotyped by ELISA, as described29. 
 
3.2.4 Anti-α-gal mAb production See Section 2.2.2 
 
3.2.5 Immunization protocol 
rRBCM expressing high levels of α-gal31 were prepared from lyzed RBC 
(50mM sodium phosphate buffer pH 8), washed (5-7X; sodium phosphate 
buffer; 10,000g; 20min; 4°C) until supernatant was hemoglobin-free, 
essentially as described 32. Membranes were collected by centrifugation 
(20,000g; 20min; 4°C), re-suspended in PBS and stored (-80°C) until used. 
Eight to ten weeks old mice received 3x108 RBC equivalents  (100µL; PBS; 
i.p.). When indicated rRBCM were emulsified in Incomplete Freund's 
Adjuvant (IFA) or Complete Freund's Adjuvant (CFA; IFA plus 
Mycobacterium tuberculosis H37 RA; 4mg/mL; DIFCO) or CFA+CpG 
(50µg/mouse; ODN M362; Invivogen) and administered subcutaneously 
(s.c.). Alternatively, rRBCM were emulsified in Aluminum hydroxide Cγ 
(Alu-Gel-S; SERVA Electrophoresis GmbH) and administered i.p. 
Emulsions were prepared at 1:1 (v/v) and administered at 200µL per 
mouse, 3x at two weeks intervals. When indicated, mice were immunized 
(s.c.) with α-gal-BSA (75µg/mouse) emulsified in CFA with two 
subsequent immunizations, 2 and 4 weeks, thereafter with α-gal-BSA 
emulsified in IFA.  
 
3.2.6 Passive immunization with anti-α-gal mAbs 
α1,3Gt-/- mice received anti-α-gal IgG1, IgG2a, IgG2b or IgG3 mAbs via a 
single i.v. injection (150µg; 100µL per mouse), 24h prior to mosquito 
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exposure. Passive anti-α-gal IgM transfer was performed using polyclonal 
IgM. Briefly, eight to ten weeks old α1,3Gt-/-Aid-/- mice received 3x108 RBC 
equivalents of rRBCM in PBS (100µL; i.p.). Serum was collected two weeks 
after the last immunization and concentration of anti-α-gal IgM was 
determined by ELISA11,33. Serum collected from naïve α1,3Gt-/-Aid-/- mice 
was used as control. α1,3Gt-/- mice received the polyclonal IgM via a single 
i.v. (150µg; 300-400µL per mouse), 24h prior to mosquito exposure. 
 
3.2.7 Anti-α-gal ELISA 
Mouse serum was collected two weeks after immunization and circulating 
anti-α-gal antibodies were quantified by ELISA, as described11,33. Briefly, 
96-well plates (PolySorp; Nunc) were coated with α-gal (α-gal-HSA or α-
gal-BSA; 50µL; 10µg/mL in 0.5M carbonate bicarbonate buffer; pH 9.5; 2h 
at 37°C or overnight at 4°C), blocked with BSA (100µL; 1% w/v in PBS; 1h; 
RT) and washed (5X; PBS/0.05% Tween-20). Plates were incubated (1h; RT) 
with serum serial dilutions in PBS, 1% BSA and washed (5x; PBS/0.05% 
Tween-20). Anti-α-gal antibodies were detected using HRP-conjugated 
anti-mouse IgM, total IgG, IgG1, IgG2a, IgG2b or IgG3 (50µL, 1:1-2000 
dilution, 1h, RT) and washed (5X; PBS/0.05% Tween-20). Purified anti-α-
gal IgM33, IgG1 (GT6-27), IgG2a and IgG2b and IgG3 (GT4-31) mAb14,34 
were used as standards. TMB Substrate Reagent Set (BD Biosciences) was 
used to reveal peroxidase activity (15-30min; RT) and reaction was stopped 
using 2N sulfuric acid. Optical densities (OD) were reported at λ=450nm 
and normalized by subtracting background OD values (λ=600nm) (Victor 3; 
PerkinElmer). Concentration of each anti-α-gal IgG subclass determined, as 
described35. Concentration of anti-α-gal antibodies in human plasma was 
analyzed using a similar assay and a standard curve to transform 
absorbance into immunoglobulin concentration was obtained by coating 8 
duplicate wells in every plate with purified human IgG and IgM (500 to 1.5 
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ng/mL) and performing the protocol described above in the absence of 
diluted serum. 
 
3.2.8 Parasites maintenance and mosquitoes rearing See Section 2.2.1 
 
3.2.9 Plasmodium transmission  
Anopheles mosquitoes (18–25 days after the infectious blood meal) were 
deprived of 10% glucose for 3-6 hours before in vivo experiments to 
increase the rate of mosquito bite. A. stephensi or gambiae mosquitoes were 
allowed to feed on anesthetized mice (ketamine; i.p.; 125 mg/kg, Imalgene 
1000, Merial; Xylazine, i.p., 12.5mg/kg, Rompun 2%; Bayer) placed on a 
warming tray. Two mosquitoes were allowed to probe and feed 
independently (90-100 sec) on a restricted edge of the mouse ear (10-12/3-4 
mm) and dissected thereafter for confirmation of sporozoites in salivary 
glands. If negative, infection was repeated. 
 
3.2.10 Disease assessment  
Mice were monitored daily for clinical symptoms of development of blood 
stage of infection verified by measuring parasitemia (%) in flow cytometry 
(FacScan analyzer; BD Biosciences) and was analyzed with FlowJo software 
(Tree Star Inc.) or blood smear using Giemsa staining, as described36,37. The 
day of mosquito exposure was considered as day 0. Blood stage of infection 
was considered positive when parasitemia, i.e. percentage of infected RBC, 
was higher than 1%.  
 
3.2.11 Isolation of sporozoites from salivary glands See Section 2.2.4 
 
3.2.12 Sporozoites inoculation 
PbAEEF1a-GFP sporozoites were inoculated i.d. in the ear pinna (750 
sporozoites in 20-30µL; 1% BSA in PBS) or i.v. (retro-orbital; 150 sporozoites 
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in 50µL; 1% BSA in PBS) using a microsyringe (NanofilTM 100µL; 33G 
beveled needle; World Precision Instruments). 
 
3.2.13 Relative gene expression of parasite in ear and liver 
For relative quantification of sporozoites at the site of inoculation, the 
mouse ear was excised immediately after mosquito feeding and frozen in 
liquid nitrogen. For quantification of sporozoites in the liver, the whole 
liver was harvested 40h after mosquito feeding. In both cases, tissues were 
homogenized in TRIzol® (Life Technologies), total RNA was isolated 
according to the manufacturer’s instructions (RNeasy Mini kit; Qiagen). 
cDNA was synthesized using random primers and oligod(T) with 
SuperScript® II Reverse Transcriptase (Invitrogen). Briefly, RNA (2µg; 
10µL) was mixed with random primers (1µL) and dNTPs (10mM; 1µL), 
incubated (65°C; 5min), placed on ice and incubated in PCR Buffer (0.1M 
DTT; 40units/µL RNaseOUT™; 2min; 42°C;). Superscript RT (SSIIRT) was 
added (1µL; 42°C; 50min) and samples were heated to finalize synthesis 




Applied Biosystems’ Power SYBR Green PCR Master Mix was used as per 
manufacturer’s instructions (ABI Prism 7000 system; Applied Biosystems). 
Data is presented as relative expression of PbA 18S rRNA normalized to 
mouse Arbp0 mRNA. 
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3.2.14 Passive transfer of RBCs of mice exposed to mosquito biting 
α1,3Gt-/- mice immunized with rRBCM and age matched naïve α1,3Gt-/- 
mice were exposed to PbAEEF1a-GFP infected mosquitoes, as described above. 
Parasitemia was monitored by flow cytometry in FacScan analyzer (BD 
Biosciences). Nine days post- mosquito feeding, blood was collected and 
injected i.p. (100-200µL) to naive α1,3Gt-/- mice. Infection was monitored 
daily for parasitemia and clinical symptoms, starting from day 3-4 post-
infection RBC administration. 
 
3.2.15 Statistical analysis 
All tests (except human cohort studies) were performed using the 
GraphPad Prism v6.0 (GraphPad Software). Human analyses were 
performed in R version 3.0.2 (http://www.R-project.org). Ab levels between 
groups were compared with the Kruskal-Wallis test. The relationship 
between Ab levels and time to P. falciparum infection and febrile malaria 
was determined by Kaplan-Meier survival analysis and the log-rank test. 
Age dependent differences in anti-α-gal IgM and IgG antibody 
concentrations in human serum were determined using non-parametric 
Mann-Whitney test. Differences in anti-α-gal antibody concentration in 
mouse serum were determined using non-parametric Kruskal-Wallis test 
with Dunn’s multiple comparison post-test. Incidence of infection was 
compared using log rank (Mantel-Cox) test. Survival curves were plotted 
using Kaplan-Meier plot and significant differences among experimental 
groups were determined using the Log-Rank (Mantel-Cox) test. Data 
corresponding to relative amount of Plasmodium in the skin and liver 
obtained from qRT-PCR was analyzed using non-parametric Mann–






3.3.1 Human anti-α-gal IgM Abs confer protection against P. 
falciparum infection in endemic area 
We initially investigated the potential implications of α-gal expression on 
Plasmodium in a cohort study in Mali where the 6-month malaria season is 
predictable and intense38. We examined the relationship between plasma 
levels of anti-α-gal NAbs measured in healthy uninfected children and 
adults before the malaria season (n=229 for IgM; n=330 for IgG) and the 
subsequent risk of P. falciparum infection (determined by bi-weekly PCR 
analysis of fingerprick blood samples) and febrile malaria (determined by 
weekly physical examination) during the ensuing 6-month malaria season. 
In children <2 years the average level of anti-α-gal IgM Abs was 33.4 
µg/mL [95% CI: 18.4-48.3 µg/mL] (Figure 3.2a) similar to that reported in 
children with no history of malaria exposure8,10,39,40. However, anti-α-gal 
IgM Abs increased with age (surrogate for malaria exposure), reaching an 
average of 123.03 µg/mL [95% CI: 79.3-166.7 µg/mL] in adults (Figure 3.2a) 
—more than twice the level reported in adults with no malaria exposure, i.e. 
51.6 µg/mL [95% CI: 14.9-88.3 µg/mL] (Figure 3.2a)8,10,39,40. The average 
level of anti-α-gal IgG Abs in children under 2 years was 1.46 µg/mL [95% 
CI: 0.22-0.69 µg/mL], and increased in adults to 3.66 µg/mL [95% CI: 
3.04-4.28 µg/mL] (Figure 3.2c). In contrast to IgM, levels of circulating anti-
α-gal IgG were similar between malaria-exposed and non-exposed adults 
suggesting that P. falciparum infection fails to drive an IgG response 
directed against the α-gal glycan8,10,39,40. Time-to-event analysis did not 
show a correlation between anti-α-gal IgM and IgG Abs levels before the 
malaria season and the subsequent risk of P. falciparum infection (p=0.76 
and p=0.08, respectively) or febrile malaria (p=0.35 and p=0.18, 
respectively). However, the average level of anti-α-gal IgM Abs in children 
>4 years of age who had no P. falciparum infections detected during the 6-
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month malaria season (n=13) was higher than those who became infected 
(n=141) (Figure 3.2b), suggesting that anti-α-gal IgM Abs plays a role in 
protecting against P. falciparum infection. Levels of circulating anti-α-gal 
IgG Abs in individuals from a malaria endemic area are on average 33-fold 
lower than levels of IgM anti-α-gal NAbs and we could not find any 
correlation between non-infected children and anti-α-gal IgG Abs (Figure 
3.2d).  
 
Figure 3.2. Anti-α-gal IgM and IgG Abs in circulation increase with age. a) Anti-
α-gal IgM Abs in individuals (dots) from an endemic area of malaria in Mali or 
from the USA. Mean (red bars) and STD. b) Levels of anti-α-gal IgM Abs in P. 
falciparum infected individuals (Pf+) vs. non-infected individuals (Pf-), same 
population as (a). c) Anti-α-gal IgG Abs in individuals (dots) from an endemic area 
of malaria in Mali or from the USA. Mean (red bars) and STD. d) Levels of anti-
α-gal IgG Abs in P. falciparum infected individuals (Pf+) vs. non-infected 
individuals (Pf-), same population as (c). Serum samples from Mali were shown 
with grey circles whereas serum samples from USA were shown with black circles. 












































































































3.3.2 Immunization against α-gal confers sterile protection against 
malaria 
To test the protective role of anti-α-gal NAbs experimentally, we took 
advantage of “human-like” α1,3Gt deficient mice that can generate anti-
α-gal Abs. Unlike humans, mice express a functional α1,3Gt gene that 
produces α-gal. As such anti-α-gal-reactive B cells are deleted from the 
peripheral B cell repertoire of mice, which fail to produce anti-α-gal Abs41. 
Deletion of the α1,3Gt gene in mice (α1,3Gt-/-)15,26 is sufficient to allow the 
generation of robust antibody responses against α-gal15. Consistent with 
previous studies42. However, under specific pathogen free conditions 
α1,3Gt-/- mice produce residual levels of circulating anti-α-gal IgM Abs, 
below 0.1-1µg/mL (Figure 3.3b). This is not the case for anti-α-gal IgG Abs. 
In contrast; α1,3Gt+/+ mice do not produce circulating anti-α-gal IgM and 
IgG Abs (Figure 3.3b). Circulating anti-α-gal IgM Abs but not IgG were 
detected in α1,3Gt-/- mice maintained under germ-free conditions, 
revealing that a fraction of anti-α-gal IgM Abs are NAbs (See Chapter 5). 
 
Immunization of α1,3Gt-/- mice against α-gal, using rabbit RBC membranes 
(rRBCM) expressing high levels of α-gal or synthetic α-gal conjugated to 
bovine serum albumin (α-gal-BSA), elicited the production of circulating 
anti-α-gal IgM and IgG Abs (Figure 3.3b). As expected, control α1,3Gt+/+ 
mice failed to produce anti-α-gal NAbs (Figure 3.3a)15,41,42. Circulating anti-
α-gal IgA and IgE Abs were undetectable in control or immunized α1,3Gt-/- 
and α1,3Gt+/+ mice (data not shown). Levels of circulating IgM Abs in 
immunized α1,3Gt-/- mice was in the range of adult individuals from an 
endemic area of malaria (Figure 3.2a) while the range of concentrations of 
anti-α-gal IgG Abs in immunized α1,3Gt-/- mice was higher to that found in 
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of adult individuals from an endemic area of malaria range (Figure 3.2b). 
IgG anti-α-gal Abs in immunized α1,3Gt-/- mice were present at higher 
concentration, predominantly from the IgG1, IgG2b and IgG3 subclasses, 
with little or no anti-α-gal IgG2a (Figure 3.3b) or IgG2c (data not shown).  
 
Figure 3.3 Concentration of anti-α-gal Abs in mice. Concentration of anti-α-gal 
Abs in the serum of a) α1,3Gt+/+ and b) α1,3Gt-/- mice immunized with rRBCM (+) 
or with α-gal-BSA (+) vs. control naïve (-) α1,3Gt-/- mice. Dots represent individual 
mice (n=12-29 mice per group) pooled from 2-3 independent experiments. Red 
bars represent mean values. Statistically significant correlations among the groups 
were determined by Kruskal-Wallis test with Dunn’s multiple comparison post-
test.  
 
Immunization against α-gal protected α1,3Gt-/- mice from PbA infection 
transmitted A. stephensi mosquitoes, as compared to control non-
immunized α1,3Gt-/- mice (Figure 3.4a). Protection was not observed in 
immunized control α1,3Gt+/+ mice, as compared to non-immunized 
α1,3Gt+/+ mice (Figure 3.4a). Immunized α1,3Gt-/- mice were also protected 
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infection, as compared to non-immunized α1,3Gt-/- mice as well as to 
immunized or non-immunized α1,3Gt+/+ mice (Figure 3.4b).  
 
Figure 3.4 Immunization against α-gal confers protection against Plasmodium 
infection in mice, irrespectively of Plasmodium strains or vector species. 
Incidence of blood stage (%) infection with respective parasitemia (%) and survival 
(%) of a) PbAEEF1a-GFP, b) P. yoelii 17XNL infection transmitted by A. stephensi 
mosquitoes and c) PbAEEF1a-GFP transmitted by A. gambiae mosquitoes to α1,3Gt-/- 
mice immunized (I) with rRBCM vs. non-immunized (NI) α1,3Gt-/- mice or control 
immunized (I) or non-immunized (NI) α1,3Gt+/+ mice. Data shown is from 3-5 
independent experiments with similar trend, (n=15-34 mice per group). Statistical 
significance between groups in incidence of infection was determined by log rank 
(Mantel-Cox) test.  
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Immunization also protected α1,3Gt-/- mice against PbA infection by other 
mosquito strains, as illustrated for Anopheles gambiae, as compared to non-
immunized α1,3Gt-/- mice as well as to immunized or non-immunized 
α1,3Gt+/+ mice (Figure 3.4c). Altogether, this shows that anti-α-gal Abs 
confer protection against Plasmodium infection irrespective of Plasmodium 
strains or vector species. 
 
Figure 3.5 Immunization against α-gal confers sterile protection against 
Plasmodium transmission. a) Schematic representation of infection protocol and 
b) incidence of blood stage of infection (%) in α1,3Gt-/- mice transferred with RBC 
from α1,3Gt-/- mice infected PbAEEF1a-GFP or protected from transmission of PbAEEF1a-
GFP infection by A. stephensi mosquitoes (2 experiments; n=19 mice per group). 
Parasitemia (%) and survival (%) are in c) and d), respectively. 
 
We then asked whether α-gal immunization provides sterile protection 
against malaria. To test this hypothesis, RBC from immunized α1,3Gt-/- 
mice protected from transmission of PbA infection by Anopheles mosquitoes 
were passively transferred to naive α1,3Gt-/- mice and disease transmission 
was followed. Schematic view of infection procedure was shown in Figure 
a 
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3.5a. Passive transfer of RBCs failed to transmit infection or disease to naïve 
α1,3Gt-/- mice (Figure 3.5b-d). In contrast, passive transfer of RBC from 
immunized α1,3Gt-/- mice not protected from PbA transmission by 
Anopheles mosquitoes, readily transmitted infection and disease to naïve 
α1,3Gt-/- mice (Figure 3.5b-d). This demonstrates that immunization against 
α-gal confers sterile protection against malaria. 
 
3.3.3 Plasmodium sporozoites are arrested in the skin  
The percentage of infected RBC, i.e. parasitemia, was similar in immunized 
α1,3Gt-/- mice not protected from PbA infection vs. control non-immunized 
α1,3Gt-/- mice as well as control non-immunized or immunized α1,3Gt+/+ 
mice and when infected, all mice succumbed to experimental cerebral 
malaria (Figure 3.4). This suggests that while protective against malaria 
transmission, α-gal immunization is not protective against the 
development of disease. In keeping with this notion, when inoculated with 
PbA infected RBC, immunized α1,3Gt-/- mice developed similar levels of 
parasitemia vs. control non-immunized α1,3Gt-/- mice as well as to control 
non-immunized or immunized α1,3Gt+/+ mice (Figure 3.6a). These results 
also suggest that protective effect against Plasmodium occurs before the 
erythrocytic stage established. In keeping with this notion, we tested this 
hypothesis via injection of PbA intravenously (i.v.) or intradermally (i.d.). 
Immunized α1,3Gt-/- mice were protected from artificial transmission of 
PbA sporozoites via intradermal inoculation vs. control non-immunized 
α1,3Gt-/- mice or control immunized or non-immunized α1,3Gt+/+ mice 
(Figure 3.6c). Protection was no longer observed when sporozoites were 
artificially inoculated intravenously (Figure 3.6b) suggesting that the 
protective effect of α-gal immunization acts in the skin via a mechanism 
that is no longer operational in blood.  
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Figure 3.6 Immunization against α-gal confers protection against Plasmodium 
infection at pre-erythrocytic stage. Incidence of blood stage infection (%), 
parasitemia (%) and survival of α1,3Gt-/- mice immunized (I) with rRBCM vs. 
control non-immunized (NI) α1,3Gt-/- mice or control immunized (I) or non-
immunized (NI) α1,3Gt+/+ mice inoculated with a) PbAEEF1a-GFP iRBC 
intraperitoneally (i.p.), b) PbAEEF1a-GFP sporozoites (i.d.) or c) PbAEEF1a-GFP sporozoites 
(i.v.). Data shown in (a) is from 1 experiment (n=4-6 mice per group) and (b-c) is 
from 3-5 independent experiments with similar trend (n=15-34 mice per group). 
Statistical significance among groups in the incidence of infection was determined 
by log rank (Mantel-Cox) test. 
 
Transmission of PbA was associated with Plasmodium 18S rRNA 
accumulation at the site of inoculation, as quantified in the ear pinna by 
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qRT-PCR (Figure 3.7a). The relative amount of Plasmodium 18S rRNA was 
similar in immunized vs. control non-immunized α1,3Gt-/- mice or control 
immunized or non-immunized α1,3Gt+/+ mice (Figure 3.7a). Immunized 
α1,3Gt-/- mice did not accumulate Plasmodium 18S rRNA in the liver vs. 
control non-immunized α1,3Gt-/- mice or non-immunized or immunized 
α1,3Gt+/+ mice (Figure 3.7b). This suggests that α-gal immunization does 
not interfere with sporozoite inoculation by Anopheles mosquitoes, but 
rather arrests sporozoite migration from the skin into the liver. 
 
Figure 3.7 Parasite burden is reduced in immunized α1,3Gt-/- livers. Plasmodium 
18s rRNA/ mouse Arbp0 mRNA in a) skin and b) liver non-immunized (Control) vs. 
immunized (rRBCM) α1,3Gt-/- mice exposed to PbAEEF1a-GFP infected A. stephensi 
mosquitoes (3-5 experiments). Infected/total mice (grey dot represents individual 
mouse). Data was pooled from 3-5 experiments and bars represent mean values. 
Significance of expression difference among the groups was determined with non-
parametric Mann–Whitney test.  
 
3.3.4 Anti-α-gal Abs are protective against Plasmodium infection 
To establish whether the protective effect of α-gal immunization is 
mediated by anti-α-gal Abs, incidence of blood stage of Plasmodium 
infection was compared in α1,3Gt-/- mice lacking specific components of 




















































Figure 3.8 Generation of double-knockout mice. α1,3Gt-/- mice were crossed with 
JHt-/-, Aid-/-, µS-/- and Tcrβ-/- to generate double-knockout mice. Representative band 
size of WT mice (+/+), Het (+/-) and KO mice (-/-) were displayed from each 
genotypes were determined with a) PCR by using genomic DNA from tail clips 
except b) µS-/- mice that was analyzed with ELISA by using mouse serum.  
 
To establish whether the protective effect of α-gal immunization is 
mediated by anti-α-gal NAbs, PbA transmission was compared in 
immunized α1,3Gt-/- vs. α1,3Gt-/-JHT-/- mice, lacking B cells27. Immunized 
α1,3Gt-/-JHT-/- mice failed to produce anti-α-gal IgM or IgG Abs vs. naïve 
α1,3Gt-/-JHT-/- mice or to immunized α1,3Gt-/-mice (Figure 3.9). Moreover, 
immunized α1,3Gt-/-JHT-/- mice were not protected against PbA transmission 
by Anopheles mosquitoes vs. control non-immunized α1,3Gt-/-JHT-/- mice 
(Figure 3.10a). This shows that the protective effect of α-gal immunization 
is mediated via a B cell-dependent mechanism. 
 
Immunization of α1,3Gt-/-Aid-/- mice, that cannot undergo Ig class switch 
recombination28, failed to induce the production of anti-α-gal IgG but not 
IgM Abs vs. naïve α1,3Gt-/-Aid-/- or immunized α1,3Gt-/- mice (Figure 3.9). 
Immunized α1,3Gt-/-Aid-/-mice were nevertheless protected against PbA 


































confirms (Figure 3.2b) that anti-α-gal IgM Abs confer protection against 
malaria transmission. 
 
Figure 3.9 Anti-α-gal Abs in double knockout mice. Relative levels of circulating 
anti-α-gal IgM and total IgG Abs, as detected by ELISA in non-immunized (NI) or 
rRBCM immunized (I) α1,3Gt-/-, α1,3Gt-/-JHt-/-, α1,3Gt-/-Aid-/-, α1,3Gt-/-µS-/- and 
α1,3Gt-/-Tcrβ-/- mice. Square and circle marker show anti-α-gal IgM and total IgG 
Abs, respectively. Data is shown as mean ± standard deviation (n=10 mice per 
group), pooled from individual mice in 2-3 independent experiments. 
 
Immunization of α1,3Gt-/-µS-/- mice, which lack circulating IgM43, failed to 
induce anti-α-gal IgM Abs, without interfering with anti-α-gal IgG Ab 
response vs. naïve α1,3Gt-/-µS-/- mice or immunized α1,3Gt-/- mice (Figure 
3.9). Immunized α1,3Gt-/-µS-/- mice were protected from PbA transmission 
vs. control naïve α1,3Gt-/-µS-/- mice (Figure 3.10c). It should be noted here 
that immunized α1,3Gt-/- mice do not produce circulating IgA or IgE anti-
α-gal Abs (data not shown) and therefore a putative protective effect for 
these Ig isotypes can be excluded. 
 
Immunization of α1,3Gt-/-Tcrβ-/- mice lacking mature αβ T cells30 
compromised the anti-α-gal IgM and IgG response vs. control immunized 
α1,3Gt-/- mice (Figure 3.9). Immunized α1,3Gt-/-Tcrβ-/- mice were not 
protected from PbA transmission vs. control naïve α1,3Gt-/-Tcrβ-/- mice 
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dependent manner16,17 and demonstrates that the protective effect of these 
Abs against Plasmodium infection occurs in a T cell-dependent manner. 
 
Figure 3.10 Protective effect against PbA transmission is mediated by anti-α-gal 
Abs. Incidence of blood stage infection (%) with respective parasitemia (%) and 
survival (%) were determined in non-immunized (NI) or rRBCM immunized (I) a) 
α1,3Gt-/-JHt-/-, b) α1,3Gt-/-Aid-/- c) α1,3Gt-/-µS-/-, and d) α1,3Gt-/-Tcrβ-/- mice after 
exposing to PbA infected mosquitoes. Data in (a-d) was pooled from 3-7 
independent experiments (n=13-41 mice per group). Statistical significance among 
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Non-immunized as well as immunized α1,3Gt-/-JHT-/-, α1,3Gt-/-Aid-/- and 
α1,3Gt-/-µS-/- mice, not protected from PbA transmission, developed similar 
levels of parasitemia and succumbed to experimental cerebral malaria 
(Figure 3.10). This was not the case for α1,3Gt-/-Tcrβ-/- mice (Figure 3.10), 
consistent with the involvement of T cells in the pathogenesis of 
experimental cerebral malaria44. 
 
We then asked whether passively transferred anti-α-gal Abs are sufficient 
per se to prevent Plasmodium infection. Passive transfer of anti-α-gal IgM to 
naïve α1,3Gt-/- mice conferred protection against PbA transmission (Figure 
3.11a). This was also the case for passive transfer of anti-α-gal IgG Abs 
from specific subclasses, including IgG2b or IgG3 but not IgG1 or IgG2a 
(Figure 3.11b-d) mAb. Relative binding of different mAbs to α-gal was 
similar, as assessed by ELISA using α-gal conjugated to BSA (Figure 2.3a) 
or by immunofluorescence using PbA sporozoites (Figure 2.3b). Moreover, 
the specificity of these mAbs binding to PbA sporozoites was shown before 
by removal of α-gal glycan by α-galactosidase, revealing that anti-α-gal 
IgM and IgG mAb recognize specifically and only α-gal glycan on the 
surface of Plasmodium sporozoites (Figure 2.4b). It is worth noticing that the 
IgG2a, IgG2b and IgG3 mAbs are class switched mutants of the anti-α-gal 
IgG1 clone and as such have similar affinities for α-gal14. This confirms that 
anti-α-gal IgM NAbs are sufficient per se to confer protection against 
malaria transmission and shows that specific anti-α-gal IgG Ab subclasses 




Figure 3.11 Passive transfer of anti-α-gal IgM, IgG2b and IgG3 to naïve α1,3Gt-/- 
mice conferred protection against PbA transmission by A. mosquitoes. Incidence 
of blood stage of infection (%) with respective parasitemia (%) and survival (%) in 
α1,3Gt-/- mice receiving polyclonal anti-α-gal IgM Abs or monoclonal anti-α-gal 
IgG Abs (150µg/mL) vs. controls (Ctr.) exposed to PbAEEF1a-GFP infected mosquitoes. 
Data was pooled from 4-7 independent experiments (n=19-32 mice per group). 
Statistical significance among groups in the incidence of infection was determined 
by log rank (Mantel-Cox) test. 













































































































































































































































3.3.5 Protective effect of anti-α-gal Abs against Plasmodium 
infection can be enhanced with CpG oligodeoxynucleotide 
We asked whether immunization against α-gal that confers protection 
against Plasmodium infection by Anopheles mosquitoes could be enhanced 
different regimes of immunization. Immunization against α-gal using 
rRBCM was associated with 61% reduction of PbA transmission by A. 
stephensi mosquitoes upon immunization without adjuvant [95% CI: 0.209-
0.726] as compared to control naïve α1,3Gt-/- or α1,3Gt+/+ mice or to 
immunized α1,3Gt+/+ mice (Figure 3.4). Immunization with rRBCM 
emulsified in either incomplete Freud’s adjuvant (IFA), complete Freud’s 
adjuvant (CFA) or Alum provided similar levels of protection against PbA 
infected mosquitoes in α1,3Gt-/- mice, as compared to immunization 
without adjuvant (Figure 3.12 and 3.13). These immunizations also 
enhanced the anti-α-gal IgG Ab response (Figure 3.12a-c). But this was not 
associated with increased protection against transmission of PbA infection 
vs. immunization without adjuvant (Figure 3.3a). Moreover, we tested 
immunization with α-gal-BSA emulsified in CFA against Plasmodium 
infection (Figure 3.13d) that conferred the same level of protection against 
PbA infection. This excludes the presence of any other antigen in rRBCM 
favoring the protective mechanism against Plasmodium infection. 
Collectively, these immunization protocols show that immunization 
against α-gal can confer sterile protection against Plasmodium infection with 
the same rate.  
 
We then asked whether introducing a PAMP with potent 
immunostimulatory properties could also be useful as an adjuvant against 
Plasmodium infection. CpG-ODN, toll like receptor 9 agonist, can induce 
production of IL-12, which enhances IFN-γ production, antibody 
production, and cytotoxicity of NK cells and CD8+ T cells45-47.  
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Figure 3.12 Immunization against α-gal using different adjuvants. Anti-α-gal 
Abs in control α1,3Gt-/- mice non-immunized (-) vs. immunized (+) with rRBCM 
emulsified in a) IFA (rRBCMIFA), b) CFA (rRBCMCFA) or c) Alum (rRBCMAlum) Dots 
represent individual mice (n=12-29 mice per group) pooled from 2-3 independent 
experiments. Bars represent mean values. Statistically significant correlations 
among the groups were determined by Kruskal-Wallis test with Dunn’s multiple 































































































Figure 3.13 Protective effect of anti-α-gal immunization using different 
adjuvants formulation. Incidence of blood stage infection (%) with respective 
parasitemia (%) and survival (%) in α1,3Gt-/- mice immunized (I) with a) IFA + 
rRBCM, b) CFA + rRBCM (two booster immunizations with IFA + rRBCM), c) 
Alum + rRBCM or d) CFA + α-gal-BSA (two booster immunizations with IFA + α-
gal-BSA) vs. non-immunized (NI) α1,3Gt-/- mice or control immunized (I) or non-
immunized (NI) α1,3Gt+/+ mice. Incidence of infection significance among groups 
was determined by log rank (Mantel-Cox) test. A p value equal to or below 0.05 
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Figure 3.14 Protective effect of anti-α-gal immunization using CpG as an 
adjuvant. Concentration of anti-α-gal Abs a) in the serum of α1,3Gt-/- mice 
immunized (I) with rRBCM emulsified in CFA and supplemented with CpG vs. 
non-immunized (NI) α1,3Gt-/- mice or control immunized (I) or non-immunized 
(NI) α1,3Gt+/+ mice. b) Incidence of blood stage infection (%) with respective 
parasitemia (%) and survival (%) mice in (a). Dots in (a) represent individual mice 
(n=6-22 mice per group) pooled from 2 independent experiments. Bars represent 
mean values. Statistically correlations among the groups were determined with 
Kruskal-Wallis with Dunn’s multiple comparison post-test. Data in (b) show is 
from 3 independent experiments (n=16-19 mice per group). Incidence of infection 
significance among groups was determined by log rank (Mantel-Cox) test.  
 
Immunization of α1,3Gt-/- mice with rRBCM emulsified in complete 
Freund´s adjuvant (CFA) supplemented with toll like receptor 9 agonist 
CpG, enhanced the anti-α-gal IgG2b and IgG3 Ab response 2-3 fold (Figure 
3.14a) vs. immunization without adjuvant. This was associated with 88% 
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0.452] vs. 61% reduction upon immunization without adjuvant [95% CI: 
0.209-0.726]. This was not observed in control α1,3Gt+/+ mice. This suggests 
that the protective effect of α-gal immunization is enhanced by specific 
adjuvants, e.g. CpG, that favor the production of anti-α-gal Abs from 
specific IgG subclasses, i.e. IgG2b and IgG3. 
 
3.5 Chapter Discussions and Conclusion 
When inoculated into the human dermis, Plasmodium spp. sporozoites are 
confronted with high levels of cytotoxic anti-α-gal IgM Abs recognizing the 
α-gal glycan (Figure 3.2a) that prevent malaria transmission, as 
demonstrated in individuals from malaria endemic area. Briefly, those who 
showed evidence of decreased P. falciparum infection risk have higher 
levels of circulating anti-α-gal IgM Abs, compared to individuals who are 
susceptible to P. falciparum infection. Levels of circulating anti-α-gal IgG 
Abs in individuals from a malaria endemic area are on average 
significantly lower than levels of anti-α-gal IgM Abs (Figure 3.2c). This 
may help explain why anti-α-gal IgG Abs are not associated with decreased 
risk of P. falciparum infection in this study (Figure 3.1d). This also suggests 
that infection by P. falciparum in malaria endemic regions fails to induce 
class switch to anti-α-gal IgG Abs. The reason for this is not clear but the 
observation that immunization with rRBCM or with synthetic α-gal-BSA 
can induce class switch to anti-α-gal IgG Abs in mice suggests that P. 
falciparum may actively repress this phenomenon. However, when present 
above a certain threshold level as it was shown in murine model (Figure 
3.3b), anti-α-gal IgG Abs are protective against malaria transmission 
(Figure 3.10 and 3.11).  
 
Anti-α-gal Abs exert a negative impact on the initial phase of Plasmodium 
infection in the dermis (Figure 3.6 and 3.7). This notion is supported by the 
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observation that human-like α1,3Gt-/- mice immunized with rRBCM 
carrying circulating anti-α-gal IgM Abs (Figure 3.3b) at similar levels to 
those of adult individuals from an endemic area of malaria (Figure 3.2a) 
are protected against transmission of Plasmodium infection by Anopheles 
mosquitoes (Figure 3.10b and 3.11a). This protective effect in α1,3Gt-/- mice 
is not complete, consistent with malaria transmission in endemic areas of 
malaria, despite the likely protective effect of these Abs in adult humans 
(Figure 3.2b).  
 
The protective effect exerted by anti-α-gal IgM Abs may be relevant to 
understand the higher rates of malaria incidence in young children, as 
compared to adults. Newborns and children under the age of 2-3 years 
have only residual levels of anti-α-gal IgM Abs, as compared to adults from 
the same endemic area of malaria (Figure 3.2a). The observation that anti-
α-gal IgM Abs are protective against malaria transmission in human 
(Figure 3.2b) and human-like α1,3Gt-/- mice (Figure 3.10b and 3.11a) 
suggests that anti-α-gal IgM should be over certain threshold. Lack of these 
Abs in newborns and young infants contributes to their higher risk of 
malaria transmission. The ability of anti-α-gal NAbs to reduce very 
significantly transmission of Plasmodium infection via Anopheles mosquitoes 
bites might also contribute to explain why malaria transmission is a rather 
inefficient process even when performed under controlled experimental 
conditions in adult humans48-50. 
 
We also asked whether the protective of these Abs in murine model is 
vector or parasite strain dependent. Plasmodium infection in mice was 
tested with P. yoelii 17XNL strain in addition to PbA strain. Since there is no 
identified gene that favors the production of α-gal sugar epitope by 
Plasmodium, one can argue that Plasmodium sporozoites might uptake α-gal 
! 171!
from mosquitoes. This would make the protective effect against PbA 
infected A. stephensi possibly vector-dependent. Therefore, we performed 
additional experiments using PbA infected A. gambiae and showed that 
anti-α-gal Abs conferred protection against infection, as transmitted by A. 
gambiae mosquitoes. Together, these results demonstrate that anti-α-gal Abs 
confer protection against Plasmodium infection irrespectively of Plasmodium 
strain or vector species (Figure 3.4). 
 
While anti-α-gal Abs can provide sterile protection against malaria in 
mouse model (Figure 3.5), this is not commonly observed in malaria 
endemic areas, possibly because the levels of circulating anti-α-gal Abs are 
below a certain threshold level required to provide sterile protection. This 
also suggests that immunization against this carbohydrate may be useful 
not only in terms of preventing individual infection but also disease 
transmission to whole populations in endemic areas of malaria. However, 
this natural mechanism of protection against malaria transmission can be 
enhanced via immunization against α-gal emulsifying in adjuvants (Figure 
3.14a) that favor the production of T cell-dependent complement fixing 
anti-α-gal IgG Abs. Moreover, if coupled to other Plasmodium antigens 
(such as CSP that is the antigen of RTS,S vaccine), this approach could 
enhance the immunogenicity51 and hence the protective efficacy of 
candidate malaria vaccines52, preventing individual infections as well as 
disease transmission. The therapeutic efficiency of this type of approach in 
which anti-α-gal Abs and parasite protein specific Abs specifically can be 
enhanced will be critically dependent on the capacity of the immunization 
protocol to induce T cell-dependent complement fixing anti-α-gal IgG 
responses that will be able to arrest Plasmodium sporozoites in the skin 




All experiments in this chapter performed by the author of this dissertation 
except ELISA of human plasma samples were performed by Silvia Portugal 
and were analyzed Tuan Tran and Peter Crompton. 
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Interface Elements of Innate and Adaptive 
Immunity Play an Active Role on Protective 














Anti-α-gal Abs are natural defense mechanism against malaria 
transmission, targeting Plasmodium sporozoites in the skin immediately 
after inoculation by Anopheles mosquitoes (Chapter 3). Here, we addressed 
mechanistically, how anti-α-gal Abs target Plasmodium sporozoites and 
inhibit the progression of infection. We demonstrate that preformed 
anti-α-gal Abs target Plasmodium sporozoites for complement-mediated 
cytotoxicity. Complement activation by anti-α-gal Abs is cytotoxic to 
sporozoites and thus is sufficient per se to prevent sporozoite migration to 
the liver and to inhibit hepatocyte invasion, suppressing the establishment 
of liver stage infection. Collectively, these observations reveal that the 
protective effect exerted by anti-α-gal Abs is strictly dependent on 




















The innate immune system of vertebrates has the ability to recognize 
evolutionarily conserved molecular patterns that are unique to 
microorganisms1. PAMPs that form molecular signatures of microbial 
invaders are detected PRRs expressed on the cell surfaces, in intracellular 
compartments or secreted extracellularly2,3 (see Section 1.4.1). This 
recognition process results in the activation of innate immune responses 
and subsequent induction of the effector functions conferring host 
resistance to pathogens. The complement system acts as one of such 
components of innate immunity that targets pathogens for cytotoxicity. 
 
The complement system was named by Belgian immunologist and 
microbiologist, Jules Bordet in 1896. An experiment on blood serum 
components led him to discover that the lytic effect of Abs is significantly 
increased by the presence of innate serum components referred to as 
complements. The complement mechanism has the ability to ‘complement’ 
the antibacterial properties of the Abs by a heat-stable fraction of serum, 
enhancing bacteria opsonization and subsequently killing. This now well-
characterized system consists of a complex network of plasma and 
membrane-associated proteins that provide a highly efficient defense 
response against bacteria, viruses or protozoan parasites4.  
 
The complement system can be activated on the surface of a pathogen in 
the early phases of an infection through three different pathways which are 
classical, alternative and lectin pathways (Figure 4.1)4-6. 
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Figure 4.1 Overview of complement activation. The complement system consists 
of three pathways leading to activation of the complement cascade. These 
pathways converge at the cleavage/activation of membrane bound C3, leading to 
generation of C3a and C5a that promotes opsonization of pathogens as well as the 
membrane attack complex (C5b-9) that disrupts the membrane integrity of 
pathogens and promotes their killing and clearance. Adapted from7. 
 
Activation of the classical and lectin pathways depends on the recognition 
of pathogens by antibodies (pentraxins and C1q that binds to an antibody 
attached to antigen in the classical pathway) and pattern recognition 
molecules (lectins and ficolins for the lectin pathway), respectively8. In the 
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classical pathway, complement activation is triggered upon the binding of 
the C1 complex, which consists of one molecule of C1q, two serine protease 
proenzymes C1r and C1s, to an Ab bound to a microbial organism9. 
Activation of C1s cleaves C4 that binds covalently to the infectious agent 
surface, cleaving C2. The lectin pathway can be activated by binding of a 
serum protein called mannan-binding lectin to carbohydrates containing 
mannose on bacteria or viruses10. This activates the Mannose Binding 
Ligand-associated serine proteases (MASPs) and leads to the cleavage of C4 
and C2 11. These two pathways meet at the level of C4b/C2a (C3-convertase 
enzyme) leading to C3 proteolysis and the generation of C3a and C3b. The 
alternative pathway, that is mechanistically distinct from these two 
pathways, is initiated spontaneously when a complement component binds 
to the surface of a pathogen, relying on spontaneous low-level formation of 
C3b (C3 tick-over)7. All three pathways generate a protease called a C3 
convertase through proteolytical activation, binding covalently C3b to 
C4bC2a and forming the C5 convertase (C4bC2aC3b complex) while in the 
alternative pathways, Factors B and D are the key players that lead to 
spontaneous C3 hydrolysis and eventual formation of C3 (C3bBb) and C5 
(C3bBbC3b) convertases. The alternative pathway stabilized and facilitated 
by properdin. The formation of convertases also generates anaphylatoxins 
(C4a/C3a/C5a) that act as potent inflammatory soluble molecules while 
forming the membrane attack complex (MAC), which creates a highly 
cytotoxic pore in the cell membranes of pathogens. Of note, opsonins (C3b) 
mark pathogens for phagocyte opsonization via the engagement of 
receptors [complement receptors 1-4 (CR1-4) and CRIg] for C3b4,12. 
 
4.1.1 Positive feedback loop between complement system and 
neutrophils 
Neutrophils are the most abundant (50-75%) type of circulating white 
blood cells in humans. Together with the complement system, neutrophils 
are a major player in the process of innate cell-mediated immunity. 
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However, neutrophils often fail to provide host defense against pathogens 
in the absence of opsonins. Neutrophils are abundant in viral, bacterial and 
fungal induced lesions where they bind opsonized pathogens as well as 
viral infected cells via an oxidative burst often triggered via the 
engagement of Ab (Fc) and complement (iC3b) receptors13. 
 
Figure 4.2 An amplification loop between complement and neutrophil. 
Engagement of PRR activates neutrophils, triggering the complement alternative 
pathway. Activation of the alternative pathway increases neutrophil and cellular 
responses. Adapted from14. 
 
Complement-neutrophil interactions are mediated via C3a, C4a, and C5a 
and their respective receptors15,16. Neutrophil proteases and oxidants can 
activate complement in fluid phase and activated neutrophils can also 
release unknown complement activating factors. Moreover, complement 
activation can be triggered by the expression of molecules on the surface of 
apoptotic or necrotic cells. Recently, Camous and colleagues (Figure 4.2) 
have shown that suboptimal levels of cytokine or coagulation-derived 
factors serve as initial stimulus to activate neutrophils and later on, to 
secrete properdin that triggers complement activation through the 
alternative pathway. This positive feedback loop enhances the activity of 





4.1.2 Anti-α-gal Abs and complement mediated cytotoxicity 
Activation of complement by anti-α-gal Abs is particularly well 
documented in the context of the xenograft rejection in which anti-α-gal 
Abs recognize α-gal expressed in the transplanted organ and activate 
complement via the classical pathway. This leads to endothelial cell 
damage, platelet aggregation, occlusion of small blood vessels and collapse 
of the vascular bed, resulting in graft rejection within minutes to hours. 
Anti-α-gal IgM Abs trigger the activation of the classical pathway of 
complement as well as the activation of MBL/MASP2 (Figure 4.1)19 
suggesting that the lectin pathway may be activated by anti-α-gal IgM 
Abs20. Mouse anti-α-gal IgG2a, IgG2b and IgG3 are also potent activators of 
complement and can mediate the xenograft rejection21-24. By comparison, 
anti-α-gal IgG1 mAb activates complement poorly22 although it can act in a 
cytotoxic manner via the activation of Fc-γ receptors expressed on several 
cell types, including NK cells23. Anti-α-gal IgG subclasses vary on their 
ability to engage Fc-γ receptors, i.e. IgG1>IgG2b >>IgG2a =IgG324. 
 
In this chapter, we asked whether complement activation contributes to the 
protective effect exerted by anti-α-gal Abs against Plasmodium infection. We 
determined the subclass(es) of anti-α-gal IgG that confer protection against 
Plasmodium infection and asked whether neutrophils have a role on this 
protective mechanism driven by anti-α-gal Abs. 
 
4.2 Materials and Methods 
4.2.1 Mice See also Section 3.2.2 
To generate α1,3Gt-/-C3-/- double knockout mice, C57BL/6 α1,3Gt-/- mice 
were crossed with homozygous C57BL/6 complement 3 deficient (C3-/-; 
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line B6.129S4-C3tm1Crr/J) mice25. Animals were genotyped by PCR using 
the following primers: 
 
In addition, mouse complement factor 3 in serum was determined using 
highly sensitive two-site enzyme linked immunosorbent (ELISA), as 
described in the manufacturer’s instructions (GenWay Biotech, Inc., USA). 
 
4.2.2 Passive immunization with anti-α-gal mAbs 
α1,3Gt-/-C3-/- mice received anti-α-gal IgM, IgG2b and IgG3 Abs (150µg; 
100µl per mouse) via a single intravenous injection, 24h prior to mosquito 
exposure.  See Section 2.2.2 and Section 3.2.6 for more details. 
 
4.2.3 In vivo PMN depletion  
Anti-Gr1 mAb (Clone: RB6-8C5; RB6-8C5 hybridoma) was produced at the 
Instituto Gulbenkian de Ciência under serum-free conditions using a 
CELLine (Integra, Switzerland)26. Neutrophils were depleted in α1,3Gt-/- 
mouse by a single intravenous anti-Gr1 mAb injection (250µg), 48h prior to 
mosquito biting. PMN depletion was confirmed by staining for CD11b-
FITC (Integrin α[M] chain, Mac-1α chain, CR3, BD PharmingenTM) and 
Anti-Gr1-PE (1A8, BD PharmingenTM) and analyzed in flow cytometry27 
(CyAn™ ADP Analyzer, Beckman Coulter). 
 
4.2.4 Parasites maintenance and mosquitoes rearing See Section 2.2.1 
 
4.2.5 Plasmodium transmission See Section 3.2.9 
 
4.2.6 Disease assessment  See Section 3.2.10 
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4.2.7 Isolation of sporozoites from salivary glands See Section 2.2.4 
 
4.2.8 C3b deposition on Plasmodium  
PbAHsp70-GFP sporozoites were exposed to anti-α-gal mAbs (150µg/mL; in 
50µL DMEM; 60min; 4°C) and subsequently to naive C57BL/6 mouse 
plasma (1:5 in 0.1% gelatin in Veronal Buffer (VB)++; 50µL; 60min; 37°C) 
(Lonza), used as a source of complement. Samples were washed (1X; PBS) 
and mouse C3 deposition was detected using APC labeled anti-
C3/C3b/iC3b (Clone: 6C9; 1:100; 50µL; 45min; 4°C) and analyzed in 
CyAnTM ADP Analyzer (Beckman Coulter). 
 
4.2.9 Complement mediated cytotoxicity in Plasmodium  
PbAHsp70-GFP sporozoites (10-50x103) were incubated with anti-α-gal or 
isotype matched anti-DNP mAbs (150µg/mL mAb in 10µL DMEM 
GlutaMAXTM; 60min; 4°C). Naive C57BL/6 mouse plasma (1:5) or baby 
rabbit complement (1:10; Cedarlane Laboratories) was added (0.1% gelatin 
in VB++) as a source of complement (60min; 37°C). Cytotoxicity was 
quantified according to GFP expression of Plasmodium sporozoites in 
Andor Spinning Disk Confocal Microscopy (Andor Technology).  
 
4.2.10 Invasion/Wounding Assay (Cell Traversal) 
Human hepatoma cells (HepG2; kindly provided from Robert Menard, 
Institut Pasteur, France) were cultured (4x104/well; 200µL in 96-well plates) 
in DMEM (GlutaMAXTM, 10% FBS, 100U/mL penicillin/streptomycin; 
Life Technologies) (37°C; 5%CO2; 2 days). PbAHsp70-GFP sporozoites (19-25 
days post-infection) were pre-incubated with anti-a-gal or isotype matched 
control anti-DNP mAbs (150µg/mL in 20-50µL; 60min; 4°C). Plasma from 
C57BL/6 mice (1:5 in 20-50µL 0.1% gelatin in VB++ buffer; Lonza) was 
added (60min; 37°C) as a source of complement and sporozoites were 
immediately transferred onto HepG2 cells at a 1:4 parasite/cell ratio. Co-
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cultures were incubated (120min; 37°C) with Tetramethylrhodamine-
Dextran (10,000MW, 1:1; 2mg/mL; Molecular Probes®), washed (2X; PBS) 
and trypsinized (30-50µL; 0.05% Trypsin-EDTA, Phenol Red (Gibco®). 
Wounded (%) and parasite-invaded (%) cells was determined by flow 
cytometry analysis (FACScan, BD Biosciences), gating on FL1 (GFP; 
invasion) and FL2 (Dextran-Red; wounding). Sporozoite maturation was 
determined by quantifying the number of EEFs per field and EEF area after 
40h co-culture in 15 µ-Slide 8 well (ibiTreat; IBIDI; Germany) using 
fluorescence microscopy (Screening Microscopy; Nikon Eclipse TE2000-S). 
Images were obtained at 20X magnification. Pictures were analyzed using 
Image J software (NIH). 
 
4.2.11 Statistical analysis 
All tests were performed using the GraphPad software V6.0 (Prism) and 
statistical significance was determined by repeated measures one-way 
ANOVA, when data assumed Gaussian distribution after arcsin 
transformation, and followed by Tukey’s multiple comparison post-test. 
Survival curves were plotted using Kaplan-Meier plot, and significant 
differences between groups were determined with the Log-Rank (Mantel-




4.3.1 Generation of α1,3Gt−/−C3−/− mice 
α1,3Gt-/- mice were crossed with mice lacking complement C3 (C3-/- mice) 
and C3 gene deletion was confirmed by PCR (Figure 4.3a). α1,3Gt-/-C3-/- 
mice are viable and fertile. Depletion of soluble C3 was confirmed by 
ELISA in mouse plasma samples (Figure 4.3b). Complement C3 in normal 
mouse plasma ranges from 0.18-1.26 mg/mL with an average 
concentration of 1 mg/mL28 that is comparable with α1,3Gt-/- mice (Figure 
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4.3b). In α1,3Gt-/-C3-/- mice complement C3 concentration was reduced to 
zero, as expected. Anti-α-gal IgM titers after immunization with rRBCM 
are equal in α1,3Gt-/- and α1,3Gt-/-C3-/- mice (Figure 4.3c). However, anti-α-
gal IgG Abs in α1,3Gt-/-C3-/- mice were relatively but not significantly lower 
than in α1,3Gt-/- mice and showed bigger variation among the serum 
samples (Figure 4.3c). 
 
Figure 4.3 C3 concentration and anti-α-gal antibodies levels in α1,3Gt-/-C3+/+ and 
α1,3Gt−/−C3−/− mice. a) Complement C3 gene deletion was determined by PCR 
detecting the absence of the WT C3 allele PCR product (lower band) and presence 
of the mutated allele (upper band). b) Concentration of complement C3 protein in 
plasma of α1,3Gt-/-C3+/- and α1,3Gt-/-C3-/- mice (n=19-21 mice per group) was 
determined by C3 ELISA. c) Antibody levels of α1,3Gt-/-C3+/+ and α1,3Gt-/-C3-/- 
mice (n=13-20 mice per group) after immunization. Error bars indicate standard 
deviation. 
 
4.3.2 Protective effect driven by anti-α-gal Abs is complement 
dependent 
We asked whether the protective effect exerted by anti-α-gal Abs was 
mediated via a mechanism involving complement activation24,29. Passive 
transfer of anti-α-gal IgM Abs and anti-α-gal IgG2b mAb to α1,3Gt-/-C3-/- 
mice, which lack C3 and cannot activate the complement cascade, failed to 
confer protection against PbA transmission vs. control α1,3Gt-/-C3-/- mice 
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(Figure 4.4a and 4.4b). Passive transfer of anti-α-gal IgG3 mAb to α1,3Gt-/-
C3-/- mice conferred negligible protection vs. control α1,3Gt-/-C3-/- mice 
(Figure 4.4c). This shows that the protective effect of IgM and IgG2b but 
not that of IgG3 anti-α-gal Abs acts via a mechanism that is strictly 
complement-dependent. Once infected, mice developed the same level of 
blood stage of infection and succumbed to ECM, regardless of genotype or 
immunization. 
 
Figure 4.4 Protective effect of anti-α-gal IgM, IgG2b, but not IgG3 Abs occurs via 
complement activation mechanism. Incidence of blood stage of infection (%), 
parasitemia (%) and survival (%) in α1,3Gt-/-C3-/- mice receiving anti-α-gal a) IgM, 
b) IgG2b and c) IgG3 Abs vs. controls (Control) not receiving Abs, exposed to 
PbAEEF1a-GFP or PbAHsp70-GFP infected mosquitoes. Data was pooled from 2-4 
independent experiments (n=9-21 mice per group). Error bars indicate standard 
deviation. Significance between anti-α-gal Abs receiving and controls groups (a-c) 













































































































































4.3.3 Protective effect of anti-α-gal Abs involves PMN cells 
We asked whether the protective effect of anti-α-gal Abs involves PMN 
cells. Depletion of PMN cells was performed via the administration of anti-
Ly-6G (Gr-1) mAb and assessed by flow cytometry using anti-Gr1 and anti-
CD11b Abs (Figure 4.5). Non-depleted control α1,3Gt-/- mice have around 
5% PMN cells (Figure 4.5a) whereas anti-Gr1 administered α1,3Gt-/- mice 
have no or very few PMN cells in the blood circulation (Figure 4.5b).  
 
Figure 4.5 Assessment of PMN depletion in mice. Gating strategy for detection of 
PMN by flow cytometry in control a) and b) anti-Ly-6G (Gr-1) mAb administered 
α1,3Gt-/- mice blood. Data was representative of 3-4 independent experiments. 
 
Passive transfer of anti-α-gal IgG2b Abs to α1,3Gt-/- mice depleted from 
PMN cells by the administration of anti-Ly-6G (anti-Gr-1) mAb failed to 
confer protection against PbA infection (Figure 4.6b). In contrast, passive 
transfer of anti-α-gal IgM Abs and anti-α-gal IgG3 mAb to PMN cells 











100 101 102 103 104
SSC










100 101 102 103 104


















4.6a and 4.6c). This suggests that the protective effect of anti-α-gal IgG2b 
but not of IgM or IgG3 Abs is dependent on PMN cells. Depletion of PMN 
cells did not interfere per se with the incidence of Plasmodium infection30 
while preventing the onset of cerebral malaria (Figure 4.6), consistent with 
previous findings31.  
 
Figure 4.6 Protective effect of anti-α-gal Ig2b Ab, but not IgM and IgG3 Abs, is 
PMN cells dependent. Incidence of blood stage of infection (%), parasitemia (%) 
and survival (%) in PMN cells depleted α1,3Gt-/- mice receiving anti-α-gal a) IgM, 
b) IgG2b and c) IgG3 Abs vs. controls (Control) not receiving Abs, exposed to 
PbAEEF1a-GFP or PbAHsp70-GFP infected mosquitoes. Data was pooled from 2-4 
independent experiments (n=9-21 mice per group). Error bars indicate standard 
deviation. Significance between anti-α-gal Abs receiving and control groups (a-c) 
were determined by log rank (Mantel-Cox) test. 
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4.3.4 Anti-α-gal Abs are cytotoxic to Plasmodium sporozoites 
Once bound to the surface of Plasmodium sporozoites, anti-α-gal IgM, 
IgG2b and IgG3 mAbs, activated the classical pathway of complement24,29, 
as assessed by C3 deposition (Figure 4.7b). Anti-α-gal IgG1 or IgG2a mAbs 
failed to activate complement (Figure 4.7b). Complement activation was 
not observed in the absence of anti-α-gal Abs (Figure 4.7b), showing that 
the alternative and lectin pathways are not activated by sporozoites. 
 
Figure 4.7 Anti-α-gal antibody mediated C3 deposition on Plasmodium 
sporozoites. a) Gating strategy for flow cytometry of GFP+ PbAHsp70-GFP sporozoites. 
b) Detection of C3 deposition on the surface of PbAHsp70-GFP sporozoites, gated as 
indicated in (a). PbAHsp70-GFP sporozoites were incubated in vitro with anti-α-gal or 
control anti-DNP mAbs plus mouse complement (C). Control PbAHsp70-GFP 
sporozoites were incubated with vehicle. C3 was detected using an anti-
C3/C3b/iC3b mAb. Histograms are representative of 3 experiments. 
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Complement activation by anti-α-gal IgM, IgG2b or IgG3 mAb is cytotoxic 
to sporozoites in vitro, as assessed by quantification of GFP+ PbAHsp70-GFP 
sporozoites before and after the treatments (Figure 4.8a). Anti-α-gal IgG1 
and IgG2a mAbs, which did not activate complement when bound to 
Plasmodium sporozoites, were not cytotoxic (Figure 4.8a). The cytotoxic 
effect of anti-α-gal IgM, IgG2b and IgG3 was similar when using mouse or 
rabbit complement, but was strictly dependent on the presence of 
complement (Figure 4.8a). Moreover, isotype matched Abs against 
dinitrophenol were not cytotoxic to Plasmodium sporozoites (Figure 4.8a).  
 
4.3.5 Anti-α-gal Abs inhibit hepatocytes infection by Plasmodium  
We asked whether anti-α-gal mAbs inhibit PbA sporozoites migration 
through hepatocytes (wounding) and/or hepatocyte invasion32. In the 
presence of complement, anti-α-gal IgM, IgG2b and IgG3 Abs, albeit less 
pronounced, inhibited hepatocyte transmigration and invasion (Figure 
4.8b), as assessed in vitro for PbAHsp70-GFP sporozoites. This inhibitory effect 
was not observed when using anti-α-gal IgG1 or IgG2a Abs or 
isotype/subclass matched control anti-DNP Abs (Figure 4.8b). These 
observations suggest that the recognition of the α-gal glycan by anti-α-gal 
mAbs on the surface of PbA sporozoites inhibits hepatocyte infection via a 
complement dependent mechanism. 
 
Lastly, we assessed whether anti-α-gal mAbs inhibit the development of 
EEFs of Plasmodium sporozoites. Complement activation by anti-α-gal IgM, 
IgG2b and IgG3 Abs reduced the number of EEFs (Figure 4.9a) as well as 
the average EEF size (Figure 4.9b and 4.9c) formed in vitro by PbAHsp70-GFP 
sporozoites. Anti-α-gal IgG1 Abs did not show this inhibitory effect, while 
anti-α-gal IgG2a Abs did not reduce the number of EEFs (Figure 4.9a) but 
had a residual inhibitory effect on EEF size (Figure 4.9b and 4.9c). 
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Isotype/subclass matched control anti-DNP Abs did not modulate EEF 
numbers (Figure 4.9a) or average size (Figure 4.9b and 4.9c), 
demonstrating that the anti-α-gal Abs are capable of activating 
complement to limit Plasmodium development in the liver. 
 
Figure 4.8 Protective effect of anti-α-gal mAbs against hepatocyte infection. a) 
Mean (%) of viable GFP+ PbAHsp70-GFP sporozoites incubated with anti-α-gal (α-gal) 
or anti-DNP mAbs (Control) plus mouse or rabbit complement. b) Mean (%) of 
HepG2 cells wounded (Dextran-Red+) or invaded (GFP+) by PbAHsp70-GFP incubated 
with anti-α-gal or anti-DNP mAbs (Control) plus mouse complement. Data in (a) 
and (b) were pooled from 3-4 and 6 independent experiments. Graphs show mean 
values and error bars indicate standard deviation. Differences between anti-α-gal 
Abs treated groups and control groups in (a and b) were analyzed by repeated 
measures ANOVA followed by Tukey’s multiple comparison post-test. 
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Figure 4.9 Protective effect of anti-α-gal Abs against Plasmodium maturation in 
hepatocytes. a) Number of EEF per field (dots) (20-23 fields). b) Area of individual 
EEF (dots) (n=111-256 EEFs counted in 20-23 fields). c) Total area of EEF (dots) per 
field (20-23 fields). Data is representative of 2 independent experiments with the 
same trend. All in HepG2 cells after PbAHsp70-GFP sporozoites exposure to anti-α-gal 
or anti-DNP mAbs in the presence of mouse complement. 
 
 

























































































































































4.4 Chapter Discussions and Conclusion 
In this chapter, we examined whether the complement systems can be 
activated via anti-α-gal Abs once these recognize Plasmodium sporozoites, 
as assessed by C3 deposition on Plasmodium sporozoite surface using flow 
cytometry analysis (Figure 4.7 and 4.8). We found that this is the case and 
complement system is critical to support the protective role of anti-α-gal 
Abs against Plasmodium infection (Figure 4.4). 
 
Once bound to the surface of Plasmodium sporozoites anti-α-gal IgM, IgG2b 
and IgG3 Abs induced the deposition of C3b while this was not the case for 
anti-α-gal IgG1, IgG2a mAbs and control samples (Figure 4.7b). Despite the 
detectable ability of anti-α-gal IgG3 Abs to induce C3 deposition, 
complement-mediated lysis of Plasmodium sporozoites was less 
pronounced, as compared to anti-α-gal IgM and IgG2b Abs (Figure 4.8a). 
Complement-mediated lysis was not observed for anti-α-gal IgG1 and 
IgG2a. Moreover, in vivo experiments performed by administrating the 
anti-α-gal IgG2b and IgG3 Abs in α1,3Gt-/-C3+/++ mice reflected the same 
pattern. This data argues that complement activation is strictly required to 
sustain the protective effect of anti-α-gal IgM and IgG2b Abs but not that of 
anti-α-gal IgG3 Abs (Figure 4.4).  
 
The chemoattractant role of C3a and C5a promote the biologic activity of 
anti-α-gal IgG2b33 and IgG334 Abs. In keeping with this notion, the 
protective effect of anti-α-gal IgG2b is lost in the absence of PMN cells, 
while PMN cells are not strictly required to sustain the protective effect of 
anti-α-gal IgM and IgG3 Abs (Figure 4.5). It is well established that binding 
of different IgG subclasses to FcγR varies significantly35,36 and that there is a 
synergistic functional interaction between FcγR-mediated and complement 
mediated effects. Anti-α-gal IgG3 appears to act predominately via 
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complement activation while anti-α-gal IgG1, IgG2a and IgG2b Abs acting 
via both complement activation and presumably FcγR24. In the absence of 
the complement component C3, there is a compensatory mechanism in 
which thrombin can act as a C5 convertase, generating C5a and activating 
the complement machinery37. This may also help explaining the partial 
dependency of IgG3 anti-α-gal on C3 for its protective effect against 
Plasmodium infection. Other yet undefined complex regulatory and 
compensatory mechanisms may also be operational, such as those 
involving the interactions between FcγR, C5a and thrombin, where C5aR 
that can promote inflammatory responses and leukocyte chemotaxis. The 
role of FcγR in protection mediated by anti-α-gal Abs against Plasmodium 
infection needs to be further investigated. 
 
Anti-α-gal IgM, IgG2b and IgG3 Abs suppress Plasmodium sporozoite cell 
traversal activity thus preventing the progression of infection from the 
dermis into the liver38. Activation of complement by anti-α-gal IgM, IgG2b 
and IgG3 Abs also has an inhibitory effect on sporozoite migration through 
hepatocytes that is less pronounced for anti-α-gal IgG3 antibody (Figure 
4.8b). Anti-α-gal IgM and IgG2b Abs reduced hepatocyte wounding and 
invasion profoundly, suggesting that complement activation by anti-α-gal 
Abs damages the surviving sporozoites. These appear to trigger a response 
in which sporozoites quickly invade hepatocytes without their usual 
migratory pattern. Presumably, Plasmodium sporozoites are damaged by 
the anti-α-gal Abs, their maturation inside of hepatocytes is also impaired 
(Figure 4.9).  
 
The positive feedback amplification loop occurring between PMN cells and 
complement system led us to test the protective role of anti-α-gal Abs in 
PMN cells deficient conditions. We found that in the absence of PMN cells 
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the protective effect of anti-α-gal IgG2b Abs was lost whereas the 
protective effect of anti-α-gal IgM and IgG3 Abs was totally or partially 
preserved. The interaction between anti-α-gal Abs and PMN leading to 
protection against Plasmodium infection needs to be further characterized. 
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The human anti-glycan Ab repertoire was probably tailored through 
evolution via natural selective pressure, as illustrated for the inactivation of 
the α1,3GT gene, which suppressed the expression of the α-gal in 
anthropoid primates and allowed for the production of anti-α-gal NAbs. 
As for other NAbs, anti-α-gal Abs are found at high levels in the absence of 
traceable immunization. However, their production may result from 
ongoing antigenic exposure by specific components of the intestinal 
microbiota that express α-gal. Here, we tested this hypothesis specifically 
and asked whether a specific bacterial component of the gut microbiota 
elicits a protective anti-α-gal Ab response against Plasmodium infection. We 
found that gut colonization as well as systemic infection by an E. coli strain 
expressing α-gal induces the production anti-α-gal Abs, which are 
protective against Plasmodium infection. This chapter demonstrates specific 
gut pathobiont expressing α-gal can recapitulate the normal etiology of the 















5.1 Introduction  
Individuals are in continuous interactions with microorganisms starting 
immediately at birth and throughout life. This results from the colonization 
of specific niches of the human body by complex communities of 
microorganisms that contribute crucially to many host physiologic 
functions. Colonization by microorganisms is particularly prevalent barrier 
tissues, such as skin, oral cavity, intestinal, respiratory and urogenital 
tracts1. These resident microorganisms constitute the microflora of the host 
and are called the microbiota. The total number of microorganisms 
dwelling in human body is estimated at 100 trillion cells, that is 10 times 
more than the number of host cells. The microbiota contains about 3 million 
genes, that is, 100 times more than host human genes2. The gut microbiota 
is distributed physically along the gastrointestinal (GI) tract with 
preferential regions being colonized by specific bacterial strains such as the 
stomach, e.g., Lactobacilli, or colon, e.g. E.coli3. These have several important 
roles, which cannot be executed by the host, e.g., breaking down plant 
carbohydrates or glycans present in mother’s milk. While the host 
establishes a mutualistic interaction with its gut microbiota, in extreme 
conditions, this interaction can be reverted into a pathogenic relationship 
reducing host fitness, i.e. disease3. The variety of microorganisms in gut is 
associated with the different type of response by host immune system. 
 
The immune system is extremely effective in preventing the access of gut 
pathogens to the host inner milieu while providing a delicate balance to 
host–gut microbiota relationship5. Lymphocytes elicit specific responses 
that are critical to the establishment and maintenance of the microbiota5. In 
healthy individual, mucosal surfaces are the initial site of interactions with 
microbial population, providing a first line of defense exerted by highly 
specialized cellular and molecular components such as epithelial cells and 
gut-associated lymphoid tissues (GALT). These mucosal surfaces can sense 
specific microbial components and generate anti-microbial peptides as well 
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as IgA Abs, which are secreted into the lumen where they impact on the 
composition and biologic activity of specific components of the microbiota 
(Figure 5.1)4,6,7. Gut microbiota can play crucial roles in promoting B %cell 
development in local lymph nodes called the Payer’s patches and modulate 
of T or B-cell-mediated immune responses, either locally or systemically 
(Figure 5.1)8.  
 
Figure 5.1 Immune response in intestine and role of gut flora. Commensal 
bacteria shape the immune response in intestine via secretion anti-microbial 
peptide by Paneth cells and antigen presentation by dendritic cells to lymphocytes 
to produce Abs. Adapted from4. 
 
Generally, T and B cell-mediated responses generate a repertoire of Abs 
that reflects the history of immune response to pathogens and prepare the 
host to respond to upcoming infections. However, under healthy 
conditions, where no history of a pathogen was recorded, natural 
antibodies (NAbs) are apparently produced without prior immunization9. 
NAbs are thought to produced by often auto-reactive B cells subjected to 
positive selection, and playing an important role on the maintenance of 
homeostasis while defending the host against a broad spectrum of 
infections10-12. Among other antigens, NAbs can recognize carbohydrate 
structures, including blood group antigens, do not found during first 
weeks of life13. G.F. Springer showed that anti-glycan NAbs directed 
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against blood group antigens, may be generated in response to bacterial O-
antigens and LPS expressed by components of the gut microbiota14. This 
notion is in keeping with the observation that healthy individuals have 
high levels of circulating NAbs, directed many other glycan structures, 
including soluble as well as integral glycoconjugates that act as part of cell 
membranes attached to proteins or lipids structures15. 
 
Anti-α-gal Abs are amongst this class of NAbs, present in a considerable 
amount (1-5% of circulating Igs) under steady state conditions16,17. 
Production of α-gal specific NAbs is thought to be driven mainly by 
exposure to microbiota expressing α-gal, including Klebsiella spp., Serratia 
spp. and Escherichia coli spp18. These Enterobacteriaceae can express galactosyl 
residues α-linked to LPS, components of the bacterial capsule or cell wall 
glycoproteins. When present in some of these bacterial components, α-gal 
glycan acts as a strong immunogen supporting the production of high 
levels of anti-α-gal Abs production. Presumably expression of α-gal in the 
outer membrane of enterobacteria in human gut may provide PRR 
engagement to B cells leading to the production of anti-α-gal T cell 
independent IgM NAbs, in a similar manner to anti-ABO blood group 
antigens18.  
 
Gut colonization by the human pathobiont E. coli O86:B719 is informative 
for the etiology of anti-α-gal Ab production. E. coli O86:B7, a gram-negative 
bacteria, presenting α-gal structures on the cell wall or LPS20 was used as a 
model bacterial strain to study the generation of anti-blood group NAbs in 
humans. It was hypothesized that human anti-α-gal NAbs are induced by 
enteric exposure, in a similar manner to the development of Abs against 
ABO blood group antigens. In support of this notion, the production of Abs 
directed against the α-gal related anti-B blood group glycan be induced in 
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germ-free (GF) chickens upon gut colonization by E. coli O86:B721. 
Moreover, intravenous injection of LPS from E. coli O86:B7 can neutralize 
these Abs. An experimental study performed on sick and healthy humans 
(from 1 week to 70 years old) by introducing heat-killed E. coli O86:B7 
administered via nasal inhalation or feeding showed that anti-blood Abs 
related with α-gal were readily elicit14. Afterwards, studies on primates 
showed that removal of aerobic gram-negative bacteria is associated with a 
gradual decrease of circulating anti-α-gal Abs, thus suggesting that steady 
state production of these Abs is modulated by gram-negative bacteria in 
the gut22 Lastly, oral inoculation of live E. coli O86:B7 leads to gut 
colonization of streptomycin treated α1,3Gt-/- mice elicits the production of 
cytolytic anti-α-gal Abs23. This argues that gut colonization by E. coli 
O86:B7 may be particularly relevant in triggering the production of α-gal 
specific Abs presumably contributing to the high titers of these circulating 
Abs in healthy human adult18. The production of the Abs is not only 
triggered upon interaction between host and its gut flora, but it can also 
occur in pathogenic conditions driven by gram-negative bacteria from 
Salmonella spp. or for protozoan parasites from Trypanosoma spp., as 
illustrated24. 
 
In this chapter, we tested whether colonization or systemic infection of 
α1,3Gt-/- mice with E. coli O86:B7 can induce the production of anti-α-gal 
Abs, in a similar manner to induction of natural anti-ABO Abs in humans 
colonized by this bacterial strain. We used E. coli O86:B7, originally isolated 
from a human infant14 and E. coli K12, isolated from a stool sample of a 
diphtheria patient25, to test whether anti-α-gal Abs can be induced by 
enteric exposure to these bacterial strains and if this was the case whether 
these Abs can confer protection against Plasmodium infection. We 
demonstrate that gut colonization with α-gal expressing bacteria elicits the 
production of anti-α-gal IgM Abs and in α1,3Gt-/- mice, recapitulating the 
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normal etiology of human anti-α-gal Abs, thought to be induced by enteric 
exposure to α-gal expressing bacteria. Importantly, anti-α-gal Abs 
produced in response to gut colonization by E. coli O86:B7, confer 
protection against malaria transmission. 
 
5.2 Materials and Methods 
5.2.1 GF Mice 
C57BL/6 α1,3Gt-/- mice were re-derived via caesarean section from SPF into 
GF conditions at the Instituto Gulbenkian de Ciência, as described in detail 
elsewhere6. Briefly, pregnant female α1,3Gt-/- mice were euthanized (20 
days post-coitum), uteri were immersed in 1% VirkonS, rinsed in sterile 
water and pups were transferred to surrogate mothers kept in GF isolators 
(Gettinge-La Calhéne, France). GF status was monitored every third week 
onwards. For gnotobiotic colonization, 8-12 weeks GF α1,3Gt-/- mice were 
transferred into sterile micro-isolator Ventiracks (Biozone, Margate, UK), 
fed ad libitum with a standard autoclaved chow diet and water and GF 
status was monitored every third week onwards.  
 
5.2.2 Bacterial strains and growth conditions 
Frozen E. coli O86:B7 (ATCC® 12701TM; Rockville, Md.) and E. coli K12 
(ATCC® 10798) (~107 CFU/ml; 50% glycerol solution; -80°C) stocks were 
inoculated into Luria broth (LB; 50 mL; 37°C; overnight) on a shaker rack. 
Spectrophotometric absorbance was measured at 600nm (Optical Density-
OD600) and adjusted to OD600 ~0.2 in order to harvest bacteria during 
exponential growth corresponding to an OD600 of 2. The approximate cell 
number was determined according to spectrophotometric measurement 
and confirmed with most probable numbers (MPN) technique, also known 




5.2.3 Detection of α-gal on bacterial cultures 
E. coli O86:B7 and E.coli K12 were cultured (LB; 50 mL; 37°C; overnight), 
washed (2X; PBS; 4000g; 5min; 4°C) and re-suspended in PBS. Bacteria 
were fixed (200 µL; 4% PFA in PBS; 20-30 min; RT) and washed (1X; PBS; 
4000g; 5min; RT). 108-109 CFU/mL were stained with BSI-IB4-FITC (200µL; 
50µg/mL; 20min; RT) for flow cytometry analysis using FacScan analyzer 
(BD Biosciences). In parallel, IFA were performed using 10 µL stained 
samples after air-drying (20 min; RT). Samples were washed (1X; PBS), 
incubated with 4',6-diamidino-2-phenylindole (DAPI) (200µL; 10 µg/mL; 
10min; RT; Molecular Probes®) and washed (1X; PBS). 
Immunofluorescence images were obtained by Spinning Disk Confocal 
microscopy Revolution xD (Andor Technology; USA) at 100X 
magnification and images were processed with ImageJ (NIH) software.  
 
5.2.4 Systemic infection with live bacteria 
Bacterial cultures of E. coli O86:B7 and E.coli K12 were washed (2X; PBS; 
4000g; 5min; 4°C) and resuspended (PBS; 108 CFU/mL). 107 CFU/100 µl of 
bacterial samples were administered intraperitoneally to α1,3Gt-/- mice (3 
times at two weeks intervals). 
 
5.2.5 Gut colonization of mice 
GF and SPF α1,3Gt-/- mice treated with streptomycin sulphate (5g/L in 
drinking water for 7 days; Gibco), were starved for 12 hours and colonized 
with E. coli O86:B7 (ATCC® 12701TM; Rockville, Md.) or E. coli K12 
(ATCC® 10798) (~107 CFU/100 µL Luria-Bertani-LB medium) via oral 
gavage, using a 20-gauge stainless steel animal feeding needle (Cadence 
Science Inc., Japan). Control mice were inoculated with sterile LB medium. 
Colonization protocol was administered 3 times at two weeks intervals. 
Samples were stained to check colonization as described before in Section 
5.2.3 to assess colonization. 
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5.2.6 Anti-α-gal ELISA See Section 3.2.7 
 
5.2.7 Parasites maintenance and mosquitoes rearing See Section 2.2.1 
 
5.2.8 Plasmodium transmission See Section 3.2.9 
 
5.2.9 Disease assessment See Section 3.2.10 
 
5.2.10 Statistical analysis See Section 3.2.15 
 
5.3 Results 
5.3.1 Growth of E. coli K12 and E. coli O86.B7 strains  
E. coli O86:B714 and E. coli K1225 were cultured and determined the growth 
kinetics of them. Bacteria were cultured initially with OD600 0.05 in LB 
medium and followed until reaching to the stationary phase of their 
growth at 37°C (Figure 5.2).  Growth of E. coli O86.B7 and E. coli K12 cells 
led to similar final cellular yields (Figure 5.2). Growth curve plots obtained 
for two independent experiments indicate that doubling under exponential 
growth corresponding to about 20-30 minutes. Both E. coli strains reached 
stationary phase around 6 hours. 
Based on these data we decided 
to harvest bacterial samples for 
all in vivo experiments around 
2-3 hours after initial culturing, 
corresponding to an OD600 ~0.2.  
 
Figure 5.2 Growth kinetics of E. 
coli O86.B7 and E. coli K12. Overnight-cultured E.coli strains were adjusted to 
same initial OD and every 1-3h thereafter; a sample was collected to measure OD600 
over 12 hour. Representative of two independent experiments. 
 












5.3.2 Detecting the α-gal glycan on E. coli strains 
We asked whether α-gal is expressed on E. coli O86.B7 and E. coli K12 using 
BSI-IB4-FITC. As previously reported20, E. coli O86.B7 expressed high levels 
of α-gal while expression of α-gal was relatively low or absent on E. coli 
K12, as assessed by flow cytometry (Figure 5.3a) and immunofluorescence 
(Figure 5.3b). These results confirmed the presence of terminal α-gal 
containing glycoconjugates in E. coli O86.B7 and their relative absence on E. 
coli K12. 
 
Figure 5.3 Detection of α-
gal glycan on E. coli 
O86.B7 but not on E. coli 
K12. The presence of α-gal 
on E. coli strains was 
detected by a) flow 
cytometry and b) IFA. 
Results are representative 
of 2-3 independent 
experiments. Images in (b) 
represent composite 
staining, i.e α-gal (green) 
and DNA (blue) at 100X 




5.3.3 Anti-α-gal Abs induced upon systemic infection are 
protective against Plasmodium infection 
We used the E. coli O86.B7 and E. coli K12 strains to infect α1,3Gt-/- mice. 
Initially, we established a sub-lethal dose of inoculation (i.p.; 3 times at two 
weeks intervals), i.e. infection. Administration of 105–108 CFU of either E. 
coli strain was not associated with incidence of mortality and selected the 
107 CFU/mouse. Infection by live E. coli O86.B7 but not E. coli K12 elicited 
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(Figure 5.4a). Circulating anti-α-gal IgA and IgE Abs were undetectable in 
the circulation of α1,3Gt-/- (data not shown).  
 
Figure 5.4 Systemic infections by live E. coli O86.B7 but not E. coli K12, induces 
anti-α-gal Abs and confers protection against Plasmodium infection. a) Mean ± 
STD of relative absorbance of anti-α-gal Abs from non-infected (Naïve), E. coli K12 
(E. coli K12) or E. coli O86.B7 (E. coli O86.B7) infected α1,3Gt-/- mice. b) Incidence of 
blood stage of Plasmodium infection (%) in mice infected with bacteria as in (a) and 
exposed to PbAEEF1a-GFP infected mosquitoes, c) parasitemia (%) and d) survival (%) 
of the same mice as in (b) infected with PbAEEF1a-GFP. Data shown in (a) is 2-3 
independent experiments (n=4-6 mice per group) and (b-d) is from 3 independent 
experiments (n=11-31 mice per group). Statistical significance among groups in the 
incidence of infection was determined by log rank (Mantel-Cox) test. 
 
Administration of 107 CFU/mouse of E. coli K12 or E. coli O86.B7 to 
α1,3Gt+/+ mice did not induce the production of circulating anti-α-gal Abs 






















































































































coli O86.B7, α1,3Gt-/- mice were protected from subsequent PbA infection 
by A. stephensi mosquitoes. Infection with live E. coli O86.B7 protected 
α1,3Gt-/- mice from PbA infection vs. naïve α1,3Gt-/- mice (Figure 5.4b). 
This was not the case for E. coli K12 infection (Figure 5.4b). When infected 
by PbA, all mice developed similar levels of parasitemia (Figure 5.4c) and 
succumbed to experimental cerebral malaria, irrespectively of the E. coli 
strain used (Figure 5.4d). These results suggest that systemic infection by a 
bacterial strain expressing α-gal elicits an anti-α-gal Ab response that is 
protective against malaria transmission. 
 
5.3.4 Gut colonization with bacteria expressing α-gal elicits 
protective Ab response against Plasmodium infection 
The high titer of anti-α-gal NAbs detected in human serum throughout 
life27 suggests that the production of these NAbs may be induced by 
components of the gut flora. To test this hypothesis, we colonized α1,3Gt-/- 
mice with E. coli O86.B7 or E. coli K12 strains that express α-gal glycan or 
not, respectively (Figure 5.3a and 5.3b).  
 
In order to eliminate the endogenous gut flora, α1,3Gt-/- mice maintained 
under specific pathogen free (SPF) conditions were treated with 
streptomycin for 7 days (streptomycin sulphate; 5g/L in drinking water) 
and colonized thereafter with either E. coli O86.B7 or E. coli K12. This 
approach was not associated with discernable morbidity, including weight 
loss or diarrhea. Colonization of α1,3Gt-/- mice by E. coli O86:B7, after 
antibiotic treatment increased the levels of circulating anti-α-gal IgM Abs 
from 1.4 µg/mL [95% CI: 1.1-1.8 µg/mL] up to 162.9 µg/mL [95% CI: 95.89-
230.1 µg/mL] before and after colonization, respectively (Figure 5.5a). 
Levels of anti-α-gal IgM Abs in E. coli O86:B7 colonized α1,3Gt-/- mice were 
in the range of adult individuals from a malaria endemic region (Figure 
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3.2). Levels of circulating anti-α-gal IgG Abs remained at residual levels, i.e. 
<1 µg/mL (Figure 5.5b), in the range of adult individuals from a malaria 
endemic region (Figure 3.2). Colonization by E. coli K12 did not induce the 
production of anti-α-gal Abs in α1,3Gt-/- mice (Figure 5.5a and 5.5b).  
 
Figure 5.5 Gut colonization using E. coli O86.B7, but not E. coli K12, triggers 
anti-α-gal Abs production and confers protection against Plasmodium infection. 
Concentration of anti-α-gal a) IgM and b) IgG Abs in the serum of SPF α1,3Gt-/- 
mice that are non-colonized (SPF), colonized by E. coli K12 or colonized by E. coli 
O86.B7. Bars are mean. c) Incidence of blood stage of Plasmodium infection (%) in 
mice colonized as in (a and b) and exposed to PbAEEF1a-GFP infected mosquitoes (17-
34 mice per group). d) parasitemia (%) and e) survival (%) of α1,3Gt-/- mice as in (a 
and b), infected with PbAEEF1a-GFP (n=11-14 mice per group). Data shown in (a and 
b) is 2-3 independent experiments (n=12 mice per group) and (c) is from 3-5 
independent experiments (n=17-34 mice per group). Statistically significant 
correlations among the groups were determined by Kruskal-Wallis test with 
Dunn’s multiple comparison post-test. Statistical significance among groups in the 
incidence of infection was determined by log rank (Mantel-Cox) test. 
 
We next asked whether anti-α-gal Abs produced in the E. coli O86:B7 
colonized α1,3Gt-/- mice exert a protective effect against Plasmodium 






































































































































α1,3Gt-/- mice from PbA transmission by infected A. stephensi mosquitoes 
(Figure 5.5c). This was not the case when α1,3Gt-/- mice were colonized by 
E. coli K12 (Figure 5.5c). Parasitemia was similar among mice that were not 
protected from PbA infection (Figure 5.5d), succumbing thereafter to 
experimental cerebral malaria (Figure 5.5e). These results suggest that gut 
colonization with bacteria expressing α-gal elicits a protective anti-α-gal Ab 
response against Plasmodium infection. 
 
To determine whether the protective effect associated with gut colonization 
by E. coli O86.B7 is mediated by anti-α-gal Abs, similar colonization 
experiments were performed in α1,3Gt-/-JHT-/-, α1,3Gt-/-µS-/- or α1,3Gt-/-Aid-/- mice. 
Gut colonization by E. coli O86.B7 failed to protect α1,3Gt-/-JHT-/- (Figure 5.6a) 
and α1,3Gt-/-µS-/- (Figure 5.6c) but not α1,3Gt-/-Aid-/- (Figure 5.6b) mice from 
PbA infected Anopheles mosquitoes, as compared to control mice not 
colonized or colonized by E. coli K12. This shows that the protective effect 
of gut colonization by E. coli O86.B7 acts via a mechanism mediated by 
anti-α-gal IgM Abs that do not undergo somatic hypermutation. 
 
Figure 5.6 Protective effect driven by gut flora against Plasmodium infection is 
antibody dependent. Incidence of blood stage of Plasmodium infection (%) in a) 
α1,3Gt-/-JHT-/-, b) α1,3Gt-/-Aid--/- and c) α1,3Gt-/-µS-/- mice that are non-colonized (SPF), 
colonized by E. coli K12 or colonized by E. coli O86.B7. Data shown in (a-c) is 1-2 
experiments (n=4-10 mice per group). Statistical significance among groups in the 
incidence of infection was determined by log rank (Mantel-Cox) test. 
 
Incoming microorganism do not compete with other microorganism when 
colonized in germ-free (GF) mice. Colonization of GF mice by a single 
































































bacterial strain is called mono-colonization28. GF α1,3Gt-/- mice had low but 
detectable levels of anti-α-gal IgM Abs, i.e. 0.87 µg/mL [95% CI: 0.66-1.1 
µg/mL], confirming that these are NAbs since they are produced in the 
absence of a discernable foreign antigen (Figure 5.7a). This was not the case 
for anti-α-gal IgG Abs that were almost undetectable (Figure 5.7b). When 
mono-colonized by either E. coli O86.B7 or E. coli K12 for three times with 2 
weeks intervals mono-colonized GF α1,3Gt-/- mice showed no apparent 
morbidity or mortality. When mono-colonized by E. coli O86:B7, the levels 
of circulating anti-α-gal IgM Abs in α1,3Gt-/- mice increased to 96.62 µg/mL 
[95% CI: 59.32-133.9 µg/mL] (Figure 5.7a), without concomitant induction 
of anti-α-gal IgG Abs (Figure 5.7b). We then asked whether anti-α-gal Abs 
induced by mono-colonization of GF α1,3Gt-/- mice by E. coli expressing α-
gal confers protection against Plasmodium infection by A. stephensi 
mosquitoes. Mono-colonization by E. coli O86:B7 but not by E. coli K12 
protected α1,3Gt-/- mice from PbA transmission by A. stephensi mosquitoes 
(Figure 5.7c). Percentage (%) of infected RBC, i.e. parasitemia, was similar 
among mice not protected from PbA infection, succumbing thereafter to 
experimental cerebral malaria (Figure 5.7d and 5.7e). This suggests that 
mono-colonization by a specific pathobiont expressing α-gal glycan 
recapitulates the normal etiology of the human anti-α-gal Ab response and 
is associated with protection against Plasmodium infection, such as observed 
in a malaria endemic region (Figure 3.2). 
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Figure 5.7 Colonization by E. coli O86.B7 protects GF mice against Plasmodium 
infection. Concentration of anti-α-gal a) IgM and b) IgG Abs in the serum of GF 
α1,3Gt-/- mice that are non-colonized (GF), colonized by E. coli K12 or colonized by 
E. coli O86.B7. Data is representative of 2-3 independent experiments (12 mice per 
group) and red bars are mean. c) Incidence of blood stage of Plasmodium infection 
(%) in mice colonized as in (a and b) and exposed to PbAEEF1a-GFP or PbAHSP70 infected 
mosquitoes (n=9-13 mice per group). d) Parasitemia (%) and e) survival (%) of 
α1,3Gt-/- mice as in (a and b), infected with PbAEEF1a-GFP (n=7-10 mice per group). 
Data were pooled from 4 independent experiments. Statistically significant 
correlations among the groups in (a and b) were determined by Kruskal-Wallis test 
with Dunn’s multiple comparison post-test. Statistical significance among groups 
in the incidence of infection in (c) was determined by log rank (Mantel-Cox) test. 
 
5.4 Chapter Discussions and Conclusion 
Mammals have a complex microbiota that starts to be shaped quickly after 
birth, through colonization by vast number of essentially non-pathogenic 
or pathobiont microorganism along the body surface. The existence of a 
highly co-evolved relationship with host immune system has promoted 
beneficial co-existence and interdependency over millions of years. Host-
microbiota interaction can modulate T or B cell mediated immune 







































































































































immunity profoundly and regulating immune responses ensuring host-
microbial mutualism29.  
 
In this part of the thesis, we showed that under SPF conditions, α1,3Gt-/- 
mice produce residual levels of circulating IgM anti-α-gal Abs, which are 
also detected under GF conditions, confirming that these are NAbs (Figure 
5.5a and 5.7a). Moreover, anti-α-gal Abs in SPF α1,3Gt-/- mice do not 
increase appreciably over time (data not shown) in contrast to adult humans 
who have high levels of circulating IgM anti-α-gal Abs when compared to 
newborns (Figure 3.2a). This may be explained by the composition of SPF 
α1,3Gt-/- mice gut flora that does not change much over time as compared 
to human. Anti-α-gal IgM Abs in humans are relatively low in the first 
years of their lives and increase with age (Figure 3.2a). The reason for this 
may relate to lack of gut flora components expressing α-gal glycan30. 
Alternatively, daily dietary intake that alters the composition of the gut 
flora and may influence gut flora composition and as such as meat-based 
diet increase the bile-tolerant bacteria and decrease plant polysaccharides 
metabolizing bacteria31. For instance, colonization of Clostridium cluster 
XIVa seems to be established at the age of 4 years after birth, however, 
composition of Bacteroidetes, Bifidobacteria and Clostridium cluster IV phyla 
gradually change with age30. Moreover, diet consumption composed of 
animal or plant products could alter the human gut flora and might 
promote colonization by microbiota expressing α-gal glycan, therefore 
inducing the production of anti-α-gal NAbs31. Presumably, this does not 
occur in SPF α1,3Gt-/- mice which are maintained under a rather control 
diet and as such should have relatively constant gut as compared to 
humans. This may explain why the levels of anti-α-gal Abs in plasma of 
SPF α1,3Gt-/- mice fail to increase gradually over time (data not shown). 
Assuming that the production of anti-α-gal Abs arises from enteric 
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exposure to bacteria expressing α-gal, then specific components of the gut 
microbiota may be sufficient to induce protective mechanisms against 
pathogens expressing α-gal, such as Plasmodium. Our studies showed that 
this is the case in α1,3Gt-/- mice colonized by E. coli O86:B7 (Figure 5.5a and 
5.7a). This suggests that continuous or intermittent antigenic stimulation by 
components of the gut microbiota expressing α-gal is necessary for the life-
long production of anti-α-gal Abs.  
 
Figure 5.8 B cell development in bone marrow and in gut. B cell development 
occurs in the bone marrow and regulated by interactions with self-antigens. In 
contrast, it was shown that B cell receptor editing can occur in lamina propria of 
the gut, which induce B-cell tolerance to these resident microorganisms, and 
diversification of B cell receptors repertoire. Adapted from32. 
 
While B cells arise from the bone marrow and are activated in secondary 
lymphoid organs to produce Abs, B-cell development can also occur in the 
lamina propria of gut via a process involving BCR editing driven by gut 
microbiota33 (Figure 5.8). It is still unclear whether the NAbs that are 
generally low in the serum are produced by this population of B cells in the 
lamina propria of gut. In a similar manner, we showed that gut 
colonization with E. coli O86.B7 triggers the production of anti-α-gal IgM 
Abs produced most probably by B1 cells in the gut34. Local physical trauma 
or inflammation associated with the gavage process may promote 
inflammation and/or allow low numbers of microbes to infiltrate into the 
mucosal surface, and induce further the production of anti-α-gal Abs by B1 
cells, in the peritoneal cavity. Moreover, there may be a yet undefined 
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mechanism in which B cells can sample antigens from the gut without 
breaching the mucosal barrier and act as a link between innate and 
adaptive immune systems to provide defense mechanisms against 
microbial invasion. 
 
Gut colonization by E. coli O86.B7 triggers the production of anti-α-gal Abs 
of the IgM but not the IgG isotypes, suggesting that E. coli O86.B7 fails to 
induce Ig class switch, usually associated with B2 cell responses and 
assisted by T cells after colonization with commensal bacteria34. This 
suggests that E. coli O86.B7 may not be efficient in inducing B2 cells to 
produce anti-α-gal IgG Abs. Our work also demonstrates that gut 
colonization by specific strains of microbiota can contribute to the pool of 
circulating anti-α-gal IgM Abs. However, the levels of anti-α-gal Abs IgM 
Abs produced upon gut colonization are lower than those produced via 
immunization against α-gal glycan, but in similar concentration when 
compared to human adults (Figure 3.3, 3.12, 5.5a and 5.7a). This is 
sufficient however, to confer protection against Plasmodium infection 
(Figure 5.4b and 5.5b). This suggests that gut colonization with bacteria 
expressing α-gal is the main source of anti-α-gal Ab production but not the 
only one. When naïve α1,3Gt-/- mice are immunized against the α-gal 
glycan (Figure 3.3 and 3.12), the protective effect against Plasmodium 
transmission is higher than α1,3Gt-/- mice colonized with E. coli O86.B7.  
 
In conclusion, host can encounter many different types of pathogens 
expressing α-gal such as S. pneumoniae, H. influenza, S. aureus, E. coli, 
Salmonella or Clostridium. These can lead to inflammation and trigger 
activation of the immune system and subsequently, the production of anti-
α-gal Abs that are protective against Plasmodium infection. Other anti-
glycan Abs, that need to be further investigated, may have a similar 
protective role against several pathogens including Plasmodium. 
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Additionally, anti-α-gal Abs induced by the gut flora may also play a role 
against other vector borne protozoan parasites expressing α-gal, such as 
Leishmania spp. and Trypanosoma spp., the causative agents of Leishmaniasis 
and Trypanosomiasis, respectively24.  
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Plasmodium infection is still a major global threat to mankind. Despite 
recent progresses in reducing the global burden imposed by malaria, 
Plasmodium infection kills around 700.000 people per year, mostly children 
under the age of 3-4 years living in sub-Saharan Africa and South East 
Asia1. Moreover, over 200 million malaria cases are reported per year 
worldwide, mostly affecting children, to whom malaria imposes mortality 
or major sequels over life1. The recent breakthroughs provided by malaria 
control interventions (i.e. insecticide-impregnated bed nets, indoor 
insecticide spraying and anti-malarial drugs) managed to reduce malaria 
morbidity and mortality but there are still no available vaccines conferring 
sterile protection against Plasmodium infection. Phase III trials with what is 
considered as the most promising vaccine candidate, i.e. RTS,S/AS01,  in 
infants and children from malaria endemic areas show only modest 
protection with 50% efficacy in the first 3–4 months after immunization that 
decreases with exposure to Plasmodium infected mosquitoes. Therefore, the 
protective effect provided by this vaccine is too low to be used clinically2.  
 
The reason why children under the age of 3-4 years are more susceptible to 
this deadly disease seems to rely on a defective adaptive immunity against 
Plasmodium. The increasing knowledge about the biological features of 
Plasmodium infection and the immune system of its human host should 
allow to develop a better preventive and protective vaccine in children. 
This PhD thesis is centered around one such solution: to define a natural 
protective mechanism against this vector borne protozoan parasite, which 
is relatively absent in children, while innately present in adults. We found 
that Abs directed against α-gal and present at high levels in adults but not 
in children under the age of 3-4 years, effectively prevent Plasmodium 
infection. Presumably, this contributes to explain why children are more 
susceptible to Plasmodium infection as compared to adults. As a final touch 
of this study, we showed that the host gut flora can shape the generation of 
these NAbs and confer protection against Plasmodium infection. 
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In the final synthesis of this thesis, the main findings will be briefly 
reviewed focusing on the questions we asked since the beginning of this 
project:  
 
“Do we have a natural immune mechanism of defense against Plasmodium 
infection and if it is the case, can we enhance its effect to achieve the maximum 
level of protection?” 
 
6.1 Brief Overview and Conclusions of the Thesis 
Glycans associated with intracellular proteins as well as extracellular 
proteins/lipids on the cell surface, have a variety of essential biologic 
functions3. Regulation/distribution of glycan expression in mammals is 
under the control of glycosyltransferases that produce di-, tri-, oligo- and 
polysaccharides. Organisms can differ in the classes of glycans, with most 
organisms expressing N-glycans, while others are restricted to the 
expression of specific glycans, as is the case for hyaluronic acid in 
vertebrates and sialic acids in deuterostomes. Moreover, specific glycans 
are absent from very constrained taxa, e.g. α-gal and N-glycolylneuraminic 
acid (Neu5Gc) that are expressed by most vertebrates except humans4. The 
biologic relevance of some glycans has been probed by the deletion of 
specific galactosyltransferase genes, indicating that some of these are 
essential for development and other vital biologic processes. 
 
Loss of function mutations in genes encoding specific glycosyltransferases 
lead to the elimination of the end product glycan generated by these 
enzymes and are probably under natural selective pressure. As such, the 
complete loss of a particular glycan might occur in an attempt to restrain 
pathogen invasion. In this case, host interaction with glycan-expressing 
pathogens promotes immune recognition of that glycan, as illustrated for 
the production of anti-glycan Abs. Therefore, an evolutionary process is 
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thought to have provided acquired resistance against pathogens expressing 
such glycans, as illustrated in this thesis for the α-gal glycan5,6. 
 
Much of the attention related to anti-α-gal NAbs has been framed in the 
context of on xenotransplantation, that is, the transplantation of cells, 
tissues or organs across different specifies. In particular, pig organs have 
been argued to be suitable for transplantation into humans. However, pig 
cells express high levels of α-gal glycan at their surfaces, leading to 
hyperacute rejection of pig to human xenografts via a cytotoxic mechanism 
mediated by anti-α-gal NAbs. While many studies have addressed 
methodologies to overcome this type of rejection, relatively few studies 
asked what is the physiologic role, if any, of these anti-α-gal Abs7-11. Several 
studies also identified the presence of the α-gal glycan in pathogens 
including Serratia spp.12, Leishmania spp.13, Trypanosoma spp.14 and 
Plasmodium spp.15,16. Others studies have also associated infections by these 
pathogens with increasing anti-α-gal Abs17 levels and analyzed whether 
these anti-α-gal Abs targets these pathogens in vitro13,18-20. However, 
whether anti-α-gal Abs confer resistance to infection by these pathogens 
has never been tested in vivo.  In this thesis, we tested this hypothesis in the 
context of Plasmodium infection, the causative agent of malaria and a major 
driving force that shaped the evolution of anthropoid primates, including 
humans21,22. 
 
Under Chapter 2, we demonstrated that Plasmodium spp. express the α-gal 
glycan in the exo-erythrocytic stages. However, bioinformatics tools did 
not give any hit for candidate genes in Plasmodium genome encoding 
enzymes that may transfer α-gal to proteins or lipids. As such, we reasoned 
that Plasmodium obtains α-gal from its vector. Therefore, we asked whether 
α-gal is expressed by Anopheles mosquitoes. We detected the glycan in the 
! 234!
salivary glands of non-infected Anopheles mosquitoes, which led us to 
hypothesize that Plasmodium may be coated by mosquito components 
containing α-gal. Presumably, this may enable Plasmodium ookinetes or 
sporozoites to avoid the mosquito’s immune system as they emerge from 
the epithelial cells of the midgut. One candidate protein that could coat 
Plasmodium ookinetes or sporozoites during its development in the 
mosquito is laminin, a ubiquitous non-collagenous connective tissue 
glycoprotein expressed by insects as well as by mammalian, avian, reptilian, 
and amphibian cells and known to be decorated with α-gal23. The notion 
that laminin may confer avoidance from mosquito’s immunity is supported 
by the following observation: when injected into the hemocoel of A. aegypti 
female mosquitoes, negatively charged carboxymethyl (CM)-Sephadex 
beads are usually not melanized as they become coated with mosquito-
derived laminin24. In reverse, electrically neutral G-Sephadex beads are 
easily melanized. Since mosquito laminin prevents melanization, the 
melanization of mouse laminin coated-beads was tested in the mosquito 
abdominal body cavity and found to be significantly reduced. This 
suggests that mouse laminin prevents melanization in mosquitoes and that 
perhaps other insect-derived proteins expressing α-gal may also interact 
with Plasmodium spp. and mask them to avoid the immune system of the 
mosquito24-26. Thus, the α-gal detected on Plasmodium spp. surface might be 
derived from the Anopheles mosquito. However, we cannot exclude the 
possibility that there may be a yet unidentified homologue of the α1,3Gt 
gene in Plasmodium sporozoites presenting alternative mechanisms to 
utilize the host UDP-Gal and add it to the non-reducing termini of 
oligosaccharide chains of its own proteins or lipids. 
 
We confirmed that α-gal is also expressed during the erythrocytic stage of 
Plasmodium spp. infection27, as demonstrated in RBC from α1,3Gt-/- mice as 
well as in human RBC that inherently lack the expression of α-gal. It is 
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possible therefore that while Plasmodium spp. do not express an active 
enzyme capable of producing α-gal glycoconjugates, it may obtain those 
from its host. In support of this notion, Vanderberg and co-workers have 
shown that Plasmodium sporozoites extracted from salivary glands of A. 
mosquitoes are not recognized by lectins detecting D-glucose (SBA, RCA I 
and PNA), α-methyl-D-mannoside (ConA), N-acetyl-D-glucosamine 
(WGA), N-acetyl-D-galactosamine (DBA), fucose (UEA) or N-acetyl-
neuraminic acid (LPA)28. However, when sporozoites were incubated with 
mammalian host serum, host plasma glycoproteins or host glycolipids 
absorbed by sporozoites that were then positively stained for ConA and 
RCA I28, suggesting that Plasmodium are able to integrate host 
glycoconjugates into their cell surface structures. However, this was never 
tested for lectin BSI-IB4 that detects the α-gal glycan. 
 
The α-gal glycan was detected in Plasmodium infected RBC of α1,3Gt-/- mice 
or human. This shows that since α1,3Gt-/- mice and human do not express α-
gal in RBCs, parasites can retain α-gal from host serum component and 
utilized in a way that can be conjugated in α-1,3-gal form if Plasmodium 
does not constitutively express α-gal glycan. Additionally, the hepatocyte 
membranes have galactose detecting receptors, which help to uptake 
glycoproteins with terminal galactose residues. Therefore, upon liver 
invasion, glycoproteins containing terminal galactose coating the parasites 
would assist them to invade hepatocytes29. As mentioned before, 
Plasmodium sporozoite surface is a highly active and dynamic structure. If 
by any chance, Plasmodium sporozoites lose the α-gal glycan through the 
capping process when deposited into dermis, an interaction with host 
serum might provide them with terminal galactose residues. However, this 
needs to be further characterized.   
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We can argue that Plasmodium transmission, which is rather inefficient is 
hinting at a natural mechanism of protection, presumably targeting the 
initial phases of the Plasmodium life-cycle30-32. In Chapter 3, we 
demonstrated that anti-α-gal Abs are a natural defense mechanism, 
reducing malaria transmission by Anopheles mosquitoes. When inoculated 
into the dermis via mosquito bite, Plasmodium sporozoites are confronted 
with high levels of cytotoxic anti-α-gal IgM Abs that prevent malaria 
transmission, as demonstrated by three independent lines of evidence. First, 
individuals from malaria endemic areas that show evidence of decreased P. 
falciparum infection risk have higher levels of circulating anti-α-gal IgM Abs, 
compared to individuals susceptible to P. falciparum infection. Second, anti-
α-gal IgM Abs -when present in α1,3Gt-/- mice at levels similar to those 
observed in individuals from a malaria endemic area- are associated with 
protection from malaria transmission. Third, passive transfer of anti-α-gal 
IgM Abs protects α1,3Gt-/- mice from Plasmodium infection. This suggests 
that relative absence of anti-α-gal IgM Abs in children under the age of 3-4 
years compared to adults may help explain higher susceptibility malaria33. 
 
In contrast, the levels of circulating anti-α-gal IgG Abs found in individuals 
from a malaria endemic region as well as in α1,3Gt-/- mice colonized with 
the α-gal glycan expressing E. coli O86:B7 are ~30 fold and ~40-70-fold, 
respectively, lower than levels of anti-α-gal IgM Abs. This may help to 
explain why anti-α-gal IgG Abs are not associated with decreased risk of P. 
falciparum infection in this study. This also suggests that infection by P. 
falciparum in malaria endemic regions fails to induce class switch for the 
production of anti-α-gal IgG Abs. However, when present above a certain 
threshold level, anti-α-gal IgG Abs are also protective against malaria 
transmission as shown in the murine model. We found that this protective 
effect can be further enhanced by immunization protocols favoring the 
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production of complement-fixing subclasses of anti-α-gal IgG Abs. In this 
regard, immunization of α1,3Gt-/- mice with rRBCM emulsified in complete 
Freund´s adjuvant (CFA) supplemented with the Toll like receptor 9 
agonist CpG, enhanced the anti-α-gal IgG2b and IgG3 Ab response 2-3 fold 
vs. immunization without adjuvant and with association of 88% reduction 
in the relative risk of infection vs. 61% reduction upon immunization 
without adjuvant. Immunization of α1,3Gt-/- mice using several different 
adjuvants also enhanced the anti-α-gal IgG Ab response (Chapter 3). 
However, this was not associated with increased protection against 
Plasmodium infection, suggesting that the protective effect of α-gal 
immunization can be enhanced in the presence of specific adjuvants, e.g. 
CpG, that favor the production of anti-α-gal Abs from specific IgG 
subclasses, i.e. IgG2b and IgG3. 
 
While anti-α-gal Abs can provide sterile protection against malaria in mice 
(Chapter 3), this is not commonly observed in malaria endemic regions 
where, despite adult individuals have circulating anti-α-gal Abs, possibly 
these Abs are present at levels below a threshold level required to provide 
sterile protection. Nonetheless, we showed that this natural mechanism of 
protection can be enhanced via immunization using adjuvants that favor 
the production of T cell-dependent complement fixing anti-α-gal IgG Abs. 
Moreover, when coupled to other Plasmodium antigens, this approach 
should increase the immunogenicity34 of such antigens. Furthermore, this 
approach should be useful in preventing not only individual infections as 
well as disease transmission35. 
 
It is important to emphasize that anti-α-gal Abs are not protective once 
Plasmodium sporozoites reach the bloodstream or during the later 
erythrocytic stage of the infection. The lack of protection against 
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Plasmodium sporozoites in the bloodstream might be related with the short 
time frame required to reach the liver36, which may not allow for the 
efficient detection and targeting by anti-α-gal Abs. Additionally, when 
Plasmodium sporozoites invade hepatocytes, they become covered with  PV 
membrane, which is derived from the host hepatocyte plasma membrane 
and forms a barrier between the host cell cytosol and the parasite surface37, 
thus protecting the parasite against the antagonistic environment of the 
host. Therefore, PV membrane might block the interaction of anti-α-gal Abs 
with Plasmodium, making Abs ineffective against parasites. In the same 
extent, during erythrocytic stage of the infection when Plasmodium infects 
RBCs, both PV membrane and the RBC membrane also protect the parasite. 
Two layers of membrane might contribute to render Plasmodium 
inaccessible for anti-α-gal Abs and hence, to abrogate protection at this 
stage of infection. 
 
Complement-mediated cytotoxicity was shown to be the prevalent 
mechanism mediating the protective effect of anti-α-gal Abs against 
Plasmodium infection (Chapter 4).  When bound to Plasmodium sporozoites, 
anti-α-gal Abs activate the complement system, which is cytotoxic to 
sporozoites and inhibits Plasmodium migration through hepatocytes and the 
establishment of intracellular hepatocyte infection.  
 
These observations led us to propose the following model: when inoculated 
in the dermis via the bite of a female Anopheles mosquitoe38 Plasmodium 
sporozoites migrate to the liver in a matter of 15 minutes to a few hours39,40. 
As the Anopheles mosquitoes probes for a blood meal, it leads to the 
formation of edema and eventually micro-hematomas, i.e. a collection of 
blood outside of a blood vessel, inside the skin41. This might contribute to 
the mobilization of anti-α-gal Abs and complement components from 
blood circulation into the skin, allowing for sporozoites to be tagged by 
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anti-α-gal Abs that in turn activate the complement system and as a 
consequence, Plasmodium sporozoites lose their ability to reach the liver to 
establish a successful hepatocyte infection. For those sporozoites that spend 
very little time (only a couple of minutes) in the skin and rapidly reach to 
blood circulation, they are able to succeed an infection in the host. 
 
Figure 6.1 Protective effect of anti-α-gal Abs at the skin level is driven by the gut 
flora. An Anopheles mosquito deposits Plasmodium sporozoites into the dermis of 
the mammalian host. When sporozoites encounter anti-α-gal IgM Abs, induced 
upon gut colonization, they lose their infectivity and are not able to infect the host. 
Gut colonization with bacteria do not express α-gal does not induce anti-α-gal Abs 
production and hence, Plasmodium is able to successfully infect the host. 
 
Under Chapter 5, we examined the connection between anti-α-gal Abs and 
the gut flora. The presence of high levels of circulating anti-α-gal Abs 
throughout life, as seen in malaria endemic areas, has led us to ask whether 
these Abs could arise from a continuous exposure to specific components 
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of the gut flora, as enteric bacteria expressing α-gal42. We initially observed 
that, when kept under specific pathogen-free conditions, α1,3Gt-/- mice can 
produce only residual levels of circulating anti-α-gal Abs, below 0.01-
1µg/mL (Chapter 3)43. These mice are exposed to strict controlled food and 
environmental conditions that apparently maintain the gut flora of mice at 
a constant steady state of composition over time. Presumably, these mice 
have low number of bacteria expressing α-gal in their gut flora allowing for 
the production of anti-α-gal Abs. However, in this study the gut flora of 
α1,3Gt-/- mice was not characterized for the presence of bacteria expressing 
α-gal. Additionally, a microbial imbalance of the intestinal gut flora, i.e. 
dysbiosis, could promote the growth of pathobiont bacterial strains such as 
Proteobacteria or adherent/invasive E. coli that could in turn influence the 
production of circulating anti-α-gal Abs. However, dysbiosis is not likely to 
occur under these controlled conditions in mice44,45 when it is induced there 
is no effect on levels of anti-α-gal Abs. In contrast, the situation in humans 
is quite different. Humans are continuously exposed to a complex consortia 
of bacteria (pathogenic or non-pathogenic) that form the microbiota that 
can quickly change depending on the daily diet, a major factor influencing 
the composition and metabolism of the colonic microbiota46. 
 
To test whether specific components of human enteric α-gal expressing 
bacteria can induce the production of anti-α-gal Abs, we introduced an 
α-gal expressing pathobiont into the gut of α1,3Gt-/- mice, which resulted in 
the effective production of anti-α-gal IgM Abs. This shows that specific 
components of the human gut microbiota expressing α-gal can trigger the 
production of anti-α-gal Abs. It should be noted that circulating anti-α-gal 
IgM Abs are detected in non-colonized α1,3Gt-/- mice maintained under GF 
conditions, confirming that these are natural Abs. Interestingly, the levels 
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of anti-α-gal IgM NAbs, presumably produced by the natural Abs 
producing B1 cells, are significantly higher in SPF vs. GF α1,3Gt-/- mice. 
This suggests that specific stimulation driven by the gut flora is required 
for further stimulation of B1 cells to mount additional IgM responses and 
that this stimulation can depend on gut colonization by specific strains of 
bacteria. However, this is not the case for anti-α-gal IgG Abs, as these 
antibodies are not produced upon gut colonization by bacteria expressing 
α-gal.  
 
We then asked whether the gut flora could control the activation of anti-α-
gal B cells to afford protection against Plasmodium infection (Figure 6.1). We 
found that the anti-α-gal IgM Abs produced upon gut colonization by E. 
coli O86.B7 confers protection against Plasmodium infection in antibiotic 
treated SFP as well as in GF mono-colonized mice. Our results are 
consistent with previous findings on oral inoculation of E. coli O86.B7 and 
indicate that α1,3Gt-/- mice may be useful to elucidate the role of these Abs, 
mainly of the IgM subclass, in human resistance mechanisms to pathogens 
that expresses α-gal. Gut colonization by α-gal expressing bacteria thus 
leads to the production of anti-α-gal IgM Abs, comparable in titer and 
cytolytic activity to that of human serum, conferring protection against 
Plasmodium infection in GF or antibiotic treated SPF groups. This suggests 
that E. coli O86.B7 colonization in α1,3Gt-/- mice can recapitulate the normal 
etiology of anti-α-gal IgM Ab production in humans.  
 
6.2 Some Ideas for the Future Studies 
The main finding in this dissertation was that anti-α-gal Abs confer 
protection against Plasmodium infection. However, we believe that this 
study will largely assist to future studies investigating other vector-borne 
protozoan parasites expressing α-gal such as Leishmania spp. and 
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Trypanosoma spp., the causative agents of Leishmaniasis and 
Trypanosomiasis, respectively13. Similar vaccination approaches as the ones 
developed under this PhD thesis may be considered against these 
infectious diseases. In a similar manner, other naturally occurring anti-
glycan Abs should be considered to test the protective role against 
pathogens including bacteria, viruses and protozoan parasites.  
 
While detected on the Plasmodium surface the mechanism responsible for 
introducing α-gal glycan in Plasmodium proteins or lipids was not 
determined. Although we have speculated that the expression of α-gal in 
Plasmodium could be inherited from mosquito’s components the origin of α-
gal glycan in Plasmodium needs to be further characterized.  
 
The protective effect associated with immunization against α-gal was 
enhanced using protocols of immunization that incorporate adjuvants such 
as the CpG, a TLR9 agonist. This shows that the Abs response driven by α-
gal immunization can be enhanced, paving the way for the generation of an 
improved vaccine against Plasmodium infection via modulation of the 
natural anti‐α-gal Ab response. This will promise to profoundly enhance 
the protective immune response currently obtained via immunization with 
protein/sub‐unit vaccine formulations such as CSP, the core antigenic 
components of the RTS,S vaccine. This type of immunization protocol can 
enhance the generation of a robust, long-lasting, T cell-dependent, 
complement fixing, cytotoxic anti-α-gal and anti-CSP Abs targeting 
Plasmodium sporozoites in the skin as well as the generation of TH and TC 
cells targeting the liver stage of infection, supporting the notion of α-gal 
epitopes can increase the protective effect of the RTS,S vaccine, which is 
initially very low2,47,48. The relative efficacy of this approach can be tested in 
murine models as well as in humans. Moreover, the inhibiting capacity of 
! 243!
anti-α-gal Abs from rodents as well as from protected volunteers can also 
be tested functionally with in vitro assays. 
 
Protection against Plasmodium infection, as driven by anti-α-gal Abs, is 
complement and/or PMN cell dependent. It is likely that Fc receptors 
expressed by PMN cells may be involved in the mechanism via which 
anti-α-gal Abs confer protection against Plasmodium infection. Accordingly, 
studies related to xenotransplantation revealed that anti-α-gal Abs can 
mediate xenograft rejection via mechanisms involving Fcγ receptor49. Our 
results showed that anti-α-gal IgG3 Abs are partially protective in the 
absence of complement or PMN cells in contrast to a study that reported 
anti-α-gal IgG3 Abs to be strictly complement dependent.  Nevertheless, 
this result led us to think that there might be other immune cells, i.e. NK 
cells, providing a partial protection against Plasmodium infection in 
presence of anti-α-gal IgG3 Abs. Therefore, investigating the role of NK 
cells and FcγR in context of anti-α-gal IgG3 mediated protection should be 
considered as a next step. 
 
Our comprehension of dynamics of the gut microbiota is still scarce and its 
physiological action and its role in certain diseases have been neglected 
until recently. However, today, scientists attempt to resolve it by many 
leading works on the interaction of the microflora with its host. In this 
context, one of the mysteries that require more attention is the role of the 
gut flora on the production of NAbs. Here, we showed that gut 
colonization by one specific strain of bacteria is able to induce the 
production of anti-α-gal NAbs that in turn elicit protective mechanisms 
against infection by a protozoan parasite. Other bacterial strains may also 
induce the generation of NAbs, apart from anti-α-gal Abs, and confer 
protection against different pathogens. This should be further explored. 
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In sum, this thesis provides original experimental evidence on the 
protective role of NAbs elicited by the gut flora against an infectious agent. 
It opens new doors to be explored in the light of biological science. Similar 
vaccination approaches as the one proposed hereby for malaria may be 
tested against other vector-borne protozoan parasites expressing α-gal, 
such as Leishmania spp. and Trypanosoma spp. 
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SUMMARY
Glycosylation processes are under high natural se-
lection pressure, presumably because these can
modulate resistance to infection. Here, we asked
whether inactivation of the UDP-galactose:b-galac-
toside-a1-3-galactosyltransferase (a1,3GT) gene,
which ablated the expression of the Gala1-3Galb1-
4GlcNAc-R (a-gal) glycanandallowed for theproduc-
tion of anti-a-gal antibodies (Abs) in humans, confers
protection against Plasmodium spp. infection, the
causative agent of malaria and a major driving force
in human evolution. We demonstrate that both Plas-
modium spp. and the human gut pathobiont E. coli
O86:B7 express a-gal and that anti-a-gal Abs are
associated with protection against malaria transmis-
sion in humans as well as in a1,3GT-deficient mice,
which produce protective anti-a-gal Abs when
colonized by E. coli O86:B7. Anti-a-gal Abs target
Plasmodium sporozoites for complement-mediated
cytotoxicity in the skin, immediately after inoculation
by Anophelesmosquitoes. Vaccination against a-gal
confers sterile protection against malaria in mice,
suggesting that a similar approach may reduce
malaria transmission in humans.
INTRODUCTION
Humans have relatively high levels of circulating antibodies
(Abs) recognizing xeno-glycans expressed by pathogens (Oye-
laran et al., 2009). As for other antigens, xeno-glycans cannot
be targeted by the immune system when also expressed as
self-glycans. This limitation can be bypassed by natural selec-
tion of mutations that inactivate the expression of self-glycans
(Bishop and Gagneux, 2007). Presumably, natural selection of
such loss-of-function mutations tailored the human anti-glycan
immune repertoire through evolution (Bishop and Gagneux,
2007). This notion is supported by the inactivation of the cyti-
dine monophosphate-N-acetylneuraminic acid hydroxylase-
like (CMAH) gene in humans, which suppressed the expression
of N-glycolylneuraminic acid (Neu5Gc) (Hayakawa et al., 2001)
and allowed for immune reactivity against Neu5Gc (Tangvora-
nuntakul et al., 2003). In a similar manner, inactivation of the
a1,3GT gene, which suppressed the expression of the Gala1-
3Galb1-4GlcNAc-R (a-gal) carbohydrate in ancestral anthropoid
primates that gave rise to humans (Galili and Swanson, 1991),
also allowed for immune reactivity against a-gal (Galili et al.,
1984). While it has been argued that this evolutionary process
is driven to a large extent by the acquisition of immune-resis-
tance against pathogens expressing such glycans (Bishop and
Gagneux, 2007; Cywes-Bentley et al., 2013), this was never
tested experimentally.
Humans do not express a-gal and up to 1%–5% of the reper-
toire of circulating immunoglobulin M (IgM) and immunoglobulin
G (IgG) in healthy adults is directed against this glycan (Macher
and Galili, 2008). Production of a-gal-specific Abs is thought to
be driven by exposure to bacterial components of the microbiota
expressing a-gal (Macher and Galili, 2008), including specific
members of the Klebsiella spp., Serratia spp., and Escherichia
coli spp. (Galili et al., 1988). Expression of a-gal by these Entero-
bacteriaceae is associatedwith the bacterial capsule and cell wall
glycoproteins, as well as with lipopolysaccharide (LPS) (Galili
et al., 1988). Gut colonization by the human pathobiont E. coli
O86:B7 (Pal et al., 1969) recapitulates the etiology of anti-a-gal
Ab production in mice (Posekany et al., 2002) and in primates
(Mañez et al., 2001), as well as the production of Abs directed
against the a-gal-related anti-B blood group glycan in chickens
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(Springer et al., 1959) and humans (Springer and Horton, 1969).
This argues that gut colonization by E. coliO86:B7may be partic-
ularly relevant in triggering the production of a-gal-specific Abs,
presumably contributing to the high titers of these circulating
Abs in healthy adult humans (Galili et al., 1988). Moreover, anti-
a-gal Absmay also be produced in response to infection by path-
ogens expressinga-gal, such illustrated for gram-negative bacte-
ria fromSalmonella spp. or for protozoan parasites from Trypano-
soma spp. (Avila et al., 1989).
Anti-a-gal Abs are cytotoxic toward a-gal-expressing patho-
gens, as demonstrated in vitro for bacteria (Galili et al., 1988),
protozoan parasites (Avila et al., 1989), and viruses enveloped
by xenogeneic a-gal-expressing cell membranes (Takeuchi
et al., 1996). Whether anti-a-gal Abs confer resistance to these
and/or other pathogens in vivo has, to the best of our knowledge,
not been established. Here, we tested this hypothesis specif-
ically for Plasmodium spp. infection, the causative agent of
malaria and a major driving force that shaped the evolution of
anthropoid primates, including humans.
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Figure 1. Detection of a-Gal in Plasmodium
Sporozoites
(A) Composite images of GFP/actin (green), a-gal
(red; white arrows), and DNA (blue) in Plasmodium
sporozoites.
(B) Same staining as (A), after removal of a-gal by
a-galactosidase. Images are representative of 2–3
independent experiments. Scale bar, 5 mm.
(C) Detection of a-gal in PbAHsp70-GFP sporozoites
by flow cytometry, representative of three inde-
pendent experiments.
(D) Detection of a-gal in proteins extracted from
salivary glands of noninfected (NI), P. falciparum
3D7 (Pf), PbAHsp70-GFP (Pb), or P. yoelii 17XNL (Py)-
infected A. mosquitoes. Histone H3 (Hist3) and
GFP were detected as loading controls. When
indicated, a-gal was digested using a-galactosi-
dase (E).
(E and F) Detection of a-gal (E) and CSP (F)
in PbAHsp70-GFP sporozoites treated or not with
phospholipase C (+PLC). Control is not stained.
Data representative of 2–4 independent experi-
ments.
See also Figure S1.
Malaria is transmitted to humans by the
inoculation of Plasmodium sporozoites
via the bite of female Anopheles (A.)
mosquitoes (Ménard et al., 2013). While
transmission may be rather efficient,
only a fraction of the inoculated parasites
manage to progress toward the establish-
ment of infection (Rickman et al., 1990;
Sauerwein et al., 2011; Verhage et al.,
2005), hinting at a natural mechanism of
protection that presumably targets the
initial phases of the Plasmodium life cy-
cle. Here, we demonstrate that produc-
tion of anti-a-gal Abs in response to the
gut E. coliO86:B7 pathobiont contributes
critically to this natural defense mechanism, reducing malaria
transmission by A. mosquitoes.
RESULTS
Plasmodium spp. Express the a-Gal Glycan
The a-gal glycan was detected on the surface of Plasmodium
sporozoites, as assessed by immunofluorescence for the human
pathogen Plasmodium falciparum 3D7, as well as for the trans-
genic GFP-expressing strains of the rodent pathogens Plasmo-
dium berghei ANKA (PbA) or Plasmodium yoelii 17XNL, using
the lectin Bandeiraea (Griffonia) simplicifolia-I isolectin IB4 (BSI-
B4) (Galili et al., 1985) or an anti-a-gal monoclonal antibody
(M86 mAb) (Galili et al., 1998) (Figure 1A; Figures S1A and
S1B available online). Specificity of a-gal detection was
confirmed by its enzymatic removal using a-galactosidase (Fig-
ures 1B and 1C). Expression of a-gal was associated with
proteins, as assessed by western blot in whole-cell extracts
from P. falciparum 3D7, PbA, or P. yoelii 17XNL sporozoites
1278 Cell 159, 1277–1289, December 4, 2014 ª2014 The Authors
(Figure 1D) and confirmed by enzymatic removal of a-gal
(Figure 1D). Residual levels of a-gal were detected in the salivary
glands of noninfected mosquitoes, suggesting that this glycan
may be generated, at least partially, by A. mosquitoes
(Figure 1D).
Expression of a-gal by PbA sporozoites was reduced by !4-
fold when the glycosylphosphatidylinositol (GPI) anchor was
cleaved by phospholipase C (PLC), as assessed by flow cytom-
etry (Figure 1E). In contrast, GPI cleavage failed to reduce the
expression of circumsporozoite protein (CSP), the main protein
expressed at the surface of Plasmodium sporozoites (Figure 1F).
This suggests that a-gal is bound to GPI-anchored surface pro-
teins, including or not CSP, which despite being GPI-anchored
(Moran and Caras, 1994) is resistant to PLC cleavage (Kimmel
et al., 2003) (Figure 1F).
a-Gal-Specific IgM Abs Are Associated with Protection
from P. falciparum Infection in Humans
We investigated whether a correlation exists between the levels
of anti-a-gal Abs in healthy uninfected children and adults before
the malaria season (n = 330 for IgG; n = 229 for IgM) and subse-
quent risk of P. falciparum infection (determined by biweekly
PCR analysis of fingerprick blood samples) and febrile malaria
(determined byweekly physical examination), during the ensuing
6 month malaria season in a cohort study in Mali, where this sea-
son is predictable and intense (Tran et al., 2014). In children <2
years, the average level of anti-a-gal IgM Abs was 33.4 mg/ml
(95% confidence interval [CI]: 18.4–48.3 mg/ml) (Figure 2A),
similar to that reported in children with no history of malaria
exposure (Avila et al., 1992; Doenz et al., 2000; Galili et al.,
1984; Parker et al., 1999). However, anti-a-gal IgM Abs
A B 
C D
Figure 2. Anti-a-Gal IgM Abs Are Asso-
ciated with Protection against Malaria
Transmission in Individuals from a Malaria
Endemic Region
(A) Anti-a-gal IgM Abs in individuals from a malaria
endemic region in Mali (gray dots) or from the
United States (black dots). Mean (red bars) ± SD.
(B) Levels of anti-a-gal IgM Abs in P. falciparum-
infected (Pf+) versus noninfected (Pf") children >4
years of age are shown as box plots in the same
population as in (A).
(C) Anti-a-gal IgG Abs in individuals from a malaria
endemic region in Mali (gray dots) or from the
United States (black dots). Mean (red bars) ± SD.
(D) Levels of anti-a-gal IgG Abs in P. falciparum-
infected (Pf+) versus noninfected (Pf") children >4
years of age are shown as box plots in the same
population as in (C).
increased with age, reaching an average
of 123.03 mg/ml (95% CI: 79.3–
166.7 mg/ml) in adults— more than twice
the level reported in adults with nomalaria
exposure, i.e., 51.6 mg/ml (95% CI: 14.9–
88.3 mg/ml) (Figure 2A) (Avila et al., 1992;
Doenz et al., 2000; Galili et al., 1984;
Parker et al., 1999). The average level of
anti-a-gal IgM Abs in children >4 years of age who had no
P. falciparum infections detected during the 6-month malaria
season (n = 13) was higher than those who became infected
(n = 141) (Figure 2B). This suggests that there is a positive corre-
lation between the levels of anti-a-gal IgM Abs and incidence of
P. falciparum infection.
The average level of anti-a-gal IgG Abs in children <2 years
was 1.46 mg/ml (95% CI: 0.22–0.69 mg/ml) and increased in
adults to 3.66 mg/ml (95% CI: 3.04–4.28 mg/ml) (Figure 2C). In
contrast to IgM, the levels of circulating a-gal-specific IgG
were similar between malaria-exposed and nonexposed adults,
suggesting that P. falciparum infection fails to drive an IgG
response directed against a-gal (Figure 2D). This also suggests
that there is no correlation between anti-a-gal IgG Abs and inci-
dence of P. falciparum infection. Time-to-event analysis did not
show a correlation between a-gal-specific IgM and IgG levels
before the malaria season and subsequent risk of P. falciparum
infection (p = 0.76 and p = 0.08, respectively) or febrile malaria
(p = 0.35 and p = 0.18, respectively).
Gut Colonization by E. coli O86:B7 Elicits a Protective
a-Gal-Specific IgM Ab Response against Malaria
Transmission
To test whether anti-a-gal IgMAbs are protective against malaria
transmission, we took advantage of ‘‘human-like’’ a1,3Gt-defi-
cient mice. Unlike humans, wild-type mice have a functional
a1,3Gt gene and express a-gal on secreted and cell-surface gly-
coconjugates, suppressing the development of anti-a-gal immu-
nity (Yang et al., 1998). Deletion of a1,3Gt gene eliminates a-gal
(Tearle et al., 1996), allowing for anti-a-gal Ab production in
a1,3Gt"/" mice (Chiang et al., 2000; Tearle et al., 1996; Yang
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et al., 1998). However, a1,3Gt!/! mice are known to produce
only residual levels of circulating anti-a-gal Abswhenmaintained
under specific pathogen-free (SPF) conditions (Chiang et al.,
2000). Production of anti-a-gal Abs can be enhanced upon
enteric exposure to E. coli O86:B7 (Posekany et al., 2002). We
confirmed that E. coli O86:B7 expresses high levels of a-gal (Yi
et al., 2006), which is not the case for the E. coli K12 strain (Fig-
ures 3A and 3B). Colonization of a1,3Gt!/! mice by E. coli
O86:B7 after antibiotic treatment (streptomycin sulfate; 5 g/l in
drinking water for 7 days prior to colonization) increased the
levels of circulating anti-a-gal IgM Abs from 1.4 mg/ml (95% CI:
1.1–1.8 mg/ml) to 162.9 mg/ml (95% CI: 95.89–230.1 mg/ml)
before and after colonization, respectively (Figure 3C). Levels
of anti-a-gal IgM Abs in colonized a1,3Gt!/! mice were in the
range of adult individuals from a malaria endemic region (Fig-
ure 2A). In contrast, the levels of circulating anti-a-gal IgGAbs re-
mained at residual levels, i.e., <1 mg/ml (Figure S2A), again in the





Figure 3. Gut Colonization by E. coli
Expressing a-Gal Protects against Plasmo-
dium Infection
(A and B) Detection of a-gal in E. coli strains by (A)
flow cytometry and (B) immunofluorescence.
Representative of 2–3 independent experiments.
Composite images in (B), i.e., a-gal (green) and
DNA (blue) at 1003 magnification. Scale bar,
10 mm.
(C and D) a1,3Gt!/! mice maintained under SPF
were treated with streptomycin for 7 days. (C) Anti-
a-gal IgM Abs levels were measured in a1,3Gt!/!
mice not colonized (SPF), colonized with E. coli
K12, or colonized with O86.B7 strains (2–3 exper-
iments; n = 12). (D) Incidence of blood stage of
Plasmodium infection (%) in mice colonized as in
(C) and exposed to PbAEEF1a-GFP-infected
A. stephensi mosquitoes (four experiments; n =
17–34).
(E) Incidence of blood stage of Plasmodium
infection (%) in a1,3Gt!/!JHT
!/!, a1,3Gt!/!Aid!/!,
and a1,3Gt!/!mS !/! mice colonized as in (C) and
exposed to PbAHsp70-GFP-infected A. stephensi
mosquitoes (1–2 experiments; n = 4–10).
(F) Anti-a-gal IgM Abs were measured in GF
a1,3Gt!/! mice not colonized (GF), colonized
with E. coli K12, or colonized with O86.B7 strains
(2–3 experiments; n = 12). (G) Incidence of blood
stage of Plasmodium infection (%) in mice colo-
nized as in (F) and exposed to PbAEEF1a-GFP-in-
fected A. stephensimosquitoes (four experiments;
n = 9–13).
Mean (red bars).
See also Figure S2.
ure 2C). Colonization by E. coli K12 did
not induce the production of circulating
anti-a-gal Abs (Figure 3C). Gut coloniza-
tion by E. coli O86.B7 was associated
with protection of a1,3Gt!/! mice from
PbA transmission by infected Anopheles
stephensi mosquitoes (Figure 3D). This
was not the case when a1,3Gt!/! mice were or were not colo-
nized by E. coli K12 (Figure 3D).
To determinewhether the protective effect associatedwith gut
colonization by E. coli O86.B7 is mediated by anti-a-gal Abs, we
performed similar colonization experiments in a1,3Gt!/!JHT
!/!
lacking B cells (Gu et al., 1993), a1,3Gt!/!mS!/! mice lacking
circulating IgM (Ehrenstein et al., 1998) or a1,3Gt!/!Aid!/!
mice that fail to undergo Ig class switch recombination or so-
matic hypermutation (Muramatsu et al., 2000). Gut colonization
by E. coli O86.B7 failed to protect a1,3Gt!/!JHT
!/! and
a1,3Gt!/!mS!/!, but not a1,3Gt!/!Aid!/! mice from PbA-in-
fected mosquitoes, as compared to genetic-matched control
mice colonized or not by E. coli K12 (Figure 3E). This shows
that the protective effect of gut colonization by E. coli O86.B7
acts via a mechanism mediated by anti-a-gal IgM Abs that do
not undergo somatic hypermutation.
Germ-free (GF) a1,3Gt!/! mice had low but detectable levels
of anti-a-gal IgM Abs, i.e., 0.87 mg/ml (95% CI: 0.66–1.1 mg/ml),
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suggesting that these are natural Abs (Figure 3F). The production
of anti-a-gal IgM Abs in GF a1,3Gt!/! mice being driven by
expression of these glycans in food components is possible,
but this has not been tested. GF a1,3Gt!/!mice did not produce
anti-a-gal IgG Abs (Figure S2C). Susceptibility to PbA transmis-
sion by infected A. mosquitoes was similar in SPF versus GF
a1,3Gt!/! mice (Figures 3D and 3G). When GF a1,3Gt!/! mice
were monocolonized by E. coli O86:B7, the levels of circulating
anti-a-gal IgM Abs increased to 96.62 mg/ml (95% CI: 59.32–
133.9 mg/ml) (Figure 3F), which is the range in which adult individ-
uals from amalaria endemic region (Figure 2A), without concom-
itant induction of anti-a-gal IgG Abs (Figure S2C). Monocoloniza-
tion by E. coli O86:B7, but not by E. coli K12, protected
a1,3Gt!/! mice from PbA transmission by A. mosquitoes (Fig-
ure 3F). This suggests that gut colonization by a specific patho-
biont expressing a-gal recapitulates to a large extent the normal
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Figure 4. Protective Effect of a-Gal Immuni-
zation
(A) Anti-a-gal Abs in the serum of control (!) versus
rRBCM (+) or a-gal-BSA (+) immunized a1,3Gt!/!
mice (2–3 experiments; n = 12–29).
(B–D) Incidence of blood stage of infection (%) in
a1,3Gt!/!mice treated as in (A) and exposed to (B)
PbAEEF1a-GFP-infected A. stephensi mosquitoes
(seven experiments; n = 27–44), (C) P. yoelii
17XNL-infected A. stephensi mosquitoes (five
experiments; n = 28–39), or (D) PbAEEF1a-GFP-in-
fected A. gambiae mosquitoes (four experiments;
n = 27–34).
(E) Incidence of blood stage of infection (%)
in nonimmunized (control) versus immunized
(rRBCM) a1,3Gt!/! mice receiving PbAEEF1a-GFP
sporozoites (3–4 experiments; n = 17–28).
(F) Plasmodium 18 s rRNA/Arbp0 mRNA in skin
and liver of nonimmunized (control) versus immu-
nized (rRBCM) a1,3Gt!/! mice exposed to
PbAEEF1a-GFP-infected A. stephensi mosquitoes
(3–5 experiments). Infected/total mice (gray nbrs).
(G) Same as (A) in control (!) versus immunized
(+; rRBCM emulsified in CFA+CpG) a1,3Gt!/!
mice (two experiments; n = 6–23).
(H) Incidence of blood stage of infection (%) in
a1,3Gt!/! mice treated as in (G) and infected as in
(B) (three experiments; n = 16–19). In (A), (F), and
(G), dots are individual mice and mean (red bars).
See also Figures S3 and S4.
duces protection against Plasmodium
infection, such as observed in a malaria
endemic region (Figure 2).
It should be noted that the percentage
of infected red blood cell (RBC), i.e., para-
sitemia, and incidence of mortality were
similar among those a1,3Gt!/! mice that
were infected by PbA regardless of
colonization (Figures S2B and S2D). This
suggests that gut colonization by E. coli
O86:B7 protects against Plasmodium
transmission, but not against disease once the erythrocytic
stage of infection is established.
Immunization against a-Gal Protects from Plasmodium
Transmission
Immunization of a1,3Gt!/! mice against a-gal, using rabbit RBC
membranes (rRBCM) expressing high levels of a-gal or synthetic
a-gal conjugated to BSA (a-gal-BSA) elicited the production of
circulating anti-a-gal IgM and IgG Abs (Figure 4A). Control
a1,3Gt+/+ mice failed to produce anti-a-gal Abs (Chiang et al.,
2000; Tearle et al., 1996; Yang et al., 1998) (Figure S3A). Circu-
lating anti-a-gal immunoglobulin A (IgA) and immunoglobulin E
(IgE) Abs were undetectable in control or immunized a1,3Gt!/!
and a1,3Gt+/+ mice (data not shown). The concentration of
anti-a-gal IgM Abs in the plasma of immunized a1,3Gt!/! mice
was in the range of adult individuals from malaria endemic re-
gions (Figure 2A). Circulating anti-a-gal IgG Abs in immunized
Cell 159, 1277–1289, December 4, 2014 ª2014 The Authors 1281
a1,3Gt!/!mice, predominantly from IgG1, IgG2b, and IgG3 sub-
classes, were present at higher concentrations, as compared to
total IgG in adult individuals from malaria endemic regions. Little
or no circulating IgG2a (Figure 4A) or IgG2c (data not shown)
were detected in immunized a1,3Gt!/! mice.
Immunization against a-gal protected a1,3Gt!/! mice from
PbA (Figure 4B) and P. yoelli 17XNL (Figure 4C) transmission
by infected A. stephensimosquitoes, as well as from PbA trans-
mission by A. gambiae mosquitoes (Figure 4D) versus control
nonimmunized a1,3Gt!/! mice. Control immunized a1,3Gt+/+
mice were neither protected from PbA (Figure S3B) nor
P. yoelli 17XNL (Figure S3C) transmission by A. stephensi
mosquitoes nor against PbA transmission by A. gambiae
mosquitoes (Figure S3D) versus naive a1,3Gt+/+ mice.
Immunized a1,3Gt!/! mice were protected from artificial
transmission of PbA sporozoites via intradermal inoculation
versus control nonimmunized a1,3Gt!/! mice (Figure 4E) or
control immunized or nonimmunized a1,3Gt+/+ mice (Fig-
ure S3E). Protection was no longer observed when sporozoites
were inoculated intravenously (Figures 4E and S3E). This
suggests that the protective effect of a-gal immunization is
exerted in the dermis, presumably via an anti-a-gal Ab driven
mechanism that is no longer effective once sporozoites reach
the blood.
PbA transmission was associated with accumulation of Plas-
modium 18S rRNA at the site of inoculation, as quantified in
the ear pinna by qRT-PCR (Figure 4F). The relative amount of
Plasmodium 18S rRNA was similar in immunized versus control
nonimmunized a1,3Gt!/! mice (Figure 4F) or control immunized
or nonimmunized a1,3Gt+/+ mice (Figure S3F). Immunized
a1,3Gt!/! mice did not accumulate Plasmodium 18S rRNA in
the liver, when compared to control nonimmunized a1,3Gt!/!
mice (Figure 4F) or control nonimmunized or immunized
a1,3Gt+/+ mice (Figure S3F). This suggests that a-gal immuniza-
tion arrests the transit of inoculated sporozoites from the skin
into the liver, without interfering with sporozoite inoculation by
A. mosquitoes.
TLR9 Agonist Adjuvant Enhances the Protective Effect
of a-Gal Immunization
Immunization of a1,3Gt!/! mice with rRBCM emulsified in com-
plete Freund’s adjuvant (CFA), supplemented with toll-like re-
ceptor 9 agonist CpG, enhanced anti-a-gal IgG2b and IgG3 Ab
response by 2- to 3-fold (Figure 4G) versus immunization without
adjuvant (Figure 4A). This was associated with 88% reduction
in the relative risk of transmission of PbA infection by A.
mosquitoes (95% CI: 0.032–0.452) versus 61% reduction upon
immunization without adjuvant (95% CI: 0.209–0.726) (Figures
4B and 4H). This protective effect was not observed in control
a1,3Gt+/+ mice (Figures S3G and S3H).
Parasitemias were similar in immunized a1,3Gt!/! mice not
protected from PbA infection versus control nonimmunized
a1,3Gt!/! mice as well as control nonimmunized or immunized
a1,3Gt+/+ mice (data not shown). Moreover, when infected, all
mice succumbed to experimental cerebral malaria. This sug-
gests that while protective against malaria transmission, a-gal
immunization is not protective against the development of se-
vere disease if Plasmodium manages to establish infection. In
keeping with this notion, when inoculated with PbA-infected
RBC, immunized a1,3Gt!/!mice developed similar levels of par-
asitemia and disease severity, as compared to control nonimmu-
nized a1,3Gt!/! mice as well as to control nonimmunized or
immunized a1,3Gt+/+ mice (Figure S4A).
We tested further whether the protective effect conferred by
a-gal immunization is associated with sterile protection, i.e.,
inability of Plasmodium to establish blood stage of infection.
Passive transfer of RBCs harvested from protected immunized
a1,3Gt!/!mice at day 8–9 post-PbA transmission by A.mosqui-
toes failed to transmit disease to naive a1,3Gt!/! mice (Fig-
ure S4B). In contrast, passive transfer of RBC harvested from
nonprotected immunized a1,3Gt!/! mice, readily transmitted
disease to naive a1,3Gt!/!mice (Figure S4B). This demonstrates
that the protective effect of immunization against a-gal is asso-
ciated with sterile protection against malaria.
Anti-a-Gal IgM and IgG Abs Produced in Response to
a-Gal Immunization Confer Protection against Malaria
Transmission
We asked whether the protective effect of a-gal immunization
is mediated by anti-a-gal IgM and/or IgG Abs. Immunized
a1,3Gt!/!JHT
!/! mice failed to produce anti-a-gal IgM or IgG
Abs versus naive a1,3Gt!/!JHT
!/! mice or immunized
a1,3Gt!/! mice (Figure 5A). Moreover, immunized a1,3Gt!/!
JHT
!/! mice were not protected against PbA transmission by
A. mosquitoes versus control nonimmunized a1,3Gt!/!JHT
!/!
mice (Figure 5B). This shows that the protective effect
of a-gal immunization is mediated via a B cell-dependent
mechanism.
Immunization of a1,3Gt!/!Aid!/! mice failed to induce the
production of anti-a-gal IgG, but not IgM Abs, versus naive
a1,3Gt!/!Aid!/! or immunized a1,3Gt!/! mice (Figure 5A).
Immunized a1,3Gt!/!Aid!/! mice were nevertheless pro-
tected against PbA transmission by A. mosquitoes versus non-
immunized a1,3Gt!/!Aid!/! mice (Figure 5B). This confirms
that anti-a-gal IgM Abs can confer protection against malaria
transmission (Figure 2B) and that the protective effect of a-gal-
specific IgM Abs does not require somatic hypermutation.
Immunization of a1,3Gt!/!mS!/! mice failed to induce anti-
a-gal IgM Abs, without interfering with anti-a-gal IgG Ab
response versus naive a1,3Gt!/!mS!/! mice or immunized
a1,3Gt!/! mice (Figure 5A). Immunized a1,3Gt!/!mS-/- mice
were nevertheless protected from PbA transmission by A.
mosquitoes versus control naive a1,3Gt!/!mS!/! mice (Fig-
ure 5B). Immunized a1,3Gt!/! mice did not produce circulating
anti-a-gal IgA or IgE Abs (data not shown) and a putative protec-
tive effect for these Ig isotypes was excluded. This demonstrates
that anti-a-gal IgG Abs produced in response to immunization
confer protection against malaria transmission.
Immunization of a1,3Gt!/!Tcrb!/! mice lacking mature ab
T cells (Mombaerts et al., 1992) compromised anti-a-gal IgM
and IgG response versus control immunized a1,3Gt!/! mice
(Figure 5A). Immunized a1,3Gt!/!Tcrb!/! mice were not pro-
tected from PbA transmission by A. mosquitoes versus control
naive a1,3Gt!/!Tcrb!/! mice (Figure 5B). This shows that anti-
a-gal Abs produced in response to immunization are T cell-
dependent (Cretin et al., 2002) and so is their protective effect.
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Naive and immunized a1,3Gt!/!JHT
!/! (Figure S5A),
a1,3Gt!/!Aid!/!, (Figure S5B) and a1,3Gt!/!mS!/! (Figure S5C)
mice, not protected from PbA transmission, developed similar
levels of parasitemia and succumbed to experimental cerebral
malaria. This was not the case for a1,3Gt!/!Tcrb!/! mice (Fig-
ure S5D), consistent with the involvement of T cells in the path-
ogenesis of experimental cerebral malaria (Belnoue et al., 2002).
Passive transfer of anti-a-gal IgM to naive a1,3Gt!/! mice
conferred protection against PbA transmission byA.mosquitoes
(Figure 5C). This was also the case for passive transfer of anti-
a-gal Abs from specific IgG subclasses, namely, IgG2b and
IgG3 (Figure 5C), but not IgG1 or IgG2a (Figure 5C). Relative
binding to a-gal was similar for all mAbs tested, as assessed
by ELISA using a-gal-BSA as a solid-phase antigen (Figure S6A)
or by immunofluorescence using PbA sporozoites (Figure S6B).
Specificity of anti-a-gal binding to Plasmodium sporozoites was
assessed by enzymatic removal of a-gal, confirming that these
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Figure 5. Protective Effect of Anti-a-Gal Abs
(A) Relative absorbance of anti-a-gal Abs (Mean ±
SD) in serial serum dilutions from nonimmunized
(NI) or rRBCM-immunized (I) a1,3Gt!/! mice (two
experiments; n = 10).
(B) Incidence of blood stage infection (%) in spe-
cific immune component-deleted a1,3Gt!/! mice
immunized (I) or not (NI) as in (A) and exposed to
PbAEEF1a-GFP-infected mosquitoes (3–7 experi-
ments; n = 13–41).
(C) Incidence of blood stage of infection (%) in
a1,3Gt!/! mice after passive transfer of anti-a-gal
Abs versus controls (no passive transfer; ctr.)
exposed to PbAEEF1a-GFP-infected mosquitoes
(4–7 experiments; n = 19–32).
(D) C3 deposition in PbAHsp70-GFP sporozoites not
exposed (ctr.) or exposed to anti-a-gal Abs plus
mouse complement (C). Representative of three
independent experiments.
(E) Incidence of blood stage of infection (%) in
a1,3Gt!/!C3!/!mice after passive transfer of anti-
a-gal IgM (m), IgG2b (g2b), or IgG3 (g3) Abs versus
controls (ctr.; no passive transfer) not receiving
Abs, exposed to PbAEEF1a-GFP-infected mosqui-
toes (four experiments; n = 21–37).
(F) Same as (E) in PMN-depleted a1,3Gt!/! mice
(four experiments; n = 15–25).
See also Figures S5 and S6.
face of Plasmodium sporozoites (Fig-
ure S6C). IgG2a, IgG2b, and IgG3 mAbs
are class-switched mutants derived from
the original anti-a-gal IgG1 clone and as
such have similar affinities for a-gal
(Ding et al., 2008). These data reveal that
while IgM anti-a-gal Abs are sufficient
per se to confer protection against ma-
laria transmission, this protective effect
can be enhanced when specific sub-
classes anti-a-gal IgG Abs are present at
sufficient high levels.
Once bound to the surface of Plasmodium sporozoites, anti-
a-gal IgM, IgG2b, and IgG3 mAbs activated the classical
pathway of complement, as assessed by C3 deposition (Fig-
ure 5D). Anti-a-gal IgG1 or IgG2a mAbs failed to activate com-
plement (data not shown), and complement activation was
also not observed in the absence of anti-a-gal Abs (Figures 5D
and S7), showing that the alternative and lectin pathways of
complement are not activated by Plasmodium sporozoites.
We then asked whether the protective effect exerted by anti-
a-gal Abs is mediated via a mechanism involving the activation
of the complement cascade (Figure 5D) (Ding et al., 2008; Miya-
take et al., 1998). Passive transfer of anti-a-gal IgM Abs or anti-
a-gal IgG2b mAb to a1,3Gt!/!C3!/! mice, which lack C3 and
cannot activate the complement cascade, failed to confer protec-
tion against PbA transmission versus control a1,3G!/!C3!/!
mice (Figure 5E). Passive transfer of anti-a-gal IgG3 mAb
to a1,3Gt!/!C3!/! mice conferred residual but significant
protection versus control a1,3G!/!C3!/! mice (Figure 5E). This
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suggests that the protective effect exerted by anti-a-gal IgM and
IgG2b Abs acts via a mechanism that is strictly complement
dependent, whereas the protective effect of anti-a-gal IgG3 Abs
is partially but probably not strictly dependent on complement
activation. Infection incidence was similar in control a1,3Gt!/!
C3!/! versus a1,3Gt!/!C3+/+ mice (Figures 5C and 5E).
Complement activation generates C3a and C5a chemoattrac-
tants that promote IgG-dependent polymorphonuclear (PMN)
cell cytotoxicity (Ding et al., 2008; Nimmerjahn and Ravetch,
2008; Yin et al., 2004). Therefore, we asked whether the protec-
tive effect of anti-a-gal Abs involves PMN cells. Passive transfer
of anti-a-gal IgG2b Abs to a1,3Gt!/! mice, depleted from PMN
cells by the administration of anti-Ly-6G (Gr-1) (Porcherie
et al., 2011), failed to confer protection against PbA transmission
by A. mosquitoes, whereas passive transfer of anti-a-gal IgM or
IgG3 Abs conferred protection (Figure 5F). This suggests that the
protective effect exerted by anti-a-gal IgM and IgG2b Abs acts
via a mechanism strictly dependent on PMN cells, whereas the
protective effect of anti-a-gal IgG3 Abs is partially but probably
not strictly dependent on PMN cells. Depletion of PMN cells
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Figure 6. Protective Effect of Anti-a-Gal Abs
against Hepatocyte Infection
(A) Mean percentage (%) of viable GFP+
PbAHsp70-GFP sporozoites ± STD (3–4 experiments)
after exposure in vitro to anti-a-gal or control anti-
DNPmAbs in the presence of mouse complement.
(B and C) Mean percentage (%) of HepG2 cells (B)
wounded (Dextran-Red+) or (C) invaded (GFP+) by
PbAHsp70-GFP sporozoites treated as in (A) ± SD (six
experiments).
while preventing the onset of cerebral ma-
laria (data not shown), consistent with
previous findings (Chen et al., 2000).
Anti-a-Gal Abs Are Cytotoxic to
Plasmodium Sporozoites
Complement activation by anti-a-gal IgM,
IgG2b, or IgG3mAb was cytotoxic to PbA
sporozoites in vitro, as assessed by
sporozoite GFP expression (Figure 6A).
Anti-a-gal IgG1 and IgG2a mAbs, which
did not activate complement when bound
to Plasmodium sporozoites (data not
shown), were not cytotoxic (Figure 6A).
The cytotoxic effect of anti-a-gal IgM,
IgG2b, and IgG3 was similar when using
mouse (Figure 6A) or rabbit (Figure S7A)
complement but was strictly dependent
on the presence of complement (Fig-
ure S7B). A similar cytotoxic effect was
observed when quantifying viable ‘‘cres-
cent-shaped’’ sporozoites (Figure S7C),
an independent readout for sporozoite
viability (Hegge et al., 2010). Isotype-
matched control anti-dinitrophenyl (DNP)
Abs were not cytotoxic to PbA sporozoites in vitro (Figures 6A
and S7A–S7C).
Anti-a-Gal Abs Inhibit Hepatocyte Invasion by
Plasmodium Sporozoites
We asked whether anti-a-gal Abs inhibit hepatocyte transmigra-
tion (wounding) and/or hepatocyte invasion by Plasmodium spo-
rozoites (Mota et al., 2001). Complement activation by anti-a-gal
IgM, IgG2b, and IgG3 Abs inhibited hepatocyte transmigration
(Figure 6B) and invasion (Figure 6C), as assessed in vitro for
PbA sporozoites. This inhibitory effect was not observed when
using anti-a-gal IgG1 or IgG2a Abs or isotype/subclass-matched
control anti-DNP Abs (Figures 6B and 6C).
We then assessed whether anti-a-gal Abs inhibit the develop-
ment of exoerythrocytic forms (EEF) of Plasmodium. Comple-
ment activation by anti-a-gal IgM, IgG2b, and IgG3 Abs reduced
the number of EEF (Figure 7A), as well as the average EEF size
(Figures 7B and 7C) formed in vitro by PbA sporozoites. Anti-
a-gal IgG1 Abs did not show this inhibitory effect, while anti-
a-gal IgG2a Abs did not reduce the number of EEF (Figure 7A)
but had a residual inhibitory effect on EEF size (Figures 7B and
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7C). Isotype/subclass-matched control anti-DNP Abs did not
modulate EEF numbers (Figure 7A) or average size (Figures 7B
and 7C).
DISCUSSION
When inoculated in humans through the bite of an A. mosquito,
Plasmodium sporozoites are confronted with relatively high
levels of cytotoxic anti-a-gal IgM Abs (Figure 2A). That these
Abs are protective against malaria transmission is supported
by three independent lines of evidence. First, individuals from a
malaria endemic region that show evidence of decreased
P. falciparum infection risk have higher levels of circulating
a-gal-specific IgM Abs, as compared to individuals who are sus-
ceptible to P. falciparum infection (Figure 2B). Second, when
present at levels similar to those observed in individuals from a
malaria endemic region—in a1,3Gt!/! mice colonized by human
gut pathobiont E. coli O86:B7 expressing a-gal (Figure 3) or in
immunized a1,3Gt!/! mice (Figures 4A and 4B)—anti-a-gal
IgM Abs confer protection against malaria transmission. Third,
passive transfer of anti-a-gal IgM Abs is sufficient per se to pro-

















































































































































Figure 7. Protective Effect of Anti-a-Gal
Abs against Plasmodium Maturation in
Hepatocytes
(A) Number of EEF per field (dots; 20–23 fields).
(B) Area of individual EEF (dots) (n = 111–256 EEFs
counted in 20–23 fields).
(C) Total area of EEF (dots) per field (20–23 fields).
HepG2 cells were incubated with PbAHsp70-GFP
sporozoites, previously exposed to anti-a-gal or
control anti-DNP mAbs in the presence of com-
plement (A–C).
See also Figure S7.
The protective effect exerted by anti-
a-gal IgM Abs should be relevant to un-
derstand why malaria incidence is higher
in children versus adults from malaria
endemic regions (Modiano et al., 1996).
Relative absence of these antibodies
in children under the age of 2–3 years
should favor malaria transmission, as
compared to adults that have higher
levels of circulating anti-a-gal IgM Abs
(Figure 2A). This relative absence of anti-
a-gal IgM in children may be explained
by the (1) kinetics of establishment of an
adult-like gut microbiota (Ringel-Kulka
et al., 2013), (2) requirement of environ-
mental and dietary exposure in the estab-
lishment of an adult-like gut microbiota,
and/or (3) the kinetics of the establish-
ment of adult-like B cell repertoire,
including anti-a-gal B cells.
The protective effect exerted by anti-
a-gal IgM Abs might also contribute to
explain why only a small fraction of Plasmodium sporozoites
inoculated by mosquitoes manage to progress toward the
establishment of infection in humans. This is true even when
Plasmodium sporozoites are inoculated under controlled exper-
imental conditions in adults (Rickman et al., 1990; Sauerwein
et al., 2011; Verhage et al., 2005). Presumably, when present
at sufficient high levels in adults, circulating anti-a-gal IgM Abs
prevent the large majority of Plasmodium sporozoites from es-
tablishing a successful infection. However, infection is estab-
lished if as few as a couple of Plasmodium sporozoites manage
to escape this natural mechanism of protection.
Whether a-gal detected at the surface of Plasmodium sporo-
zoites (Figure 1) is produced by Plasmodium and/or by the mos-
quito is not clear. The salivary glands of noninfected mosquitoes
express low levels of a-gal, as detected bywestern blot (Figure 1)
and immunostaining (data not shown). Plasmodium sporozoites
aremasked bymosquito laminin (Warburg et al., 2007), an evolu-
tionary conserved glycoprotein that in other species contains
a-gal (Takahashi et al., 2014). It is possible therefore that anti-
a-gal Abs recognize laminin or another mosquito-derived protein
expressing a-gal, masking Plasmodium sporozoites (Warburg
et al., 2007).
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It is now well established that specific components of the gut
microbiota can modulate immunity and resistance to infection
(Belkaid and Hand, 2014; Honda and Littman, 2012). In support
of this notion, resistance to viral and bacterial (Fagundes et al.,
2012) infections is impaired in GF mice (Dolowy and Muldoon,
1964) or mice subjected to antibiotic-driven dysbiosis (Ichinohe
et al., 2011). We reasoned that xeno-glycans expressed by spe-
cific components of the gut microbiota might trigger a protective
immune response against pathogens expressing the same xeno-
glycans.Weshow that this is thecase fora-gal, a xeno-glycan ex-
pressed by the human gut pathobiont E. coli O86:B7, as well by
Plasmodium spp. (Figures 1, 3A, and 3B). When colonized by
E. coli O86:B7, a1,3Gt!/! mice produce an anti-a-gal IgM Ab
response (Figures 3C and 3F) that confer protection againstPlas-
modium infection (Figures 3D, 3E, 3G, and 5C) via a lytic mecha-
nism mediated by complement activation (Figures 5E and 6A). It
is worth noticing that in a similar manner to other microbiota-
driven resistance mechanisms, the protective effect exerted by
E. coli O86:B7 acts at the level of a tissue barrier, i.e., the skin,
to prevent Plasmodium transmission (Figures 4E and 4F).
Levels of circulating anti-a-gal IgG Abs in individuals from a
malaria endemic region (Figure 2C), as well as in a1,3Gt!/!
mice colonized with E. coli O86:B7 (Figures S2A and S2C), are
"30-fold and "40 to 70-fold, respectively, lower than levels of
IgM anti-a-gal Abs. This may explain why basal levels anti-
a-gal IgG Abs in individuals from a malaria endemic region are
not associated with decreased risk of P. falciparum infection
(Figure 2D). This also suggests that P. falciparum infection fails
to induce class switch of the anti-a-gal Ig Ab response in those
individuals. It is possible therefore that P. falciparum represses
Ig class-switch recombination, explaining the residual levels of
circulating anti-a-gal IgG Abs (Figure 2C).
While anti-a-gal Abs can provide sterile protection against
malaria in mice (Figures 5B, 5C, and S4B), this is not commonly
observed in malaria endemic regions in which adult individuals
have circulating anti-a-gal IgM Abs, possibly because the levels
of these Abs are below a threshold level required to provide ster-
ile protection (Figure 2). However, we show that this natural
mechanism of protection can be enhanced via immunization us-
ing adjuvants that favor the production of T cell-dependent com-
plement fixing anti-a-gal IgG Abs (Figures 4G and 4H). Moreover,
when coupled to Plasmodium antigens, this approach should
enhance the immunogenicity of such antigens (Benatuil et al.,
2005) and boost the protective efficacy of candidate malaria
vaccines based on such antigens (Olotu et al., 2013). This
approach should be useful in preventing not only individual infec-
tions but also disease transmission given the protective effect of
anti-a-gal Abs.
It is possible that the protective effect of ‘‘attenuated’’ sporo-
zoite vaccine trials against malaria (Seder et al., 2013) is driven to
some extent by an anti-a-gal Ab response, given the expression
of a-gal by Plasmodium falciparum sporozoites (Figure 1).
Whether a correlation can be established between the effective-
ness of such candidate vaccines and a putative anti-a-gal IgGAb
response has not been established butmay be useful to consider
as a retrospective analyzes.
As a final note, we predict that in a similar manner to anti-a-gal
Abs other anti-glycan Abs may confer protection against malaria
as well as other vector-borne protozoan parasites (Huflejt et al.,
2009; Lacroix-Desmazes et al., 1995; Nagele et al., 2013). More-
over, anti-a-gal Abs may also target other vector-borne proto-
zoan parasites expressing a-gal, such as Leishmania spp. and
Trypanosoma spp., the causative agents of Leishmaniasis and
Trypanosomiasis, respectively (Avila et al., 1989). As such,
vaccination approaches similar to the one proposed here for ma-
laria may be considered against these diseases as well.
EXPERIMENTAL PROCEDURES
Cohort Study
For detailed analysis, see the Extended Experimental Procedures.
Immunization against a-Gal
Eight- to ten-week-old mice received 3 3 108 rabbit rRBCM equivalents
(100 ml; PBS; intraperitoneal [i.p.]). Adjuvants are described in the Extended
Experimental Procedures. Mouse serum was collected 2 weeks after last
immunization, and circulating anti-a-gal Abs were quantified by ELISA. See
the Extended Experimental Procedures for details on anti-a-gal ELISA.
Passive Transfer of Anti-a-Gal mAbs
a1,3Gt!/! mice received anti-a-gal IgG1, IgG2a, IgG2b, and IgG3 mAbs (Ding
et al., 2008; Yin et al., 2004) (150 mg; 100 ml per mouse) or polyclonal IgM
(150 mg; 300–400 ml per mouse) via a single intravenous (i.v.) injection 24 hr
prior to mosquito exposure.
Plasmodium Strains
Transgenic P. berghei ANKA (PbA) strains expressing GFP under the eef1a
promoter, i.e., PbAEEF1a-GFP (259cl1; MR4; MRA-865) (Franke-Fayard et al.,
2004), or under the hsp70 promoter (Ishino et al., 2006), i.e., PbAHsp70-GFP
(kindly provided by Robert Menard, Institut Pasteur), transgenic P. yoelii
17XNL strain expressing GFP under the PbA eef1a promoter (MR4; MRA-
817; kindly provided by Robert Menard, Institut Pasteur) (Weiss et al., 1989).
For sporozoite production, see the Extended Experimental Procedures.
Plasmodium Transmission
A. stephensi or gambiae mosquitoes were allowed to feed on anesthetized
mice (i.p.; 125 mg/kg ketamine; 12.5 mg/kg xylazine) placed on a warming
tray. Two mosquitoes were allowed to probe and feed independently (90–
100 s) on restricted to the edge of the mouse ear (10–12/3–4 mm) and
dissected thereafter for confirmation of sporozoites in salivary glands. If nega-
tive, infection was repeated.
Sporozoites Inoculation
PbAEEF1a-GFP sporozoites were inoculated (i.d.) in the ear pinna (750 sporozo-
ites in 20–30 ml; 1%BSA in PBS) or i.v. in the retro-orbital vein (150 sporozoites
in 50 ml; 1% BSA in PBS) using a microsyringe (Nanofil 100 ml; 33G beveled
needle; World Precision Instruments).
Detection of a-Gal in Plasmodium Sporozoites
Sporozoites were stained with Alexa Fluor 647-conjugated BSI-IB4 or Alexa
Fluor 647-conjugated anti-a-gal mAbs and detected by confocal microscope
or flow cytometer. For detection of a-gal in PbAHsp70-GFP by western blotting,
see the Extended Experimental Procedures. Green coffee bean a-galactosi-
dase (50–200 ml; 5 U/ml; 60–90 min; 25#C; Sigma Chemical) was used to hy-
drolyze terminal a-galactosyl moieties from glycolipids and glycoproteins
(Luo et al., 1999).
Statistical Analysis
All tests (except human cohort studies) were performed using the GraphPad
Prism (v. 6.0) (GraphPad Software). Human analyses were performed in R
(v. 3.0.2). Detailed analyses are described in the Extended Experimental
Procedures.
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Mice
Experiments in mice were performed in accordance with protocols approved
by the Ethics Committee of the Instituto Gulbenkian de Ciência and the Portu-
guese National Entity (DGAV-Direção Geral de Alimentação e Veterinária).
Experiments in mice were performed in accordance with the Portuguese
(Decreto-Lei no. 113/2013) and European (directive 2010/63/EU) legislation
related to housing, husbandry, and animal welfare. C57BL/6 JHT
!/! (Gu
et al., 1993), Tcrb!/! (Mombaerts et al., 1992), Aid!/! (Muramatsu et al.,
2000), mS!/! (Ehrenstein et al., 1998), and C3!/! (Circolo et al., 1999) mice
were crossed with C57BL/6 a1,3Gt!/! mice (Shinkel et al., 1997; Tearle
et al., 1996). For the details on genotyping, see the Extended Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2014.10.053.
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Synthetic a-gal linked to bovine serum albumin (BSA) or human serum albumin (HSA; Dextra Labs; Reading, UK), a-galactosidase
from green coffee beans (Sigma Chemical Co), Fluorescein isothiocyanate (FITC)-conjugated (Sigma-Aldrich Co) and Alexa Fluor
647-conjugated (Invitrogen) Bandeiraea simplicifolia lectin (BSI-IB4; Griffonia simplicifolia) (Kisailus and Kabat, 1978), rabbit RBC
(Patricell Ltd.; Nottingham, UK), incomplete Freund’s Adjuvant (IFA) (BD Difco), inactivated and dried M. tuberculosis H37 Ra (BD
Difco), Dextran, Tetramethylrhodamine, 10,000 MW, Lysine Fixable (fluoro-Ruby; Life Technologies), mouse anti-a-gal IgM (M86;
EnzoLife Sciences or kindly provided by Uri Galili, University of Massachusetts Medical School, Worcester, MA, USA) (Galili et al.,
1998), IgG1 (GT6-27), IgG2a, IgG2b and IgG3 (GT4-31) mAbs (Ding et al., 2008; Yin et al., 2004), mouse anti-dinitrophenyl IgM
(MADNP-5), IgG1 (MADNP-1), IgG2a (MADNP-2), IgG2b (MADNP-3) and IgG3 (MADNP-4) mAbs (kindly provided Hérve Bazin,
University of Louvain, Belgium) (Platteau et al., 1990). Mouse IgM, IgG1, IgG2a, IgG2b, IgG3, IgA and IgE were detected using horse-
radish peroxidase (HRP)-conjugated goat anti-mouse IgM, IgG1, IgG2a, IgG2b, IgA and IgE or a rat mAb anti-mouse IgG3 (Southern
Biotechnology Associates). Anti-CSP 3D11 (Yoshida et al., 1980) hybridoma (IgG1 mAb directed against the repeat region of
P. berghei CSP) was kindly provided by Ana Rodriguez (New York Medical School).
Cohort Study
The Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry at the University of Sciences, Technique and Technology
of Bamako, and the Institutional Review Board of NIAID-NIH approved the cohort study. In May 2011, 695 individuals aged 3months
to 25 years were enrolled in a cohort study in the rural village of Kalifabougou, Mali. Individuals were followed during the malaria
season for 7 months. Individuals were invited to participate after random selection from an age-stratified census of the entire village
population (n = 4394). Written, informed consent was obtained from adult participants and the parents or guardians of participating
children. Enrollment exclusion criteria were hemoglobin level < 7 g/dL, axillary temperatureR 37.5!C, acute systemic illness, use of
anti-malarial or immunosuppressive medications in the past 30 days and pregnancy. Clinical malaria was detected prospectively by
self-referral and weekly active clinical surveillance. All individuals with signs and symptoms of malaria and any level of Plasmodium
parasitemia detected by light microscopy were treated according to the National guidelines inMali. The research definition of malaria
was parasitemia R 2500 parasites/mL, temperature R 37.5!C and no other cause of fever discernible by physical exam. During
scheduled clinic visits, blood was collected by finger prick every two weeks on filter paper. Detection of asymptomatic Plasmodium
infection by PCR was done retrospectively at the end of the surveillance period. For each participant, PCR was performed on blood
samples in chronological order from enrollment onward until the first P. falciparum infection was detected. Detailed methods for
P. falciparum PCR detection have been described (Tran et al., 2013). a-gal-specific IgM and IgG Ab levels were determined using
ELISA on plasma collected at enrollment from the subset of individuals. Statistical analyses were described in the Statistical analysis’
section.
Genotyping
Micewere genotyped by PCR using tail genomic DNA and the following primers: i) a1,3Gt"/": 50-TCTTGACGAGTTCTTCTGAG-30, 50-
TCAGCATGATGCGCATGAAGA-30, 50-TGGCCGCGTGGTAGTAAAAA-30; ii) JHT
"/": 50-CAGTGAATGACAGATGGACCTCC-30, 50-G
CAGAAGCCACAACC ATACATTC-30, 50-ACAGTAACTCGTTCTTCTCTGC-30; iii) Aid-/-: 50-GGCCAGCTCATTCCTCCACT-30, 50-CAC
TGAGCGCACCTGTAGCC-30, 50-CCTAGTGGCCAAGGTGCAGT-30, 50-TCAGGCTGAGGTTAGGGTTCC-30; iv) Tcrb-/-: 50-TGTCT
GAAGGGCAATGACTG-30, 50-GCTGATCCGTGGCATCTATT-30, 50-CTTGGGTGGAGAGGCTATTC-30, 50-AGGTGAGATGACAGGAG
ATC-30; v) C3"/": 50-ATCTTGAGTGCACCAAGCC-30, 50-GGTTGCAGCAGTCTATGAAGG-30, 50-GCCAGAGGCCACTTGTGTAG-30.
mS-/- mice were phenotyped by ELISA, as described (Ehrenstein et al., 1998). Total genomic DNA was isolated from the tail using
a standard protocol. Briefly, tails (0,5 to 1 cm) were obtained and submerged into DirectPCR Lysis Reagent (200-300 mL; Viagen
Biotech) containing Proteinase K (100 mg/ml) and incubated (overnight; 55!C) under vigorous agitation. Next day, samples were
centrifuged (16,000 g; 5-10 s; RT) and supernatant (1 ml) was amplified by PCR: 95!C (15 min), 30 cycles of 94!C (45 s), 60!C
(90 s) (except Aid-/- genotyping; 63!C), 72!C (90 s) and 72!C (15 min). Visualizations of PCR results were done on 1.5%–2% agarose
gel (80-100V; 1-2 hr).
Extraction of Rabbit RBC Membranes
Rabbit RBC membranes (rRBCM) expressing high levels of a-gal (Eto et al., 1968) were prepared from lyzed RBC (50 mM sodium
phosphate buffer pH 8), washed (5-7X; sodium phosphate buffer; 10,000 g; 20 min, 4!C) until supernatant was hemoglobin-free,
essentially as described (Matsuzawa and Ikarashi, 1979). Membranes were collected by centrifugation (20,000 g; 20 min, 4!C),
re-suspended in PBS and stored ("80!C) until used.
Immunization
rRBCM were emulsified in Complete Freund’s Adjuvant (CFA; Incomplete Freund’s Adjuvant (IFA) plusMycobacterium tuberculosis
H37 RA; 4 mg/ml; DIFCO) with CpG (50 mg/mouse; ODNM362; Invivogen) and administered subcutaneously (s.c.). Two subsequent
immunizations were emulsified in IFA+rRBC+CpG. Emulsions were administered at 200 ml per mouse, 3 times at twoweeks intervals.
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Mice were also immunized (s.c.) with a-gal-BSA (75 mg/mouse) emulsified in CFAwith two subsequent immunizations, 2 and 4weeks
thereafter with a-gal-BSA emulsified in IFA.
Anti-a-Gal ELISA
Mouse serum was collected two weeks after immunization and circulating anti-a-gal antibodies were quantified by ELISA, as
described (Galili et al., 1998; LaTemple and Galili, 1998). Briefly, 96-well plates (PolySorp; Nunc) were coated with a-gal (a-gal-
HSA or a-gal-BSA; 50 ml; 10 mg/ml in 0.5 M carbonate bicarbonate buffer; pH 9.5; 2 hr at 37!C or overnight at 4!C), blocked with
BSA (100 ml; 1% w/v in PBS; 1 hr; RT) and washed (5X; PBS/0.05% Tween-20). Plates were incubated (1 hr; RT) with serum serial
dilutions in PBS, 1% BSA and washed (5X; PBS/0.05% Tween-20). Anti-a-gal antibodies were detected using HRP-conjugated
anti-mouse IgM, total IgG, IgG1, IgG2a, IgG2b or IgG3 (50 ml, 1:1-2,000 dilution, 1 hr, RT) and washed (5X; PBS/0.05% Tween-
20). Purified anti-a-gal IgM (Galili et al., 1998), IgG1 (GT6-27), IgG2a and IgG2b and IgG3 (GT4-31) mAb (Ding et al., 2008; Yin
et al., 2004) were used as standards. TMB Substrate Reagent Set (BD Biosciences) was used to reveal peroxidase activity
(15-30 min; RT) and the reaction was stopped using 2N sulfuric acid. Optical densities (OD) were reported at l = 450 nm and normal-
ized by subtracting background OD values (l = 600 nm) (Victor 3; PerkinElmer). Concentration of each anti-a-gal IgG subclass was
determined, as described (Spalter et al., 1999). Concentration of anti-a-gal antibodies in human plasma was analyzed using a similar
assay and a standard curve to transform absorbance into immunoglobulin concentration was obtained by coating 8 duplicate wells in
every plate with purified human IgG and IgM (500 to 1.5 ng/ml) and performing the protocol described above in the absence of diluted
serum.
Anti-a-Gal mAbs
Anti-a-gal hybridomas were cultured in RPMI 1640 (Invitrogen Life Technologies) supplemented with 0.1 mM Sodium Pyruvate,
0.01 M HEPES, 0.05 mM 2-mercaptoethanol and 2% FBS (IgG depleted). Anti-a-gal IgG2a, IgG2b and IgG3 hybridomas were
derived by sub-cloning of the original IgG1 (GT6-27) hybridoma and as such have similar affinities for a-gal, as described (Ding
et al., 2008; Yin et al., 2004). Antibodies were purified by affinity chromatography using HiTrap Protein G columns (GE Healthcare
Life Sciences). Anti-a-gal IgG3 purification was carried out by a nonchromatographic method taking advantage of its euglobulin
properties, as described (Garcı́a-González et al., 1988). Purified mAbs were extensively dialyzed against PBS. Protein concentration
was determined using NanoDrop ND-1000 spectrophotometer (l = 280 nm; Thermo Scientific) and purity confirmed by SDS-PAGE
analysis. When indicated, mAbs were labeled with Alexa Fluor 647 Protein Labeling Kit (A20173), as per manufacturer recommen-
dations (Molecular Probes, Invitrogen). Anti-mouse IgM total-A647 (Clone: R33.24.12) was used to reveal anti-a-gal IgM mAb in
immunofluorescence assay.
Passive Anti-a-Gal mAbs Transfer
a1,3Gt"/" mice received anti-a-gal IgG1, IgG2a, IgG2b or IgG3 mAbs via a single i.v. injection (150 mg; 100 ml per mouse), 24 hr prior
to mosquito exposure. Passive anti-a-gal IgM transfer was performed using polyclonal IgM. Briefly, eight to ten weeks old
a1,3G"/"Aid"/" mice received 3x108 RBC equivalents of rRBCM in PBS (100 ml; i.p.). Serum was collected two weeks after the
last immunization and concentration of anti-a-gal IgMwas determined by ELISA (Galili et al., 1998; LaTemple andGalili, 1998). Serum
collected from naive a1,3G"/"Aid"/" mice was used as control. a1,3Gt"/" mice received the polyclonal IgM via a single i.v. (150 mg;
300-400 ml per mouse), 24 hr prior to mosquito exposure.
Plasmodium Strains
For sporozoite production, P. berghei ANKA infected RBC (1x106) were administered i.p. to BALB/c mice and the presence of game-
tocyte-stage parasites capable of exflagellation wasmonitored in fresh blood preparations. Infected BALB/c mice were used to feed
3 to 4-day-old female mosquitoes (#1 hr), which were used 18-25 days postinfection for subsequent infections. When infected with
P. berghei ANKA mosquitoes were maintained at 21!C (IHMT) whereas mosquitoes infected with P. yoelii 17XNL-GFP(Ono et al.,
2007) were maintained (24-25!C; Centre for Production and Infection of Anopheles; CEPIA, Pasteur Institute, France). Alternatively,
P. yoelii 17XNL (MR4; MRA-593) (Weiss et al., 1989) infected mosquitoes were purchased from Radboud University Nijmegen Med-
ical Centre (Nijmegen, Netherlands). P. falciparum 3D7 strain (kindly provided by Robert Menard, Institut Pasteur, France) (Walliker
et al., 1987) were used for a-gal detection in infected RBC by immunofluorescence assay.
Sporozoites Isolation and Inoculation
Mosquitoes were narcotized ("20!C; 3-5 min), washed in 70% ethanol (1X; 10-20 s) and PBS (3X; 10-20 s; Ambion). Salivary glands
were obtained by dissection under a zoom stereomicroscope (3X magnification; Nikon SMZ800, Japan) and preserved in RPMI
1640 medium (GIBCO BRL) or PBS. Salivary glands were smashed using Pellet pestles cordless motor (10-15 s; Sigma) to release
sporozoites and centrifuged (100 g; 5 min) in LoBind microfuge tubes (Eppendorf). Supernatant was filtered (100 mm cell strainers;
BD Falco) to exclude debris. Sporozoites were counted using KOVA Glasstic Slide 10 with quantitative grid (Fisher Scientific
GMBH). PbAEEF1a-GFP sporozoites were inoculated i.d. in the ear pinna (750 sporozoites in 20-30 ml; 1% BSA in PBS) or i.v.
(retro-orbital; 150 sporozoites in 50 ml; 1% BSA in PBS) using a microsyringe (Nanofil 100 ml; 33G beveled needle; World Precision
Instruments).
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Passive RBCs Transfer
a1,3Gt!/!mice immunized with rRBCM and agematched naive a1,3Gt!/!mice were exposed to PbAEEF1a-GFP infectedmosquitoes,
as described above. Parasitemia was monitored by flow cytometry in FacScan analyzer (BD Biosciences). Nine days post-mosquito
feeding, blood was collected and injected i.p. (100-200 ml) to naive a1,3Gt!/!mice. Infection wasmonitored daily for parasitemia and
clinical symptoms, starting from day 3–4 postinfection RBC administration.
Quantification of Sporozoite mRNA
The mouse ear was excised immediately after and the whole liver was harvested 40 hr after mosquito biting. Samples were frozen in
liquid nitrogen, tissues were homogenized in TRIzol (Life Technologies), total RNA isolated according to manufacturer’s instructions
(RNeasy Mini kit; QIAGEN). Briefly, RNA (2 mg; 10 ml) was mixed to random primers (1 ml) and dNTPs (10 mM; 1 ml), incubated (65"C;
5 min.), placed on ice and incubated in PCR Buffer (0.1 M DTT; 40 units/ml RNaseOU; 2 min.; 42"C). Superscript RT (SSIIRT) was
added (1 ml; 50 min. 42"C) and samples were heated to finalize synthesis (70"C; 15 min). qRT-PCR was performed using PbA 18S
rRNA specific primers (50-AAGCATTAAATAAAGCGAATACATCCTTAC-30 and 50-GGAGA TTGGTTTTGACGTTTATGTG-30). Mouse
housekeeping Arbp0 gene (50-CTTTGGGCATCACCACGAA-30 and 50-GCTGGCTCCCACCTTGTCT-30) was amplified as control.
Applied Biosystems’ Power SYBR Green PCR Master Mix was used as per manufacturer’s instructions (ABI Prism 7000 system;
Applied Biosystems). Data are presented as relative expression of P. berghei ANKA 18S rRNA normalized to mouse Arbp0 mRNA.
Detection of a-Gal in Plasmodium Sporozoites
PbAEEF1a-GFP, PbAHsp70-GFP, P. falciparum 3D7 or P. yoelii 17XNL-GFP sporozoites, isolated from the salivary glands of Anopheles
stephensi or Anopheles gambiaemosquitoes, 18-25 days postinfection were allowed to attach to Teflon printed (10 wells, 8 mm; no-
adherent surface; Immuno-Cell Int.) or to diagnostic glass slides. Sporozoites were fixed (20-50 ml; 4% PFA; 20-30 min; RT or 37"C)
and washed gently (1X; PBS). Sporozoites were stained with Alexa Fluor 647 conjugated BSI-IB4 (100 ml; 200 mg/ml; 2 hr, RT), Alexa
Fluor 647 conjugated anti-a-gal IgG1, IgG2a, IgG2b, IgG3 mAb (100 ml; 50 mg/ml; overnight; 4"C) or with nonconjugated anti-a-gal
IgM (M86) mAb (100 ml; 50 mg/ml; overnight; 4"C) and washed (1X; PBS). Nonconjugated IgM antibodies were detected using Alexa
Fluor 647 conjugated goat anti-mouse IgM (100 ml; 10 mg/ml; overnight, 4"C) (Molecular Probes, Invitrogen). After washing (1X; PBS),
slides were incubated with 4’,6-diamidino-2-phenylindole (DAPI) (100 ml; 10 mg/ml; 10 min; RT) (Molecular Probes, washed (1X; PBS)
and dried in dark room without covering with coverslip (RT). Images of PbA sporozoites were obtained by DeltaVision Core immu-
nofluorescence microscopy (Applied Precision/Olympus) or Spinning Disk Confocal microscopy Revolution xD (Andor Technology)
at 100 3 magnification. Actin was detected using Alexa Fluor 488 Phalloidin (Molecular Probes; 100 ml; 3 units/ml; 1 hr; RT) in
P. falciparum 3D7 and P. yoelii 17XNL-GFP sporozoites to which was added ProLong Gold Antifade Reagent (Invitrogen) and wells
were covered with coverslips. Slides were visualized with Axiovert II fluorescence microscope (Zeiss). Images were analyzed using
bicubic interpolation and rescaling with ImageJ software (NIH).
For detection of a-gal by flow cytometry, PbAHsp70-GFP sporozoites were isolated from the salivary glands of A. stephensi mos-
quitoes 19-25 days postinfection (105; 30-40ul; PBS; ice cold: 30 min), fixed (30-40 ml; 4% PFA in PBS; 20-30 min; 37"C) and washed
(13 ; PBS; 9,300 g; 2min). Staining was performedwith Alexa Fluor 647 conjugated BSI-IB4 (100 mg/ml; 1 hr; 37"C). Sporozoites were
washed (1 3 ; PBS; 9,300 g; 2 min) and Alexa Fluor 647 BSI-IB4 signal was detected in CyAn
TM ADP flow cytometry (Beckman
Coulter; USA) with Summit Software (v4.3; Beckman Coulter), gating on FITC (for sporozoite detection) and APC (for a-gal detection).
For detection ofa-gal bywesternblottingPbAHsp70-GFP,P. falciparum 3D7andP. yoelii17XNL-GFPsporozoiteswere isolated from the
salivary glands of 40-70 mosquitoes, 21-25 days after infection. Briefly, salivary glands were collected into the LoBind microfuge tubes
(PBS; on ice), smashed using pellet pestles cordless motor (10-15 s; 2X) and a short spin was applied to pellet debris. Supernatant (30-
50 ml; 1-2.5 3 105 sporozoites) was transferred into LoBind microfuge tube and aliquots were stored at !80"C until used. Number of
Plasmodium sporozoites (equivalent to 105 per sample) was normalized to corresponding number of salivary glands from noninfected
mosquitoes. Sampleswere lysed (50mMTris/HCl pH7.5, 150mMNaCl, 1%TritonX-100, Roche complete EDTA-free protease inhibitor
cocktail; 1 hr; on ice) andcentrifuged (16,000g, 10min.; 4"C). Samples (supernatant)weredenaturedwith Laemmli buffer (1% b-mercap-
toethanol; 2%SDS; 95"C; 2min) and separated inSDS-PAGEgradient gel (12%acrylamide/bisacrylamidegel, 29:1; 100V; 2 hr). Proteins
were transferred into a PVDFmembrane (90 min; 12V), blocked (3% BSA) and incubated overnight with anti-a-gal IgG2b mAb (1 mg/ml;
20 ml). Membrane was washed with 20 mM Tris/HCl pH7.5, 150 mMNaCl and 0.1% Tween-20 buffer (TBST, 33 ; 5 min; RT) and incu-
bated with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG2b-HRP (SouthernBiotech, 20 ng/ml; 1 hr; 50 ml; RT). Mem-
brane was washed (TBST; 1 hr; RT) and developed (SuperSignal Chemiluminescent detection kit; West Pico, Thermo Scientific).
GPI Anchor Cleavage from Plasmodium Sporozoites
PbAHsp70-GFP sporozoites were fixed (4%PFA in PBS; 20-30min; 37"C) and treatedwith phosphatidylinositol-specific phospholipase
C (from Bacillus cereus; 5U/ml; 14-16 hr; 37"C). Detection of a-gal is described above and CSP was detected using anti-CSP
conjugated to Alexa Fluor 647 in CyA ADP Analyzer (Beckman Coulter).
Bacterial Strains and Growth Conditions
Frozen E. coli O86:B7 (ATCC 12701TM; Rockville, Md.) and E. coli K12 (ATCC 10798) (#107 CFU/ml; 50% glycerol solution; !80"C)
stockswere inoculated into Luria broth (LB; 50ml; 37"C; overnight) on a shaker rack. Spectrophotometric absorbancewasmeasured
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at 600 nm (Optical Density-OD600) and adjusted to OD600 !0.2 in order to harvest bacteria during exponential growth corresponding
to a OD600 of 2. The approximate cell number was determined according to spectrophotometric measurement and confirmed with
most probable numbers (MPN) technique, also known as the method of Poisson zeroes (Oblinger and Koburger, 1975).
Detection of a-Gal on Bacterial Cultures
E. coliO86:B7 and E.coliK12were cultured (LB; 50ml; 37"C; overnight), washed (23 ; PBS; 4,000 g; 5min; 4"C) and re-suspended in
PBS. Bacteria were fixed (200 ml; 4% PFA in PBS; 20-30 min; RT) and washed (1X; PBS; 4000 g; 5 min; RT). 108-109 CFU/ml were
stainedwith BSI-IB4-FITC (200 ml; 50 mg/ml; 2 hr, RT) for flow cytometry analysis using FacScan analyzer (BDBiosciences). In parallel,
immunofluorescence assays were performed using 10 ml stained samples after air-drying (10-20min; RT). Samples were washed (1x;
PBS), incubated with 4’,6-diamidino-2-phenylindole (DAPI) (200 ml; 10 mg/ml; 10 min; RT; Molecular Probes) and washed (13 ; PBS).
Immunofluorescence images were obtained by Spinning Disk Confocal microscopy Revolution xD (Andor Technology; USA) at 100
3 magnification and images were processed with ImageJ (NIH) software.
Rederivation of GF a1,3Gt#/# Mice
Briefly, pregnant female a1,3Gt#/# mice were euthanized (20 days postcoitum), uteri were immersed in 1% VirkonS, rinsed in sterile
water and pups were transferred to surrogate mothers kept in GF isolators (Gettinge-La Calhéne, France). GF status was monitored
every third week onward.
Gnotobiotic and SPF-Colonized Mice
a1,3Gt#/# mice were re-derived via caesarean section from SPF into GF conditions at the Instituto Gulbenkian de Ciência, as
described (http://strains.emmanet.org/protocols/GermFree_0902.pdf). For gnotobiotic colonization, 8-12 weeks GF a1,3Gt#/#
mice were transferred into sterile micro isolator Ventiracks (Biozone, Margate, UK), fed ad libitum with a standard autoclaved
chow diet and water and GF status was monitored every third week onward. GF and SPF a1,3Gt#/# mice treated with streptomycin
sulfate (5 g/l in drinking water for 7 days; GIBCO), were starved for 12 hr and colonized with E. coli O86:B7 or E. coli K12
(!107 CFU/100 ml Luria-Bertani - LB - medium) via oral gavage, using a 20-gauge stainless steel animal feeding needle (Cadence
Science, Japan). Control mice were inoculated with sterile LBmedium. Colonization protocol was administered 3 times at twoweeks
intervals.
Complement Activation
PbAHsp70-GFP sporozoites were exposed to anti-a-gal mAbs (150 mg/ml; in 50 ml DMEM; 60 min; 4"C) and subsequently to naive
C57BL/6 mouse plasma (1:5 in 0.1% gelatin in Veronal Buffer (VB)2+; 50 ml; 60 min; 37"C) (Lonza), used as a source of complement.
Samples were washed (13 ; PBS). C3 was detected using APC labeled anti-C3/C3b/iC3b (Clone: 6C9; 1:100; 50 ml; 45 min; 4"C) and
analyzed in CyA ADP Analyzer (Beckman Coulter).
Sporozoite Cytotoxicity Assays
PbAHsp70-GFP sporozoites (10-50x103) were incubated with anti-a-gal or isotype matched anti-DNP mAbs (150 mg/ml mAb in 10 ml
DMEM GlutaMA; 60 min; 4"C). Naive C57BL/6 mouse plasma (1:5) or baby rabbit complement (1:10; Cedarlane Laboratories)
was added (0.1% gelatin in VB2+) as a source of complement (60 min; 37"C). Cytotoxicity was quantified according to GFP expres-
sion in Andor Spinning Disk Confocal Microscopy (Andor Technology). Alternatively, PbAEEF1a-GFP sporozoites (10-30 3 103) were
isolated from the salivary glands of Anopheles stephensi mosquitoes, 19-25 days postinfection and incubated with anti-a-gal or
isotype matched anti-DNP mAbs (150 mg/ml mAb in 10 ml PBS, Life Technologies) (60 min; on ice). Plasma from C57BL/6
mice (1:5) or baby rabbit complement (bRC; 1:10; Cedarlane Laboratories) was added (0.1% gelatin in VB2+ buffer; Lonza) as a
source of complement (60 min; 37"C). Alternatively, sporozoite cytotoxicity was evaluated according to loss of crescent-shaped
morphology (%).
Invasion Assay
Human hepatoma cells (HepG2; kindly provided from Robert Menard, Institut Pasteur, France) were cultured (4x104/well; 200 ml in
96-well plates) in DMEM (GlutaMA, 10% FBS, 100U/ml penicillin/streptomycin; Life Technologies) (37"C; 5%CO2; 2 days).
PbAHsp70-GFP sporozoites (19-25 days postinfection) were preincubated with anti-a-gal or isotype matched control anti-DNP
mAbs (150 mg/ml in 20-50 ml; 60 min; 4"C). Plasma from C57BL/6 mice (1:5 in 20-50 ml 0.1% gelatin in VB2+ buffer; Lonza)
was added (60 min.; 37"C) as a source of complement and sporozoites were immediately transferred onto HepG2 cells at
a 1:4 parasite/cell ratio. Cocultures were incubated (120 min; 37"C) with Tetramethylrhodamine-Dextran (10,000 MW, 1:1;
2 mg/ml; Molecular Probes), washed (2X; PBS) and trypsinized (30-50 ml; 0.05% Trypsin-EDTA (1X), phenol red (GIBCO). Percent-
age of wounded and parasite-invaded cells was determined by flow cytometry analysis (FACScan, BD Biosciences), gating on FL1
(GFP; invasion) and FL2 (Dextran-Red; wounding). Sporozoite maturation was determined by quantifying the number of EEFs per
field and EEF area after 40 hr coculture in 15 m-Slide 8 well (ibiTreat; IBIDI; Germany) using fluorescence microscopy (Screening
Microscopy; Nikon Eclipse TE2000-S). Images were obtained at 20x magnification. Pictures were analyzed using Image J software
(NIH).
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PMN Cell Depletion
Anti-Gr1 mAb (Clone: RB6-8C5; RB6-8C5 hybridoma) was produced at the IGC under serum-free conditions using a CELLine (Inte-
gra, Switzerland) (Tepper et al., 1992). Neutrophils were depleted in a1,3Gt!/! mouse by a single intravenous anti-Gr1 mAb injection
(250 mg), 48 hr prior tomosquito biting. PMNdepletion was confirmed by staining for CD11b-FITC (Integrin a[M] chain,Mac-1 a chain,
CR3, BD PharMingenTM) and Anti-Gr1-PE (1A8, BD PharMingenTM) and analyzed in flow cytometry(Tsiganov et al., 2014) (CyA ADP
Analyzer, Beckman Coulter).
Statistical Analysis
All tests (except human cohort studies) were performed using the GraphPad Prism v6.0 (GraphPad Software). Human analyses were
performed in R version 3.0.2 (http://www.R-project.org). Ab levels between groups were compared with the Kruskal-Wallis test. The
relationship between Ab levels and time to P. falciparum infection and febrile malaria was determined by Kaplan-Meier survival anal-
ysis and the log-rank test. Age dependent differences in anti-a-gal IgM and IgG antibody concentrations in human serumwere deter-
mined using nonparametric Mann-Whitney test. Differences in anti-a-gal antibody concentration in mouse serum were determined
using nonparametric Kruskal-Wallis test with Dunn’s multiple comparison posttest. Incidence of infection was compared using log
rank (Mantel-Cox) test. Survival curves were plotted using Kaplan-Meier plot and significant differences among experimental groups
were determined using the Log-Rank (Mantel-Cox) test. Data corresponding to relative amount of Plasmodium in the skin and liver
obtained from qRT-PCR was analyzed using nonparametric Mann–Whitney test. Cytotoxic effect of anti-a-gal antibodies was
analyzed using repeated-measures ANOVA followed by Tukey’s multiple comparison posttest. A p value equal to or below 0.05
was considered statistically significant.
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Figure S1. Detection of a-Gal in Plasmodium Sporozoites, Related to Figure 1
(A and B) Expression of GFP (P. berghei ANKA) and actin (P. falciparum 3D7 and P. yoelli 17XNL) shown in green, a-gal shown in red and DNA (DAPI) shown in
blue. The a-gal epitope was detected with (A) anti-a-gal mAb (M86) or (B) the BSI-B4 lectin. Representative of 2-3 experiments. Arrows indicate a-gal staining.
Scale bar, 5 mm.








































































































































































Figure S2. Anti-a-Gal IgG Abs in Gut-Colonized a1,3Gt!/! Mice and Disease Assessment after Exposure to Infected Mosquitoes, Related to
Figure 3
(A) Anti-a-gal IgG subclass Ab levels in a1,3Gt!/! mice not-colonized (SPF), colonized with E. coli K12 or O86.B7 strains after streptomycin treatment (2-3
experiments; n = 12).
(B) Parasitemia (%) and survival (%) in same mice as (A) after exposure to PbAEEF1a-GFP infected A. stephensi mosquitoes (4 experiments; n = 17-34).
(C) Anti-a-gal IgG subclass Ab levels in GF a1,3Gt!/! mice not colonized (GF), colonized with E. coli K12 or O86.B7 strains (2-4 experiments; n = 12).
(D) Parasitemia (%) and survival (%) in same mice as (C) after exposure to PbAEEF1a-GFP infected A. stephensi mosquitoes (4 experiments; n = 7-10 per group).
Mean (red bars).
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Figure S3. a1,3Gt+/+ Mice Are Not Protected against Malaria Transmission, Related to Figure 4
(A) Anti-a-gal antibodies in the serum of control (-) versus rRBCM (+) or a-gal-BSA (+) immunized a1,3Gt+/+ mice (2-3 experiments; n = 12-16).
(B–D) Incidence of blood stage of infection (%) in a1,3Gt+/+ mice treated as in (A) and exposed to (B) PbAEEF1a-GFP infected A. stephensi mosquitoes (7 ex-
periments; n = 19-48), (C) P. yoelii 17XNL infected A. stephensi mosquitoes (5 experiments; n = 26-30) or (D) PbAEEF1a-GFP infected A. gambiae mosquitoes (4
experiments; n = 27-28).
(E) Incidence of blood stage of infection (%) in nonimmunized (Control) versus immunized (rRBCM) a1,3Gt+/+ mice receiving PbAEEF1a-GFP sporozoites (3-4
experiments; n = 15-26).
(F) Plasmodium 18 s rRNA/Arbp0mRNA in skin and liver of nonimmunized (Control) versus immunized (rRBCM) a1,3Gt+/+ mice exposed to PbAEEF1a-GFP infected
Anopheles stephensi mosquitoes (3-5 experiments). Infected/total mice (gray Nbrs).
(G) Same as (A) in control (-) versus immunized (+; rRBCM emulsified in CFA plus CpG) a1,3Gt+/+ mice (2 experiments; n = 5).
(H) Same as (B) in mice treated as in (G) (3 experiments; n = 15). In (A, F and G) dots are individual mice and mean (red bars).
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Figure S4. Immunization against a-Gal Is Ineffective in Protecting against Blood Stage of Infection but Confers Sterile Protection against
Malaria Transmission, Related to Figure 4
(A) Incidence of blood stage of infection (%; left panel), parasitemia (%;middle panel) and survival (%; right panel) upon inoculation ofPbAEEF1a-GFP infected RBC.
Mice were either immunized (I) with rRBCM or not immunized (NI) (One experiment; n = 3-5).
(B) Schematic representation of infection protocol (left panel) and incidence of blood stage of infection (%; right panel) in a1,3Gt!/! mice transferred with RBC
from a1,3Gt!/! mice infected PbAEEF1a-GFP or protected from transmission of PbAEEF1a-GFP infection by A. stephensi mosquitoes (2 experiments; n = 19).
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Figure S5. Blood Stage Infection and Lethality, Related to Figure 5
(A–D) Parasitemia (%; left panels) and survival (%; right panels) are shown for infected (A) a1,3Gt!/!Jht!/!, (B) a1,3Gt!/!Aid!/!, (C) a1,3Gt!/!mS!/! and (D)
a1,3Gt!/!Tcrb!/! mice immunized with rRBCM (I) vs. control nonimmunized (NI) (3-7 experiment; n = 11-22).



















































































Figure S6. Specificity of Anti-a-Gal mAbs, Related to Figure 5
(A) Comparison of relative binding of anti-a-gal mAbs (125 ng/ml of mAb) determined by ELISA using a-gal-BSA as a solid phase antigen.
(B) Comparison of relative binding capacity of anti-a-gal mAbs (50 mg/ml of mAb) determined by immunofluorescence using PbAEEF1a-GFP sporozoites as an
antigen. mAb (red), GFP (green) and DNA (blue) staining. Merged images show composite of the three staining. Representative of 2-3 experiments.
(C) Similar staining as in (B) for PbAEEF1a-GFP sporozoites treated with a-galactosidase. Composite images are shown with mAb (red), GFP (green) and DNA (blue)
staining. White arrows in (B) and (C) indicate binding of different mAb to the a-gal epitope. Scale bar, 5 mm.


































































































































































Figure S7. Cytotoxic Effect of Anti-a-Gal Antibodies, Related to Figure 7
(A) Mean percentage (%) of viable GFP+ PbAHsp70-GFP sporozoites ± STD (3-4 experiments) after in vitro exposure to anti-a-gal (a-gal) or anti-DNP mAbs in the
presence of rabbit complement.
(B) Mean percentage (%) of viable GFP+ PbAHsp70-GFP sporozoites ± STD (3-4 experiments) after in vitro exposure to anti-a-gal (a-gal) or anti-DNP mAbs in the
absence of complement.
(C) Mean percentage (%) of viable crescent shaped PbAEEF1a-GFP sporozoites ± STD (3 experiments) after in vitro exposure to anti-a-gal (a-gal) or anti-DNP (DNP)
mAb in the presence of mouse complement.
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